{
"instance": {
"achv-10q_20220630.htm": {
"axisCustom": 0,
"axisStandard": 23,
"contextCount": 175,
"dts": {
"calculationLink": {
"local": [
"achv-20220630_cal.xml"
]
},
"definitionLink": {
"local": [
"achv-20220630_def.xml"
]
},
"inline": {
"local": [
"achv-10q_20220630.htm"
]
},
"labelLink": {
"local": [
"achv-20220630_lab.xml"
]
},
"presentationLink": {
"local": [
"achv-20220630_pre.xml"
]
},
"schema": {
"local": [
"achv-20220630.xsd"
],
"remote": [
"http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
"http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
"http://www.xbrl.org/2003/xl-2003-12-31.xsd",
"http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
"http://www.xbrl.org/2005/xbrldt-2005.xsd",
"http://www.xbrl.org/2006/ref-2006-02-27.xsd",
"http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd",
"http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
"http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
"http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
"https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
"https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
"https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
"https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
"https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
"https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
"https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
"https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
"https://xbrl.sec.gov/country/2022/country-2022.xsd",
"https://xbrl.sec.gov/currency/2022/currency-2022.xsd",
"https://xbrl.sec.gov/dei/2022/dei-2022.xsd",
"https://xbrl.sec.gov/exch/2022/exch-2022.xsd",
"https://xbrl.sec.gov/naics/2022/naics-2022.xsd",
"https://xbrl.sec.gov/sic/2022/sic-2022.xsd",
"https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd"
]
}
},
"elementCount": 405,
"entityCount": 1,
"hidden": {
"http://fasb.org/us-gaap/2022": 11,
"http://xbrl.sec.gov/dei/2022": 4,
"total": 15
},
"keyCustom": 48,
"keyStandard": 190,
"memberCustom": 37,
"memberStandard": 19,
"nsprefix": "achv",
"nsuri": "http://achievelifesciences.com/20220630",
"report": {
"R1": {
"firstAnchor": {
"ancestors": [
"p",
"body",
"html"
],
"baseRef": "achv-10q_20220630.htm",
"contextRef": "C_0000949858_20220101_20220630",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "dei:DocumentType",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "document",
"isDefault": "true",
"longName": "100000 - Document - Document and Entity Information",
"role": "http://achievelifesciences.com/20220630/taxonomy/role/DocumentDocumentAndEntityInformation",
"shortName": "Document and Entity Information",
"subGroupType": "",
"uniqueAnchor": {
"ancestors": [
"p",
"body",
"html"
],
"baseRef": "achv-10q_20220630.htm",
"contextRef": "C_0000949858_20220101_20220630",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "dei:DocumentType",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R10": {
"firstAnchor": {
"ancestors": [
"body",
"html"
],
"baseRef": "achv-10q_20220630.htm",
"contextRef": "C_0000949858_20220101_20220630",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "100090 - Disclosure - Intangibles",
"role": "http://achievelifesciences.com/20220630/taxonomy/role/DisclosureIntangibles",
"shortName": "Intangibles",
"subGroupType": "",
"uniqueAnchor": {
"ancestors": [
"body",
"html"
],
"baseRef": "achv-10q_20220630.htm",
"contextRef": "C_0000949858_20220101_20220630",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R11": {
"firstAnchor": {
"ancestors": [
"body",
"html"
],
"baseRef": "achv-10q_20220630.htm",
"contextRef": "C_0000949858_20220101_20220630",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "100100 - Disclosure - License Agreements",
"role": "http://achievelifesciences.com/20220630/taxonomy/role/DisclosureLicenseAgreements",
"shortName": "License Agreements",
"subGroupType": "",
"uniqueAnchor": {
"ancestors": [
"body",
"html"
],
"baseRef": "achv-10q_20220630.htm",
"contextRef": "C_0000949858_20220101_20220630",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R12": {
"firstAnchor": {
"ancestors": [
"body",
"html"
],
"baseRef": "achv-10q_20220630.htm",
"contextRef": "C_0000949858_20220101_20220630",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:FairValueDisclosuresTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "100110 - Disclosure - Fair Value Measurements",
"role": "http://achievelifesciences.com/20220630/taxonomy/role/DisclosureFairValueMeasurements",
"shortName": "Fair Value Measurements",
"subGroupType": "",
"uniqueAnchor": {
"ancestors": [
"body",
"html"
],
"baseRef": "achv-10q_20220630.htm",
"contextRef": "C_0000949858_20220101_20220630",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:FairValueDisclosuresTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R13": {
"firstAnchor": {
"ancestors": [
"body",
"html"
],
"baseRef": "achv-10q_20220630.htm",
"contextRef": "C_0000949858_20220101_20220630",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:DebtDisclosureTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "100120 - Disclosure - Convertible Debt",
"role": "http://achievelifesciences.com/20220630/taxonomy/role/DisclosureConvertibleDebt",
"shortName": "Convertible Debt",
"subGroupType": "",
"uniqueAnchor": {
"ancestors": [
"body",
"html"
],
"baseRef": "achv-10q_20220630.htm",
"contextRef": "C_0000949858_20220101_20220630",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:DebtDisclosureTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R14": {
"firstAnchor": {
"ancestors": [
"body",
"html"
],
"baseRef": "achv-10q_20220630.htm",
"contextRef": "C_0000949858_20220101_20220630",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "100130 - Disclosure - Common Stock",
"role": "http://achievelifesciences.com/20220630/taxonomy/role/DisclosureCommonStock",
"shortName": "Common Stock",
"subGroupType": "",
"uniqueAnchor": {
"ancestors": [
"body",
"html"
],
"baseRef": "achv-10q_20220630.htm",
"contextRef": "C_0000949858_20220101_20220630",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R15": {
"firstAnchor": {
"ancestors": [
"body",
"html"
],
"baseRef": "achv-10q_20220630.htm",
"contextRef": "C_0000949858_20220101_20220630",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "100140 - Disclosure - Commitments and Contingencies",
"role": "http://achievelifesciences.com/20220630/taxonomy/role/DisclosureCommitmentsAndContingencies",
"shortName": "Commitments and Contingencies",
"subGroupType": "",
"uniqueAnchor": {
"ancestors": [
"body",
"html"
],
"baseRef": "achv-10q_20220630.htm",
"contextRef": "C_0000949858_20220101_20220630",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R16": {
"firstAnchor": {
"ancestors": [
"us-gaap:IntangibleAssetsDisclosureTextBlock",
"body",
"html"
],
"baseRef": "achv-10q_20220630.htm",
"contextRef": "C_0000949858_20220101_20220630",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "100150 - Disclosure - Intangibles (Tables)",
"role": "http://achievelifesciences.com/20220630/taxonomy/role/DisclosureIntangiblesTables",
"shortName": "Intangibles (Tables)",
"subGroupType": "tables",
"uniqueAnchor": {
"ancestors": [
"us-gaap:IntangibleAssetsDisclosureTextBlock",
"body",
"html"
],
"baseRef": "achv-10q_20220630.htm",
"contextRef": "C_0000949858_20220101_20220630",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R17": {
"firstAnchor": {
"ancestors": [
"ix:continuation",
"body",
"html"
],
"baseRef": "achv-10q_20220630.htm",
"contextRef": "C_0000949858_20220101_20220630",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "100160 - Disclosure - Fair Value Measurements (Tables)",
"role": "http://achievelifesciences.com/20220630/taxonomy/role/DisclosureFairValueMeasurementsTables",
"shortName": "Fair Value Measurements (Tables)",
"subGroupType": "tables",
"uniqueAnchor": {
"ancestors": [
"ix:continuation",
"body",
"html"
],
"baseRef": "achv-10q_20220630.htm",
"contextRef": "C_0000949858_20220101_20220630",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R18": {
"firstAnchor": {
"ancestors": [
"p",
"ix:continuation",
"body",
"html"
],
"baseRef": "achv-10q_20220630.htm",
"contextRef": "C_0000949858_20220101_20220630",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:ConvertibleDebtTableTextBlock",
"reportCount": 1,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "100170 - Disclosure - Convertible Debt (Tables)",
"role": "http://achievelifesciences.com/20220630/taxonomy/role/DisclosureConvertibleDebtTables",
"shortName": "Convertible Debt (Tables)",
"subGroupType": "tables",
"uniqueAnchor": null
},
"R19": {
"firstAnchor": {
"ancestors": [
"ix:continuation",
"body",
"html"
],
"baseRef": "achv-10q_20220630.htm",
"contextRef": "C_0000949858_20220101_20220630",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "100180 - Disclosure - Common Stock (Tables)",
"role": "http://achievelifesciences.com/20220630/taxonomy/role/DisclosureCommonStockTables",
"shortName": "Common Stock (Tables)",
"subGroupType": "tables",
"uniqueAnchor": {
"ancestors": [
"ix:continuation",
"body",
"html"
],
"baseRef": "achv-10q_20220630.htm",
"contextRef": "C_0000949858_20220101_20220630",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R2": {
"firstAnchor": {
"ancestors": [
"p",
"td",
"tr",
"table",
"div",
"body",
"html"
],
"baseRef": "achv-10q_20220630.htm",
"contextRef": "C_0000949858_20220630",
"decimals": "-3",
"first": true,
"lang": null,
"name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
"reportCount": 1,
"unitRef": "U_iso4217USD",
"xsiNil": "false"
},
"groupType": "statement",
"isDefault": "false",
"longName": "100010 - Statement - Consolidated Balance Sheets (Unaudited)",
"role": "http://achievelifesciences.com/20220630/taxonomy/role/StatementConsolidatedBalanceSheetsUnaudited",
"shortName": "Consolidated Balance Sheets (Unaudited)",
"subGroupType": "",
"uniqueAnchor": {
"ancestors": [
"p",
"td",
"tr",
"table",
"div",
"body",
"html"
],
"baseRef": "achv-10q_20220630.htm",
"contextRef": "C_0000949858_20220630",
"decimals": "-3",
"lang": null,
"name": "us-gaap:PrepaidExpenseAndOtherAssetsCurrent",
"reportCount": 1,
"unique": true,
"unitRef": "U_iso4217USD",
"xsiNil": "false"
}
},
"R20": {
"firstAnchor": {
"ancestors": [
"us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
"body",
"html"
],
"baseRef": "achv-10q_20220630.htm",
"contextRef": "C_0000949858_20220101_20220630",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "srt:ContractualObligationFiscalYearMaturityScheduleTableTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "100190 - Disclosure - Commitments and Contingencies (Tables)",
"role": "http://achievelifesciences.com/20220630/taxonomy/role/DisclosureCommitmentsAndContingenciesTables",
"shortName": "Commitments and Contingencies (Tables)",
"subGroupType": "tables",
"uniqueAnchor": {
"ancestors": [
"us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
"body",
"html"
],
"baseRef": "achv-10q_20220630.htm",
"contextRef": "C_0000949858_20220101_20220630",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "srt:ContractualObligationFiscalYearMaturityScheduleTableTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R21": {
"firstAnchor": {
"ancestors": [
"p",
"td",
"tr",
"table",
"div",
"body",
"html"
],
"baseRef": "achv-10q_20220630.htm",
"contextRef": "C_0000949858_20220630",
"decimals": "-3",
"first": true,
"lang": null,
"name": "us-gaap:RetainedEarningsAccumulatedDeficit",
"reportCount": 1,
"unitRef": "U_iso4217USD",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "100200 - Disclosure - Nature of Business, Basis of Presentation and Going Concern Uncertainty - Additional Information (Detail)",
"role": "http://achievelifesciences.com/20220630/taxonomy/role/DisclosureNatureOfBusinessBasisOfPresentationAndGoingConcernUncertaintyAdditionalInformationDetail",
"shortName": "Nature of Business, Basis of Presentation and Going Concern Uncertainty - Additional Information (Detail)",
"subGroupType": "details",
"uniqueAnchor": null
},
"R22": {
"firstAnchor": {
"ancestors": [
"p",
"td",
"tr",
"table",
"div",
"body",
"html"
],
"baseRef": "achv-10q_20220630.htm",
"contextRef": "C_0000949858_20220630",
"decimals": "-3",
"first": true,
"lang": null,
"name": "us-gaap:GrantsReceivableCurrent",
"reportCount": 1,
"unitRef": "U_iso4217USD",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "100210 - Disclosure - Government Grant - Additional Information (Details)",
"role": "http://achievelifesciences.com/20220630/taxonomy/role/DisclosureGovernmentGrantAdditionalInformationDetails",
"shortName": "Government Grant - Additional Information (Details)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"span",
"p",
"achv:GovernmentGrantsTextBlock",
"body",
"html"
],
"baseRef": "achv-10q_20220630.htm",
"contextRef": "C_0000949858_us-gaapRegulatoryAgencyAxis_achvNationalInstituteOnDrugAbuseMember_20210801_20210801",
"decimals": "-5",
"lang": null,
"name": "achv:GrantAwarded",
"reportCount": 1,
"unique": true,
"unitRef": "U_iso4217USD",
"xsiNil": "false"
}
},
"R23": {
"firstAnchor": {
"ancestors": [
"p",
"us-gaap:IntangibleAssetsDisclosureTextBlock",
"body",
"html"
],
"baseRef": "achv-10q_20220630.htm",
"contextRef": "C_0000949858_20150518",
"decimals": "-5",
"first": true,
"lang": null,
"name": "us-gaap:FiniteLivedIntangibleAssetsFairValueDisclosure",
"reportCount": 1,
"unique": true,
"unitRef": "U_iso4217USD",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "100220 - Disclosure - Intangibles - Additional Information (Detail)",
"role": "http://achievelifesciences.com/20220630/taxonomy/role/DisclosureIntangiblesAdditionalInformationDetail",
"shortName": "Intangibles - Additional Information (Detail)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"p",
"us-gaap:IntangibleAssetsDisclosureTextBlock",
"body",
"html"
],
"baseRef": "achv-10q_20220630.htm",
"contextRef": "C_0000949858_20150518",
"decimals": "-5",
"first": true,
"lang": null,
"name": "us-gaap:FiniteLivedIntangibleAssetsFairValueDisclosure",
"reportCount": 1,
"unique": true,
"unitRef": "U_iso4217USD",
"xsiNil": "false"
}
},
"R24": {
"firstAnchor": {
"ancestors": [
"p",
"td",
"tr",
"table",
"div",
"body",
"html"
],
"baseRef": "achv-10q_20220630.htm",
"contextRef": "C_0000949858_20220630",
"decimals": "-3",
"first": true,
"lang": null,
"name": "us-gaap:FiniteLivedIntangibleAssetsNet",
"reportCount": 1,
"unitRef": "U_iso4217USD",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "100230 - Disclosure - Intangibles - Components of Intangible Assets (Detail)",
"role": "http://achievelifesciences.com/20220630/taxonomy/role/DisclosureIntangiblesComponentsOfIntangibleAssetsDetail",
"shortName": "Intangibles - Components of Intangible Assets (Detail)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"p",
"td",
"tr",
"table",
"div",
"us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
"us-gaap:IntangibleAssetsDisclosureTextBlock",
"body",
"html"
],
"baseRef": "achv-10q_20220630.htm",
"contextRef": "C_0000949858_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapLicensingAgreementsMember_20220630",
"decimals": "-3",
"lang": null,
"name": "us-gaap:FiniteLivedIntangibleAssetsGross",
"reportCount": 1,
"unique": true,
"unitRef": "U_iso4217USD",
"xsiNil": "false"
}
},
"R25": {
"firstAnchor": {
"ancestors": [
"p",
"td",
"tr",
"table",
"div",
"ix:continuation",
"us-gaap:IntangibleAssetsDisclosureTextBlock",
"body",
"html"
],
"baseRef": "achv-10q_20220630.htm",
"contextRef": "C_0000949858_20220630",
"decimals": "-3",
"first": true,
"lang": null,
"name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear",
"reportCount": 1,
"unique": true,
"unitRef": "U_iso4217USD",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "100240 - Disclosure - Intangibles - Estimated Future Amortization Expense Related to Intangible Assets (Detail)",
"role": "http://achievelifesciences.com/20220630/taxonomy/role/DisclosureIntangiblesEstimatedFutureAmortizationExpenseRelatedToIntangibleAssetsDetail",
"shortName": "Intangibles - Estimated Future Amortization Expense Related to Intangible Assets (Detail)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"p",
"td",
"tr",
"table",
"div",
"ix:continuation",
"us-gaap:IntangibleAssetsDisclosureTextBlock",
"body",
"html"
],
"baseRef": "achv-10q_20220630.htm",
"contextRef": "C_0000949858_20220630",
"decimals": "-3",
"first": true,
"lang": null,
"name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear",
"reportCount": 1,
"unique": true,
"unitRef": "U_iso4217USD",
"xsiNil": "false"
}
},
"R26": {
"firstAnchor": {
"ancestors": [
"p",
"us-gaap:CollaborativeArrangementDisclosureTextBlock",
"body",
"html"
],
"baseRef": "achv-10q_20220630.htm",
"contextRef": "C_0000949858_srtCounterpartyNameAxis_achvUniversityOfBristolMember_20160731",
"decimals": "-5",
"first": true,
"lang": null,
"name": "achv:MaximumRequiredPaymentUnderLicenseAgreementUponCompletionOfVariousMilestones",
"reportCount": 1,
"unique": true,
"unitRef": "U_iso4217USD",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "100250 - Disclosure - License Agreements - Additional Information (Detail)",
"role": "http://achievelifesciences.com/20220630/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetail",
"shortName": "License Agreements - Additional Information (Detail)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"p",
"us-gaap:CollaborativeArrangementDisclosureTextBlock",
"body",
"html"
],
"baseRef": "achv-10q_20220630.htm",
"contextRef": "C_0000949858_srtCounterpartyNameAxis_achvUniversityOfBristolMember_20160731",
"decimals": "-5",
"first": true,
"lang": null,
"name": "achv:MaximumRequiredPaymentUnderLicenseAgreementUponCompletionOfVariousMilestones",
"reportCount": 1,
"unique": true,
"unitRef": "U_iso4217USD",
"xsiNil": "false"
}
},
"R27": {
"firstAnchor": {
"ancestors": [
"p",
"ix:continuation",
"body",
"html"
],
"baseRef": "achv-10q_20220630.htm",
"contextRef": "C_0000949858_20220101_20220630",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "achv:MaximumMaturityPeriodOfCashAndCashEquivalents",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "100260 - Disclosure - Fair Value Measurements - Additional Information (Detail)",
"role": "http://achievelifesciences.com/20220630/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetail",
"shortName": "Fair Value Measurements - Additional Information (Detail)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"p",
"ix:continuation",
"body",
"html"
],
"baseRef": "achv-10q_20220630.htm",
"contextRef": "C_0000949858_20220101_20220630",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "achv:MaximumMaturityPeriodOfCashAndCashEquivalents",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R28": {
"firstAnchor": {
"ancestors": [
"p",
"td",
"tr",
"table",
"div",
"us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
"ix:continuation",
"body",
"html"
],
"baseRef": "achv-10q_20220630.htm",
"contextRef": "C_0000949858_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20220630",
"decimals": "-3",
"first": true,
"lang": null,
"name": "us-gaap:AssetsFairValueDisclosure",
"reportCount": 1,
"unique": true,
"unitRef": "U_iso4217USD",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "100270 - Disclosure - Fair Value Measurements - Summary of Assets Measured at Fair Value on Recurring Basis (Detail)",
"role": "http://achievelifesciences.com/20220630/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAssetsMeasuredAtFairValueOnRecurringBasisDetail",
"shortName": "Fair Value Measurements - Summary of Assets Measured at Fair Value on Recurring Basis (Detail)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"p",
"td",
"tr",
"table",
"div",
"us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
"ix:continuation",
"body",
"html"
],
"baseRef": "achv-10q_20220630.htm",
"contextRef": "C_0000949858_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20220630",
"decimals": "-3",
"first": true,
"lang": null,
"name": "us-gaap:AssetsFairValueDisclosure",
"reportCount": 1,
"unique": true,
"unitRef": "U_iso4217USD",
"xsiNil": "false"
}
},
"R29": {
"firstAnchor": {
"ancestors": [
"p",
"td",
"tr",
"table",
"div",
"us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
"ix:continuation",
"body",
"html"
],
"baseRef": "achv-10q_20220630.htm",
"contextRef": "C_0000949858_20220630",
"decimals": "-3",
"first": true,
"lang": null,
"name": "us-gaap:CashEquivalentsAtCarryingValue",
"reportCount": 1,
"unique": true,
"unitRef": "U_iso4217USD",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "100280 - Disclosure - Fair Value Measurements - Summary of Cash Equivalents (Detail)",
"role": "http://achievelifesciences.com/20220630/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfCashEquivalentsDetail",
"shortName": "Fair Value Measurements - Summary of Cash Equivalents (Detail)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"p",
"td",
"tr",
"table",
"div",
"us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
"ix:continuation",
"body",
"html"
],
"baseRef": "achv-10q_20220630.htm",
"contextRef": "C_0000949858_20220630",
"decimals": "-3",
"first": true,
"lang": null,
"name": "us-gaap:CashEquivalentsAtCarryingValue",
"reportCount": 1,
"unique": true,
"unitRef": "U_iso4217USD",
"xsiNil": "false"
}
},
"R3": {
"firstAnchor": {
"ancestors": [
"p",
"us-gaap:StockholdersEquityNoteDisclosureTextBlock",
"body",
"html"
],
"baseRef": "achv-10q_20220630.htm",
"contextRef": "C_0000949858_20220630",
"decimals": "INF",
"first": true,
"lang": null,
"name": "us-gaap:PreferredStockParOrStatedValuePerShare",
"reportCount": 1,
"unitRef": "U_iso4217USD_xbrlishares",
"xsiNil": "false"
},
"groupType": "statement",
"isDefault": "false",
"longName": "100020 - Statement - Consolidated Balance Sheets (Parenthetical) (Unaudited)",
"role": "http://achievelifesciences.com/20220630/taxonomy/role/StatementConsolidatedBalanceSheetsParentheticalUnaudited",
"shortName": "Consolidated Balance Sheets (Parenthetical) (Unaudited)",
"subGroupType": "parenthetical",
"uniqueAnchor": {
"ancestors": [
"p",
"td",
"tr",
"table",
"div",
"body",
"html"
],
"baseRef": "achv-10q_20220630.htm",
"contextRef": "C_0000949858_20220630",
"decimals": "INF",
"lang": null,
"name": "us-gaap:CommonStockSharesIssued",
"reportCount": 1,
"unique": true,
"unitRef": "U_xbrlishares",
"xsiNil": "false"
}
},
"R30": {
"firstAnchor": {
"ancestors": [
"p",
"td",
"tr",
"table",
"div",
"ix:continuation",
"ix:continuation",
"body",
"html"
],
"baseRef": "achv-10q_20220630.htm",
"contextRef": "C_0000949858_20220630",
"decimals": "-3",
"first": true,
"lang": null,
"name": "us-gaap:DebtInstrumentFaceAmount",
"reportCount": 1,
"unitRef": "U_iso4217USD",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "100290 - Disclosure - Fair Value Measurements - Schedule of Aggregate Fair Value of Principal Amount of Convertible Debt (Detail)",
"role": "http://achievelifesciences.com/20220630/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfAggregateFairValueOfPrincipalAmountOfConvertibleDebtDetail",
"shortName": "Fair Value Measurements - Schedule of Aggregate Fair Value of Principal Amount of Convertible Debt (Detail)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"p",
"td",
"tr",
"table",
"div",
"ix:continuation",
"ix:continuation",
"body",
"html"
],
"baseRef": "achv-10q_20220630.htm",
"contextRef": "C_0000949858_20220630",
"decimals": "-3",
"lang": null,
"name": "us-gaap:ConvertibleDebtFairValueDisclosures",
"reportCount": 1,
"unique": true,
"unitRef": "U_iso4217USD",
"xsiNil": "false"
}
},
"R31": {
"firstAnchor": {
"ancestors": [
"p",
"td",
"tr",
"table",
"div",
"ix:continuation",
"ix:continuation",
"body",
"html"
],
"baseRef": "achv-10q_20220630.htm",
"contextRef": "C_0000949858_20220630",
"decimals": "-3",
"first": true,
"lang": null,
"name": "us-gaap:DebtInstrumentFaceAmount",
"reportCount": 1,
"unitRef": "U_iso4217USD",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "100300 - Disclosure - Convertible Debt - Additional Information (Details)",
"role": "http://achievelifesciences.com/20220630/taxonomy/role/DisclosureConvertibleDebtAdditionalInformationDetails",
"shortName": "Convertible Debt - Additional Information (Details)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"p",
"us-gaap:DebtDisclosureTextBlock",
"body",
"html"
],
"baseRef": "achv-10q_20220630.htm",
"contextRef": "C_0000949858_20211222_20211222",
"decimals": "4",
"lang": null,
"name": "us-gaap:DebtInstrumentBasisSpreadOnVariableRate1",
"reportCount": 1,
"unique": true,
"unitRef": "U_xbrlipure",
"xsiNil": "false"
}
},
"R32": {
"firstAnchor": {
"ancestors": [
"p",
"td",
"tr",
"table",
"div",
"ix:continuation",
"ix:continuation",
"body",
"html"
],
"baseRef": "achv-10q_20220630.htm",
"contextRef": "C_0000949858_20220630",
"decimals": "-3",
"first": true,
"lang": null,
"name": "us-gaap:DebtInstrumentFaceAmount",
"reportCount": 1,
"unitRef": "U_iso4217USD",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "100310 - Disclosure - Convertible Debt - Schedule of Convertible Debt Balance (Details)",
"role": "http://achievelifesciences.com/20220630/taxonomy/role/DisclosureConvertibleDebtScheduleOfConvertibleDebtBalanceDetails",
"shortName": "Convertible Debt - Schedule of Convertible Debt Balance (Details)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"p",
"td",
"tr",
"table",
"div",
"ix:continuation",
"ix:continuation",
"body",
"html"
],
"baseRef": "achv-10q_20220630.htm",
"contextRef": "C_0000949858_20220630",
"decimals": "-3",
"lang": null,
"name": "us-gaap:DeferredFinanceCostsNet",
"reportCount": 1,
"unique": true,
"unitRef": "U_iso4217USD",
"xsiNil": "false"
}
},
"R33": {
"firstAnchor": {
"ancestors": [
"p",
"td",
"tr",
"table",
"div",
"body",
"html"
],
"baseRef": "achv-10q_20220630.htm",
"contextRef": "C_0000949858_20220630",
"decimals": "INF",
"first": true,
"lang": null,
"name": "us-gaap:CommonStockSharesAuthorized",
"reportCount": 1,
"unitRef": "U_xbrlishares",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "100320 - Disclosure - Common Stock - Authorized - Additional Information (Detail)",
"role": "http://achievelifesciences.com/20220630/taxonomy/role/DisclosureCommonStockAuthorizedAdditionalInformationDetail",
"shortName": "Common Stock - Authorized - Additional Information (Detail)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"p",
"us-gaap:StockholdersEquityNoteDisclosureTextBlock",
"body",
"html"
],
"baseRef": "achv-10q_20220630.htm",
"contextRef": "C_0000949858_20220630",
"decimals": "INF",
"lang": null,
"name": "us-gaap:PreferredStockSharesAuthorized",
"reportCount": 1,
"unique": true,
"unitRef": "U_xbrlishares",
"xsiNil": "false"
}
},
"R34": {
"firstAnchor": {
"ancestors": [
"p",
"us-gaap:StockholdersEquityNoteDisclosureTextBlock",
"body",
"html"
],
"baseRef": "achv-10q_20220630.htm",
"contextRef": "C_0000949858_20220401_20220630",
"decimals": "INF",
"first": true,
"lang": null,
"name": "us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised",
"reportCount": 1,
"unique": true,
"unitRef": "U_xbrlishares",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "100330 - Disclosure - Common Stock - Issued and Outstanding Shares - Additional Information (Detail)",
"role": "http://achievelifesciences.com/20220630/taxonomy/role/DisclosureCommonStockIssuedAndOutstandingSharesAdditionalInformationDetail",
"shortName": "Common Stock - Issued and Outstanding Shares - Additional Information (Detail)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"p",
"us-gaap:StockholdersEquityNoteDisclosureTextBlock",
"body",
"html"
],
"baseRef": "achv-10q_20220630.htm",
"contextRef": "C_0000949858_20220401_20220630",
"decimals": "INF",
"first": true,
"lang": null,
"name": "us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised",
"reportCount": 1,
"unique": true,
"unitRef": "U_xbrlishares",
"xsiNil": "false"
}
},
"R35": {
"firstAnchor": {
"ancestors": [
"p",
"td",
"tr",
"table",
"div",
"us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock",
"ix:continuation",
"body",
"html"
],
"baseRef": "achv-10q_20220630.htm",
"contextRef": "C_0000949858_20220630",
"decimals": "INF",
"first": true,
"lang": null,
"name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
"reportCount": 1,
"unitRef": "U_xbrlishares",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "100340 - Disclosure - Common Stock - Stock Options - Additional Information (Detail)",
"role": "http://achievelifesciences.com/20220630/taxonomy/role/DisclosureCommonStockStockOptionsAdditionalInformationDetail",
"shortName": "Common Stock - Stock Options - Additional Information (Detail)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"p",
"ix:continuation",
"body",
"html"
],
"baseRef": "achv-10q_20220630.htm",
"contextRef": "C_0000949858_20220630",
"decimals": "-5",
"lang": null,
"name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
"reportCount": 1,
"unique": true,
"unitRef": "U_iso4217USD",
"xsiNil": "false"
}
},
"R36": {
"firstAnchor": {
"ancestors": [
"p",
"td",
"tr",
"table",
"div",
"us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock",
"ix:continuation",
"body",
"html"
],
"baseRef": "achv-10q_20220630.htm",
"contextRef": "C_0000949858_20211231",
"decimals": "2",
"first": true,
"lang": null,
"name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
"reportCount": 1,
"unique": true,
"unitRef": "U_iso4217USD_xbrlishares",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "100350 - Disclosure - Common Stock - Summary of Stock Options Activity (Detail)",
"role": "http://achievelifesciences.com/20220630/taxonomy/role/DisclosureCommonStockSummaryOfStockOptionsActivityDetail",
"shortName": "Common Stock - Summary of Stock Options Activity (Detail)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"p",
"td",
"tr",
"table",
"div",
"us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock",
"ix:continuation",
"body",
"html"
],
"baseRef": "achv-10q_20220630.htm",
"contextRef": "C_0000949858_20211231",
"decimals": "2",
"first": true,
"lang": null,
"name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
"reportCount": 1,
"unique": true,
"unitRef": "U_iso4217USD_xbrlishares",
"xsiNil": "false"
}
},
"R37": {
"firstAnchor": {
"ancestors": [
"p",
"td",
"tr",
"table",
"div",
"us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
"ix:continuation",
"body",
"html"
],
"baseRef": "achv-10q_20220630.htm",
"contextRef": "C_0000949858_20220101_20220630",
"decimals": "4",
"first": true,
"lang": null,
"name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
"reportCount": 1,
"unique": true,
"unitRef": "U_xbrlipure",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "100360 - Disclosure - Common Stock - Summary of Fair Value of Each Stock Award for Employees and Directors (Detail)",
"role": "http://achievelifesciences.com/20220630/taxonomy/role/DisclosureCommonStockSummaryOfFairValueOfEachStockAwardForEmployeesAndDirectorsDetail",
"shortName": "Common Stock - Summary of Fair Value of Each Stock Award for Employees and Directors (Detail)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"p",
"td",
"tr",
"table",
"div",
"us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
"ix:continuation",
"body",
"html"
],
"baseRef": "achv-10q_20220630.htm",
"contextRef": "C_0000949858_20220101_20220630",
"decimals": "4",
"first": true,
"lang": null,
"name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
"reportCount": 1,
"unique": true,
"unitRef": "U_xbrlipure",
"xsiNil": "false"
}
},
"R38": {
"firstAnchor": {
"ancestors": [
"p",
"td",
"tr",
"table",
"div",
"us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
"ix:continuation",
"body",
"html"
],
"baseRef": "achv-10q_20220630.htm",
"contextRef": "C_0000949858_20220401_20220630",
"decimals": "-3",
"first": true,
"lang": null,
"name": "us-gaap:ShareBasedCompensation",
"reportCount": 1,
"unitRef": "U_iso4217USD",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "100370 - Disclosure - Common Stock - Summary of Share-Based Compensation Expense for Stock Options, Restricted Stock and Employee Share Purchase Plan (Detail)",
"role": "http://achievelifesciences.com/20220630/taxonomy/role/DisclosureCommonStockSummaryOfShareBasedCompensationExpenseForStockOptionsRestrictedStockAndEmployeeSharePurchasePlanDetail",
"shortName": "Common Stock - Summary of Share-Based Compensation Expense for Stock Options, Restricted Stock and Employee Share Purchase Plan (Detail)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"p",
"td",
"tr",
"table",
"div",
"us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
"ix:continuation",
"body",
"html"
],
"baseRef": "achv-10q_20220630.htm",
"contextRef": "C_0000949858_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20220401_20220630",
"decimals": "-3",
"lang": null,
"name": "us-gaap:ShareBasedCompensation",
"reportCount": 1,
"unique": true,
"unitRef": "U_iso4217USD",
"xsiNil": "false"
}
},
"R39": {
"firstAnchor": {
"ancestors": [
"p",
"ix:continuation",
"body",
"html"
],
"baseRef": "achv-10q_20220630.htm",
"contextRef": "C_0000949858_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20220401_20220630",
"decimals": "-5",
"first": true,
"lang": null,
"name": "us-gaap:AllocatedShareBasedCompensationExpense",
"reportCount": 1,
"unique": true,
"unitRef": "U_iso4217USD",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "100380 - Disclosure - Common Stock - Restricted Stock Unit Awards - Additional Information (Detail)",
"role": "http://achievelifesciences.com/20220630/taxonomy/role/DisclosureCommonStockRestrictedStockUnitAwardsAdditionalInformationDetail",
"shortName": "Common Stock - Restricted Stock Unit Awards - Additional Information (Detail)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"p",
"ix:continuation",
"body",
"html"
],
"baseRef": "achv-10q_20220630.htm",
"contextRef": "C_0000949858_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20220401_20220630",
"decimals": "-5",
"first": true,
"lang": null,
"name": "us-gaap:AllocatedShareBasedCompensationExpense",
"reportCount": 1,
"unique": true,
"unitRef": "U_iso4217USD",
"xsiNil": "false"
}
},
"R4": {
"firstAnchor": {
"ancestors": [
"p",
"td",
"tr",
"table",
"div",
"body",
"html"
],
"baseRef": "achv-10q_20220630.htm",
"contextRef": "C_0000949858_20220401_20220630",
"decimals": "-3",
"first": true,
"lang": null,
"name": "us-gaap:ResearchAndDevelopmentExpense",
"reportCount": 1,
"unique": true,
"unitRef": "U_iso4217USD",
"xsiNil": "false"
},
"groupType": "statement",
"isDefault": "false",
"longName": "100030 - Statement - Consolidated Statements of Loss and Comprehensive Loss (Unaudited)",
"role": "http://achievelifesciences.com/20220630/taxonomy/role/StatementConsolidatedStatementsOfLossAndComprehensiveLossUnaudited",
"shortName": "Consolidated Statements of Loss and Comprehensive Loss (Unaudited)",
"subGroupType": "",
"uniqueAnchor": {
"ancestors": [
"p",
"td",
"tr",
"table",
"div",
"body",
"html"
],
"baseRef": "achv-10q_20220630.htm",
"contextRef": "C_0000949858_20220401_20220630",
"decimals": "-3",
"first": true,
"lang": null,
"name": "us-gaap:ResearchAndDevelopmentExpense",
"reportCount": 1,
"unique": true,
"unitRef": "U_iso4217USD",
"xsiNil": "false"
}
},
"R40": {
"firstAnchor": {
"ancestors": [
"p",
"td",
"tr",
"table",
"div",
"us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
"ix:continuation",
"body",
"html"
],
"baseRef": "achv-10q_20220630.htm",
"contextRef": "C_0000949858_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20211231",
"decimals": "INF",
"first": true,
"lang": null,
"name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
"reportCount": 1,
"unitRef": "U_xbrlishares",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "100390 - Disclosure - Common Stock - Summary of Restricted Stock Unit Award Activity (Detail)",
"role": "http://achievelifesciences.com/20220630/taxonomy/role/DisclosureCommonStockSummaryOfRestrictedStockUnitAwardActivityDetail",
"shortName": "Common Stock - Summary of Restricted Stock Unit Award Activity (Detail)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"p",
"td",
"tr",
"table",
"div",
"us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
"ix:continuation",
"body",
"html"
],
"baseRef": "achv-10q_20220630.htm",
"contextRef": "C_0000949858_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20220101_20220630",
"decimals": "INF",
"lang": null,
"name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
"reportCount": 1,
"unique": true,
"unitRef": "U_xbrlishares",
"xsiNil": "false"
}
},
"R41": {
"firstAnchor": {
"ancestors": [
"p",
"ix:continuation",
"body",
"html"
],
"baseRef": "achv-10q_20220630.htm",
"contextRef": "C_0000949858_us-gaapSubsidiarySaleOfStockAxis_us-gaapEmployeeStockMember_20220101_20220630",
"decimals": "-5",
"first": true,
"lang": null,
"name": "achv:ShareBasedCompensationMaximumNumberOfSharesAuthorizedToPurchased",
"reportCount": 1,
"unique": true,
"unitRef": "U_xbrlishares",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "100400 - Disclosure - Common Stock - Employee Share Purchase Plan - Additional Information (Detail)",
"role": "http://achievelifesciences.com/20220630/taxonomy/role/DisclosureCommonStockEmployeeSharePurchasePlanAdditionalInformationDetail",
"shortName": "Common Stock - Employee Share Purchase Plan - Additional Information (Detail)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"p",
"ix:continuation",
"body",
"html"
],
"baseRef": "achv-10q_20220630.htm",
"contextRef": "C_0000949858_us-gaapSubsidiarySaleOfStockAxis_us-gaapEmployeeStockMember_20220101_20220630",
"decimals": "-5",
"first": true,
"lang": null,
"name": "achv:ShareBasedCompensationMaximumNumberOfSharesAuthorizedToPurchased",
"reportCount": 1,
"unique": true,
"unitRef": "U_xbrlishares",
"xsiNil": "false"
}
},
"R42": {
"firstAnchor": {
"ancestors": [
"p",
"td",
"tr",
"table",
"div",
"us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
"ix:continuation",
"body",
"html"
],
"baseRef": "achv-10q_20220630.htm",
"contextRef": "C_0000949858_us-gaapClassOfWarrantOrRightAxis_achvWarrantsIssuedInSeptemberTwoThousandSeventeenMember_20220630",
"decimals": "INF",
"first": true,
"lang": null,
"name": "us-gaap:ClassOfWarrantOrRightOutstanding",
"reportCount": 1,
"unique": true,
"unitRef": "U_xbrlishares",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "100410 - Disclosure - Common Stock - Summary of Outstanding Warrants (Detail)",
"role": "http://achievelifesciences.com/20220630/taxonomy/role/DisclosureCommonStockSummaryOfOutstandingWarrantsDetail",
"shortName": "Common Stock - Summary of Outstanding Warrants (Detail)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"p",
"td",
"tr",
"table",
"div",
"us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
"ix:continuation",
"body",
"html"
],
"baseRef": "achv-10q_20220630.htm",
"contextRef": "C_0000949858_us-gaapClassOfWarrantOrRightAxis_achvWarrantsIssuedInSeptemberTwoThousandSeventeenMember_20220630",
"decimals": "INF",
"first": true,
"lang": null,
"name": "us-gaap:ClassOfWarrantOrRightOutstanding",
"reportCount": 1,
"unique": true,
"unitRef": "U_xbrlishares",
"xsiNil": "false"
}
},
"R43": {
"firstAnchor": {
"ancestors": [
"p",
"td",
"tr",
"table",
"div",
"body",
"html"
],
"baseRef": "achv-10q_20220630.htm",
"contextRef": "C_0000949858_20220101_20220630",
"decimals": "-3",
"first": true,
"lang": null,
"name": "us-gaap:ProceedsFromWarrantExercises",
"reportCount": 1,
"unitRef": "U_iso4217USD",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "100420 - Disclosure - Common Stock - Common Stock Warrants - Additional Information (Detail)",
"role": "http://achievelifesciences.com/20220630/taxonomy/role/DisclosureCommonStockCommonStockWarrantsAdditionalInformationDetail",
"shortName": "Common Stock - Common Stock Warrants - Additional Information (Detail)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"p",
"ix:continuation",
"body",
"html"
],
"baseRef": "achv-10q_20220630.htm",
"contextRef": "C_0000949858_us-gaapClassOfWarrantOrRightAxis_achvWarrantsIssuedInDecemberTwoThousandNineteenMember_20220630",
"decimals": "INF",
"lang": null,
"name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
"reportCount": 1,
"unique": true,
"unitRef": "U_xbrlishares",
"xsiNil": "false"
}
},
"R44": {
"firstAnchor": {
"ancestors": [
"p",
"td",
"tr",
"table",
"div",
"srt:ContractualObligationFiscalYearMaturityScheduleTableTextBlock",
"us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
"body",
"html"
],
"baseRef": "achv-10q_20220630.htm",
"contextRef": "C_0000949858_20220630",
"decimals": "-3",
"first": true,
"lang": null,
"name": "us-gaap:ContractualObligation",
"reportCount": 1,
"unique": true,
"unitRef": "U_iso4217USD",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "100430 - Disclosure - Commitments and Contingencies - Summary of Contractual Obligations (Detail)",
"role": "http://achievelifesciences.com/20220630/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfContractualObligationsDetail",
"shortName": "Commitments and Contingencies - Summary of Contractual Obligations (Detail)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"p",
"td",
"tr",
"table",
"div",
"srt:ContractualObligationFiscalYearMaturityScheduleTableTextBlock",
"us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
"body",
"html"
],
"baseRef": "achv-10q_20220630.htm",
"contextRef": "C_0000949858_20220630",
"decimals": "-3",
"first": true,
"lang": null,
"name": "us-gaap:ContractualObligation",
"reportCount": 1,
"unique": true,
"unitRef": "U_iso4217USD",
"xsiNil": "false"
}
},
"R45": {
"firstAnchor": {
"ancestors": [
"p",
"ix:continuation",
"body",
"html"
],
"baseRef": "achv-10q_20220630.htm",
"contextRef": "C_0000949858_20220401_20220630",
"decimals": "0",
"first": true,
"lang": null,
"name": "us-gaap:OperatingLeaseExpense",
"reportCount": 1,
"unique": true,
"unitRef": "U_iso4217USD",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "100440 - Disclosure - Commitments and Contingencies - Additional Information (Detail)",
"role": "http://achievelifesciences.com/20220630/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail",
"shortName": "Commitments and Contingencies - Additional Information (Detail)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"p",
"ix:continuation",
"body",
"html"
],
"baseRef": "achv-10q_20220630.htm",
"contextRef": "C_0000949858_20220401_20220630",
"decimals": "0",
"first": true,
"lang": null,
"name": "us-gaap:OperatingLeaseExpense",
"reportCount": 1,
"unique": true,
"unitRef": "U_iso4217USD",
"xsiNil": "false"
}
},
"R46": {
"firstAnchor": {
"ancestors": [
"p",
"td",
"tr",
"table",
"div",
"us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
"ix:continuation",
"body",
"html"
],
"baseRef": "achv-10q_20220630.htm",
"contextRef": "C_0000949858_us-gaapTypeOfArrangementAxis_achvVancouverOfficeOperatingLeaseMember_20220630",
"decimals": "-3",
"first": true,
"lang": null,
"name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
"reportCount": 1,
"unique": true,
"unitRef": "U_iso4217USD",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "100450 - Disclosure - Commitments and Contingencies - Summary of Future Minimum Annual Lease Payments (Detail)",
"role": "http://achievelifesciences.com/20220630/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfFutureMinimumAnnualLeasePaymentsDetail",
"shortName": "Commitments and Contingencies - Summary of Future Minimum Annual Lease Payments (Detail)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"p",
"td",
"tr",
"table",
"div",
"us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
"ix:continuation",
"body",
"html"
],
"baseRef": "achv-10q_20220630.htm",
"contextRef": "C_0000949858_us-gaapTypeOfArrangementAxis_achvVancouverOfficeOperatingLeaseMember_20220630",
"decimals": "-3",
"first": true,
"lang": null,
"name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
"reportCount": 1,
"unique": true,
"unitRef": "U_iso4217USD",
"xsiNil": "false"
}
},
"R47": {
"firstAnchor": {
"ancestors": [
"p",
"td",
"tr",
"table",
"div",
"achv:ScheduleOfSupplementalCashFlowsInformationRelatedToLeasesTableTextBlock",
"ix:continuation",
"body",
"html"
],
"baseRef": "achv-10q_20220630.htm",
"contextRef": "C_0000949858_20220401_20220630",
"decimals": "-3",
"first": true,
"lang": null,
"name": "us-gaap:OperatingLeasePayments",
"reportCount": 1,
"unique": true,
"unitRef": "U_iso4217USD",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "100460 - Disclosure - Commitments and Contingencies - Summary of Other Information Related to Leases (Detail)",
"role": "http://achievelifesciences.com/20220630/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfOtherInformationRelatedToLeasesDetail",
"shortName": "Commitments and Contingencies - Summary of Other Information Related to Leases (Detail)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"p",
"td",
"tr",
"table",
"div",
"achv:ScheduleOfSupplementalCashFlowsInformationRelatedToLeasesTableTextBlock",
"ix:continuation",
"body",
"html"
],
"baseRef": "achv-10q_20220630.htm",
"contextRef": "C_0000949858_20220401_20220630",
"decimals": "-3",
"first": true,
"lang": null,
"name": "us-gaap:OperatingLeasePayments",
"reportCount": 1,
"unique": true,
"unitRef": "U_iso4217USD",
"xsiNil": "false"
}
},
"R5": {
"firstAnchor": {
"ancestors": [
"p",
"td",
"tr",
"table",
"div",
"body",
"html"
],
"baseRef": "achv-10q_20220630.htm",
"contextRef": "C_0000949858_20220101_20220630",
"decimals": "-3",
"first": true,
"lang": null,
"name": "us-gaap:ProfitLoss",
"reportCount": 1,
"unique": true,
"unitRef": "U_iso4217USD",
"xsiNil": "false"
},
"groupType": "statement",
"isDefault": "false",
"longName": "100040 - Statement - Consolidated Statements of Cash Flows (Unaudited)",
"role": "http://achievelifesciences.com/20220630/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited",
"shortName": "Consolidated Statements of Cash Flows (Unaudited)",
"subGroupType": "",
"uniqueAnchor": {
"ancestors": [
"p",
"td",
"tr",
"table",
"div",
"body",
"html"
],
"baseRef": "achv-10q_20220630.htm",
"contextRef": "C_0000949858_20220101_20220630",
"decimals": "-3",
"first": true,
"lang": null,
"name": "us-gaap:ProfitLoss",
"reportCount": 1,
"unique": true,
"unitRef": "U_iso4217USD",
"xsiNil": "false"
}
},
"R6": {
"firstAnchor": {
"ancestors": [
"p",
"td",
"tr",
"table",
"div",
"body",
"html"
],
"baseRef": "achv-10q_20220630.htm",
"contextRef": "C_0000949858_20201231",
"decimals": "-3",
"first": true,
"lang": null,
"name": "us-gaap:StockholdersEquity",
"reportCount": 1,
"unitRef": "U_iso4217USD",
"xsiNil": "false"
},
"groupType": "statement",
"isDefault": "false",
"longName": "100050 - Statement - Consolidated Statements of Stockholder's Equity (Unaudited)",
"role": "http://achievelifesciences.com/20220630/taxonomy/role/StatementConsolidatedStatementsOfStockholderSEquityUnaudited",
"shortName": "Consolidated Statements of Stockholder's Equity (Unaudited)",
"subGroupType": "",
"uniqueAnchor": {
"ancestors": [
"p",
"td",
"tr",
"table",
"div",
"body",
"html"
],
"baseRef": "achv-10q_20220630.htm",
"contextRef": "C_0000949858_20210101_20210331",
"decimals": "-3",
"lang": null,
"name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
"reportCount": 1,
"unique": true,
"unitRef": "U_iso4217USD",
"xsiNil": "false"
}
},
"R7": {
"firstAnchor": {
"ancestors": [
"body",
"html"
],
"baseRef": "achv-10q_20220630.htm",
"contextRef": "C_0000949858_20220101_20220630",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "100060 - Disclosure - Nature of Business, Basis of Presentation and Going Concern Uncertainty",
"role": "http://achievelifesciences.com/20220630/taxonomy/role/DisclosureNatureOfBusinessBasisOfPresentationAndGoingConcernUncertainty",
"shortName": "Nature of Business, Basis of Presentation and Going Concern Uncertainty",
"subGroupType": "",
"uniqueAnchor": {
"ancestors": [
"body",
"html"
],
"baseRef": "achv-10q_20220630.htm",
"contextRef": "C_0000949858_20220101_20220630",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R8": {
"firstAnchor": {
"ancestors": [
"body",
"html"
],
"baseRef": "achv-10q_20220630.htm",
"contextRef": "C_0000949858_20220101_20220630",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:SignificantAccountingPoliciesTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "100070 - Disclosure - Accounting Policies",
"role": "http://achievelifesciences.com/20220630/taxonomy/role/DisclosureAccountingPolicies",
"shortName": "Accounting Policies",
"subGroupType": "",
"uniqueAnchor": {
"ancestors": [
"body",
"html"
],
"baseRef": "achv-10q_20220630.htm",
"contextRef": "C_0000949858_20220101_20220630",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:SignificantAccountingPoliciesTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R9": {
"firstAnchor": {
"ancestors": [
"body",
"html"
],
"baseRef": "achv-10q_20220630.htm",
"contextRef": "C_0000949858_20220101_20220630",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "achv:GovernmentGrantsTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "100080 - Disclosure - Government Grant",
"role": "http://achievelifesciences.com/20220630/taxonomy/role/DisclosureGovernmentGrant",
"shortName": "Government Grant",
"subGroupType": "",
"uniqueAnchor": {
"ancestors": [
"body",
"html"
],
"baseRef": "achv-10q_20220630.htm",
"contextRef": "C_0000949858_20220101_20220630",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "achv:GovernmentGrantsTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
}
},
"segmentCount": 58,
"tag": {
"achv_AccruedInterestOnSVBConvertibleDebt": {
"auth_ref": [
],
"calculation": {
"http://achievelifesciences.com/20220630/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited": {
"order": 10130.0,
"parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
"weight": -1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Accrued interest on SVB convertible debt.",
"label": "Accrued Interest On S V B Convertible Debt",
"negatedLabel": "Accrued interest on SVB convertible debt [note 7]"
}
}
},
"localname": "AccruedInterestOnSVBConvertibleDebt",
"nsuri": "http://achievelifesciences.com/20220630",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited"
],
"xbrltype": "monetaryItemType"
},
"achv_AccruedLiabilitiesClinicalCurrent": {
"auth_ref": [
],
"calculation": {
"http://achievelifesciences.com/20220630/taxonomy/role/StatementConsolidatedBalanceSheetsUnaudited": {
"order": 10150.0,
"parentTag": "us-gaap_LiabilitiesCurrent",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Accrued liabilities clinical current.",
"label": "Accrued Liabilities Clinical Current",
"terseLabel": "Accrued clinical liabilities"
}
}
},
"localname": "AccruedLiabilitiesClinicalCurrent",
"nsuri": "http://achievelifesciences.com/20220630",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/StatementConsolidatedBalanceSheetsUnaudited"
],
"xbrltype": "monetaryItemType"
},
"achv_AdjustmentsToAdditionalPaidInCapitalSharesIssuedThroughAtTheMarketOffering": {
"auth_ref": [
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Adjustments to additional paid in capital shares issued through at-the-market offering.",
"label": "Adjustments To Additional Paid In Capital Shares Issued Through At The Market Offering",
"terseLabel": "Shares issued from purchase agreement with Virtu"
}
}
},
"localname": "AdjustmentsToAdditionalPaidInCapitalSharesIssuedThroughAtTheMarketOffering",
"nsuri": "http://achievelifesciences.com/20220630",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/StatementConsolidatedStatementsOfStockholderSEquityUnaudited"
],
"xbrltype": "monetaryItemType"
},
"achv_AdjustmentsToAdditionalPaidInCapitalSharesIssuedThroughAtTheMarketOfferingShares": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Adjustments to additional paid in capital shares issued through at-the-market offering shares.",
"label": "Adjustments To Additional Paid In Capital Shares Issued Through At The Market Offering Shares",
"terseLabel": "Shares issued from purchase agreement with Virtu, Shares"
}
}
},
"localname": "AdjustmentsToAdditionalPaidInCapitalSharesIssuedThroughAtTheMarketOfferingShares",
"nsuri": "http://achievelifesciences.com/20220630",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/StatementConsolidatedStatementsOfStockholderSEquityUnaudited"
],
"xbrltype": "sharesItemType"
},
"achv_AfterEighteenMonthAnniversaryMember": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "After eighteen month anniversary.",
"label": "After Eighteen Month Anniversary [Member]",
"terseLabel": "After 18-Month Anniversary [Member]"
}
}
},
"localname": "AfterEighteenMonthAnniversaryMember",
"nsuri": "http://achievelifesciences.com/20220630",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureConvertibleDebtAdditionalInformationDetails"
],
"xbrltype": "domainItemType"
},
"achv_AmendmentToLicenseAgreementMember": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Amendment to license agreement.",
"label": "Amendment To License Agreement [Member]",
"terseLabel": "Amendment to the University of Bristol License Agreement [Member]"
}
}
},
"localname": "AmendmentToLicenseAgreementMember",
"nsuri": "http://achievelifesciences.com/20220630",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetail"
],
"xbrltype": "domainItemType"
},
"achv_AreaOfOfficeSpaceLeased": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Area of office space leased.",
"label": "Area Of Office Space Leased",
"terseLabel": "Area of office space leased"
}
}
},
"localname": "AreaOfOfficeSpaceLeased",
"nsuri": "http://achievelifesciences.com/20220630",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
],
"xbrltype": "areaItemType"
},
"achv_AtMarketSalesAgreementMember": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "At-the-Market Sales Agreement.",
"label": "At Market Sales Agreement [Member]",
"terseLabel": "At-the-Market Sales Agreement [Member]"
}
}
},
"localname": "AtMarketSalesAgreementMember",
"nsuri": "http://achievelifesciences.com/20220630",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureCommonStockIssuedAndOutstandingSharesAdditionalInformationDetail"
],
"xbrltype": "domainItemType"
},
"achv_BeforeEighteenMonthAnniversaryMember": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Before eighteen month anniversary.",
"label": "Before Eighteen Month Anniversary [Member]",
"terseLabel": "Before 18-Month Anniversary [Member]"
}
}
},
"localname": "BeforeEighteenMonthAnniversaryMember",
"nsuri": "http://achievelifesciences.com/20220630",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureConvertibleDebtAdditionalInformationDetails"
],
"xbrltype": "domainItemType"
},
"achv_BoardOfDirectorsMember": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Board of directors.",
"label": "Board Of Directors [Member]",
"terseLabel": "Board of Directors [Member]"
}
}
},
"localname": "BoardOfDirectorsMember",
"nsuri": "http://achievelifesciences.com/20220630",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureCommonStockStockOptionsAdditionalInformationDetail"
],
"xbrltype": "domainItemType"
},
"achv_ClassOfWarrantsOrRightExpirationDate": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Class of warrants or right expiration date.",
"label": "Class Of Warrants Or Right Expiration Date",
"terseLabel": "Expiration Date"
}
}
},
"localname": "ClassOfWarrantsOrRightExpirationDate",
"nsuri": "http://achievelifesciences.com/20220630",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureCommonStockSummaryOfOutstandingWarrantsDetail"
],
"xbrltype": "gYearMonthItemType"
},
"achv_CommonStockAggregateMaximumOfferingAmount": {
"auth_ref": [
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Common stock aggregate maximum offering amount.",
"label": "Common Stock Aggregate Maximum Offering Amount",
"positiveLabel": "Common stock aggregate maximum offering amount"
}
}
},
"localname": "CommonStockAggregateMaximumOfferingAmount",
"nsuri": "http://achievelifesciences.com/20220630",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureCommonStockIssuedAndOutstandingSharesAdditionalInformationDetail"
],
"xbrltype": "monetaryItemType"
},
"achv_CommonStockSharesAvailableForFutureGrant": {
"auth_ref": [
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Common stock, shares available for future grant.",
"label": "Common Stock Shares Available For Future Grant",
"terseLabel": "Common stock available for sale under offering"
}
}
},
"localname": "CommonStockSharesAvailableForFutureGrant",
"nsuri": "http://achievelifesciences.com/20220630",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureCommonStockIssuedAndOutstandingSharesAdditionalInformationDetail"
],
"xbrltype": "monetaryItemType"
},
"achv_ContingentConvertibleDebtAgreementMember": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Contingent convertible debt agreement.",
"label": "Contingent Convertible Debt Agreement [Member]",
"terseLabel": "Contingent Convertible Debt Agreement [Member]"
}
}
},
"localname": "ContingentConvertibleDebtAgreementMember",
"nsuri": "http://achievelifesciences.com/20220630",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureConvertibleDebtAdditionalInformationDetails"
],
"xbrltype": "domainItemType"
},
"achv_ContractualObligationFiscalYearMaturityScheduleLineItems": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Contractual obligation fiscal year maturity schedule.",
"label": "Contractual Obligation Fiscal Year Maturity Schedule [Line Items]",
"terseLabel": "Contractual Obligation Fiscal Year Maturity Schedule [Line Items]"
}
}
},
"localname": "ContractualObligationFiscalYearMaturityScheduleLineItems",
"nsuri": "http://achievelifesciences.com/20220630",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfContractualObligationsDetail"
],
"xbrltype": "stringItemType"
},
"achv_ContractualObligationFiscalYearMaturityScheduleTable": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Contractual obligation fiscal year maturity schedule table.",
"label": "Contractual Obligation Fiscal Year Maturity Schedule [Table]",
"terseLabel": "Contractual Obligation Fiscal Year Maturity Schedule [Table]"
}
}
},
"localname": "ContractualObligationFiscalYearMaturityScheduleTable",
"nsuri": "http://achievelifesciences.com/20220630",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfContractualObligationsDetail"
],
"xbrltype": "stringItemType"
},
"achv_ConvertibleDebtLineItems": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Convertible debt.",
"label": "Convertible Debt [Line Items]",
"terseLabel": "Convertible Debt [Line Items]"
}
}
},
"localname": "ConvertibleDebtLineItems",
"nsuri": "http://achievelifesciences.com/20220630",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureConvertibleDebtAdditionalInformationDetails"
],
"xbrltype": "stringItemType"
},
"achv_ConvertibleDebtTable": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Convertible debt.",
"label": "Convertible Debt [Table]",
"terseLabel": "Convertible Debt [Table]"
}
}
},
"localname": "ConvertibleDebtTable",
"nsuri": "http://achievelifesciences.com/20220630",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureConvertibleDebtAdditionalInformationDetails"
],
"xbrltype": "stringItemType"
},
"achv_DebtInstrumentMaturityDateExtension": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Debt instrument maturity date extension.",
"label": "Debt Instrument Maturity Date Extension",
"terseLabel": "Extendable maturity date"
}
}
},
"localname": "DebtInstrumentMaturityDateExtension",
"nsuri": "http://achievelifesciences.com/20220630",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureConvertibleDebtAdditionalInformationDetails"
],
"xbrltype": "dateItemType"
},
"achv_DebtInstrumentWithdrawalAmount": {
"auth_ref": [
],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Debt instrument withdrawal amount.",
"label": "Debt Instrument Withdrawal Amount",
"terseLabel": "Drawn amount"
}
}
},
"localname": "DebtInstrumentWithdrawalAmount",
"nsuri": "http://achievelifesciences.com/20220630",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureConvertibleDebtAdditionalInformationDetails"
],
"xbrltype": "monetaryItemType"
},
"achv_EmployeesAndConsultantsMember": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Employees and consultants.",
"label": "Employees And Consultants [Member]",
"terseLabel": "Employees and Consultants [Member]"
}
}
},
"localname": "EmployeesAndConsultantsMember",
"nsuri": "http://achievelifesciences.com/20220630",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureCommonStockStockOptionsAdditionalInformationDetail"
],
"xbrltype": "domainItemType"
},
"achv_ExtendedPercentageOfAggregatePrincipalAmountOfTermLoanAdvances": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Extended percentage of aggregate principal amount of term loan advances.",
"label": "Extended Percentage Of Aggregate Principal Amount Of Term Loan Advances",
"terseLabel": "Aggregate principal amount of term loan advances extended percentage"
}
}
},
"localname": "ExtendedPercentageOfAggregatePrincipalAmountOfTermLoanAdvances",
"nsuri": "http://achievelifesciences.com/20220630",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureConvertibleDebtAdditionalInformationDetails"
],
"xbrltype": "percentItemType"
},
"achv_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearTwo": {
"auth_ref": [
],
"calculation": {
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureIntangiblesEstimatedFutureAmortizationExpenseRelatedToIntangibleAssetsDetail": {
"order": 10040.0,
"parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Finite lived intangible assets amortization expense after year two.",
"label": "Finite Lived Intangible Assets Amortization Expense After Year Two",
"terseLabel": "Thereafter"
}
}
},
"localname": "FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearTwo",
"nsuri": "http://achievelifesciences.com/20220630",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureIntangiblesEstimatedFutureAmortizationExpenseRelatedToIntangibleAssetsDetail"
],
"xbrltype": "monetaryItemType"
},
"achv_GovernmentGrantLineItems": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Government grant.",
"label": "Government Grant [Line Items]",
"terseLabel": "Government Grant [Line Items]"
}
}
},
"localname": "GovernmentGrantLineItems",
"nsuri": "http://achievelifesciences.com/20220630",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureGovernmentGrantAdditionalInformationDetails"
],
"xbrltype": "stringItemType"
},
"achv_GovernmentGrantTable": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Government grant.",
"label": "Government Grant [Table]",
"terseLabel": "Government Grant [Table]"
}
}
},
"localname": "GovernmentGrantTable",
"nsuri": "http://achievelifesciences.com/20220630",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureGovernmentGrantAdditionalInformationDetails"
],
"xbrltype": "stringItemType"
},
"achv_GovernmentGrantsTextBlock": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Government grants.",
"label": "Government Grants [Text Block]",
"terseLabel": "Government Grant"
}
}
},
"localname": "GovernmentGrantsTextBlock",
"nsuri": "http://achievelifesciences.com/20220630",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureGovernmentGrant"
],
"xbrltype": "textBlockItemType"
},
"achv_GrantAwarded": {
"auth_ref": [
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Grant awarded.",
"label": "Grant Awarded",
"terseLabel": "Grant awarded"
}
}
},
"localname": "GrantAwarded",
"nsuri": "http://achievelifesciences.com/20220630",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureGovernmentGrantAdditionalInformationDetails"
],
"xbrltype": "monetaryItemType"
},
"achv_GrossProceedsFromIssuanceOfCommonStock": {
"auth_ref": [
],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Gross proceeds from issuance of common stock.",
"label": "Gross Proceeds From Issuance Of Common Stock",
"terseLabel": "Gross proceeds from issuance of common stock"
}
}
},
"localname": "GrossProceedsFromIssuanceOfCommonStock",
"nsuri": "http://achievelifesciences.com/20220630",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureCommonStockIssuedAndOutstandingSharesAdditionalInformationDetail"
],
"xbrltype": "monetaryItemType"
},
"achv_IncreaseDecreaseInAccruedClinicalLiabilities": {
"auth_ref": [
],
"calculation": {
"http://achievelifesciences.com/20220630/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited": {
"order": 10180.0,
"parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Increase decrease in accrued clinical liabilities.",
"label": "Increase Decrease In Accrued Clinical Liabilities",
"terseLabel": "Accrued clinical liabilities"
}
}
},
"localname": "IncreaseDecreaseInAccruedClinicalLiabilities",
"nsuri": "http://achievelifesciences.com/20220630",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited"
],
"xbrltype": "monetaryItemType"
},
"achv_IncreaseDecreaseInGrantsReceivable": {
"auth_ref": [
],
"calculation": {
"http://achievelifesciences.com/20220630/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited": {
"order": 10140.0,
"parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
"weight": -1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Increase decrease in grants receivable.",
"label": "Increase Decrease In Grants Receivable",
"negatedLabel": "Grant receivable [note 3]"
}
}
},
"localname": "IncreaseDecreaseInGrantsReceivable",
"nsuri": "http://achievelifesciences.com/20220630",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited"
],
"xbrltype": "monetaryItemType"
},
"achv_IncreaseDecreaseInLeaseObligations": {
"auth_ref": [
],
"calculation": {
"http://achievelifesciences.com/20220630/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited": {
"order": 10200.0,
"parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
"weight": -1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Increase decrease in lease obligations.",
"label": "Increase Decrease In Lease Obligations",
"negatedLabel": "Lease obligation [note 9]"
}
}
},
"localname": "IncreaseDecreaseInLeaseObligations",
"nsuri": "http://achievelifesciences.com/20220630",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited"
],
"xbrltype": "monetaryItemType"
},
"achv_IndemnificationExpense": {
"auth_ref": [
],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Indemnification expense.",
"label": "Indemnification Expense",
"terseLabel": "Expenses related to indemnification issues"
}
}
},
"localname": "IndemnificationExpense",
"nsuri": "http://achievelifesciences.com/20220630",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
],
"xbrltype": "monetaryItemType"
},
"achv_LeaseAgreementCommencementDate": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Lease agreement commencement date.",
"label": "Lease Agreement Commencement Date",
"terseLabel": "Lease agreement commencement date"
}
}
},
"localname": "LeaseAgreementCommencementDate",
"nsuri": "http://achievelifesciences.com/20220630",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
],
"xbrltype": "dateItemType"
},
"achv_LeaseSecurityDepositAnnualPayment": {
"auth_ref": [
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Lease security deposit annual payment.",
"label": "Lease Security Deposit Annual Payment",
"terseLabel": "Lease, security deposit, annual payment"
}
}
},
"localname": "LeaseSecurityDepositAnnualPayment",
"nsuri": "http://achievelifesciences.com/20220630",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
],
"xbrltype": "monetaryItemType"
},
"achv_LeaseSecurityDepositThereafter": {
"auth_ref": [
],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Lease security deposit thereafter.",
"label": "Lease Security Deposit Thereafter",
"terseLabel": "Lease, security deposit payment remaining amount"
}
}
},
"localname": "LeaseSecurityDepositThereafter",
"nsuri": "http://achievelifesciences.com/20220630",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
],
"xbrltype": "monetaryItemType"
},
"achv_LeaseSecurityDepositYearOne": {
"auth_ref": [
],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Lease security deposit year one.",
"label": "Lease Security Deposit Year One",
"terseLabel": "Lease, security deposit payment first anniversary"
}
}
},
"localname": "LeaseSecurityDepositYearOne",
"nsuri": "http://achievelifesciences.com/20220630",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
],
"xbrltype": "monetaryItemType"
},
"achv_LeaseSecurityDepositYearTwo": {
"auth_ref": [
],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Lease security deposit year two.",
"label": "Lease Security Deposit Year Two",
"terseLabel": "Lease, security deposit payment two anniversary"
}
}
},
"localname": "LeaseSecurityDepositYearTwo",
"nsuri": "http://achievelifesciences.com/20220630",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
],
"xbrltype": "monetaryItemType"
},
"achv_MaturityPeriodOfSecurities": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Maturity period of securities.",
"label": "Maturity Period Of Securities",
"terseLabel": "Maturity period of securities"
}
}
},
"localname": "MaturityPeriodOfSecurities",
"nsuri": "http://achievelifesciences.com/20220630",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetail"
],
"xbrltype": "durationItemType"
},
"achv_MaximumMaturityPeriodOfCashAndCashEquivalents": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Maximum maturity period of cash and cash equivalents.",
"label": "Maximum Maturity Period Of Cash And Cash Equivalents",
"terseLabel": "Maximum maturity period of cash and cash equivalents"
}
}
},
"localname": "MaximumMaturityPeriodOfCashAndCashEquivalents",
"nsuri": "http://achievelifesciences.com/20220630",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetail"
],
"xbrltype": "durationItemType"
},
"achv_MaximumRequiredPaymentUnderLicenseAgreementUponCompletionOfVariousMilestones": {
"auth_ref": [
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Maximum required payment under license agreement upon completion of various milestones.",
"label": "Maximum Required Payment Under License Agreement Upon Completion Of Various Milestones",
"terseLabel": "Maximum amount payable under license agreement, tied to milestones"
}
}
},
"localname": "MaximumRequiredPaymentUnderLicenseAgreementUponCompletionOfVariousMilestones",
"nsuri": "http://achievelifesciences.com/20220630",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetail"
],
"xbrltype": "monetaryItemType"
},
"achv_May2021PublicOfferingMember": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "May 2021 public offering.",
"label": "May2021 Public Offering [Member]",
"terseLabel": "May 2021 Public Offering [Member]"
}
}
},
"localname": "May2021PublicOfferingMember",
"nsuri": "http://achievelifesciences.com/20220630",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited",
"http://achievelifesciences.com/20220630/taxonomy/role/StatementConsolidatedStatementsOfStockholderSEquityUnaudited"
],
"xbrltype": "domainItemType"
},
"achv_MayTwoThousandTwentyOnePublicOfferingMember": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "May two thousand twenty one public offering member.",
"label": "May Two Thousand Twenty One Public Offering [Member]",
"terseLabel": "May 2021 Public Offering [Member]"
}
}
},
"localname": "MayTwoThousandTwentyOnePublicOfferingMember",
"nsuri": "http://achievelifesciences.com/20220630",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureCommonStockIssuedAndOutstandingSharesAdditionalInformationDetail"
],
"xbrltype": "domainItemType"
},
"achv_MinimumMarketCapitalization": {
"auth_ref": [
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Minimum market capitalization.",
"label": "Minimum Market Capitalization",
"terseLabel": "Minimum market capitalization"
}
}
},
"localname": "MinimumMarketCapitalization",
"nsuri": "http://achievelifesciences.com/20220630",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureConvertibleDebtAdditionalInformationDetails"
],
"xbrltype": "monetaryItemType"
},
"achv_MonthlyBaseRentalPayments": {
"auth_ref": [
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Monthly base rental payments.",
"label": "Monthly Base Rental Payments",
"terseLabel": "Monthly base rent"
}
}
},
"localname": "MonthlyBaseRentalPayments",
"nsuri": "http://achievelifesciences.com/20220630",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
],
"xbrltype": "monetaryItemType"
},
"achv_MonthlyBaseRentalPaymentsMaximumAnnualIncrease": {
"auth_ref": [
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Monthly base rental payments maximum annual increase.",
"label": "Monthly Base Rental Payments Maximum Annual Increase",
"terseLabel": "Monthly base rent, maximum annual increase"
}
}
},
"localname": "MonthlyBaseRentalPaymentsMaximumAnnualIncrease",
"nsuri": "http://achievelifesciences.com/20220630",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
],
"xbrltype": "monetaryItemType"
},
"achv_NationalInstituteOnDrugAbuseMember": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "National Institute on Drug Abuse.",
"label": "National Institute On Drug Abuse [Member]",
"terseLabel": "NIDA"
}
}
},
"localname": "NationalInstituteOnDrugAbuseMember",
"nsuri": "http://achievelifesciences.com/20220630",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureGovernmentGrantAdditionalInformationDetails"
],
"xbrltype": "domainItemType"
},
"achv_NationalInstitutesOfHealthMember": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "National Institutes Of Health.",
"label": "National Institutes Of Health [Member]",
"terseLabel": "NIH"
}
}
},
"localname": "NationalInstitutesOfHealthMember",
"nsuri": "http://achievelifesciences.com/20220630",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureGovernmentGrantAdditionalInformationDetails"
],
"xbrltype": "domainItemType"
},
"achv_NewEmployeeInducementGrantsMember": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "New employee inducement grants.",
"label": "New Employee Inducement Grants [Member]",
"terseLabel": "New Employee Inducement Grants [Member]"
}
}
},
"localname": "NewEmployeeInducementGrantsMember",
"nsuri": "http://achievelifesciences.com/20220630",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureCommonStockStockOptionsAdditionalInformationDetail"
],
"xbrltype": "domainItemType"
},
"achv_NonConvertibleTermLoansMember": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Non-convertible term loans.",
"label": "Non Convertible Term Loans [Member]",
"terseLabel": "Non-Convertible Term Loans [Member]"
}
}
},
"localname": "NonConvertibleTermLoansMember",
"nsuri": "http://achievelifesciences.com/20220630",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureConvertibleDebtAdditionalInformationDetails"
],
"xbrltype": "domainItemType"
},
"achv_ORCAV1ClinicalStudyCostsMember": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "ORCA-V1 Clinical study costs.",
"label": "O R C A V1 Clinical Study Costs [Member]",
"terseLabel": "ORCA-V1 Clinical Study Costs"
}
}
},
"localname": "ORCAV1ClinicalStudyCostsMember",
"nsuri": "http://achievelifesciences.com/20220630",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureGovernmentGrantAdditionalInformationDetails"
],
"xbrltype": "domainItemType"
},
"achv_OperatingLeaseConstructionAllowance": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Operating lease construction allowance.",
"label": "Operating Lease Construction Allowance",
"terseLabel": "Construction allowance"
}
}
},
"localname": "OperatingLeaseConstructionAllowance",
"nsuri": "http://achievelifesciences.com/20220630",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
],
"xbrltype": "monetaryItemType"
},
"achv_OperatingLeaseInitialMonthlyBaseRentExpenses": {
"auth_ref": [
],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Operating lease, initial monthly base rent expenses.",
"label": "Operating Lease Initial Monthly Base Rent Expenses",
"terseLabel": "Operating lease, initial monthly base rent expenses"
}
}
},
"localname": "OperatingLeaseInitialMonthlyBaseRentExpenses",
"nsuri": "http://achievelifesciences.com/20220630",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
],
"xbrltype": "monetaryItemType"
},
"achv_OperatingLeaseRevisedMonthlyBaseRentExpenses": {
"auth_ref": [
],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Operating lease, revised monthly base rent expenses.",
"label": "Operating Lease Revised Monthly Base Rent Expenses",
"terseLabel": "Operating lease, revised monthly base rent expenses"
}
}
},
"localname": "OperatingLeaseRevisedMonthlyBaseRentExpenses",
"nsuri": "http://achievelifesciences.com/20220630",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
],
"xbrltype": "monetaryItemType"
},
"achv_OtherAssetsAndRestrictedCash": {
"auth_ref": [
],
"calculation": {
"http://achievelifesciences.com/20220630/taxonomy/role/StatementConsolidatedBalanceSheetsUnaudited": {
"order": 10200.0,
"parentTag": "us-gaap_Assets",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Other assets and restricted cash.",
"label": "Other Assets And Restricted Cash",
"terseLabel": "Other assets and restricted cash [note 6]"
}
}
},
"localname": "OtherAssetsAndRestrictedCash",
"nsuri": "http://achievelifesciences.com/20220630",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/StatementConsolidatedBalanceSheetsUnaudited"
],
"xbrltype": "monetaryItemType"
},
"achv_PaymentsUnderLicenseAgreement": {
"auth_ref": [
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Payments under license agreement.",
"label": "Payments Under License Agreement",
"terseLabel": "Payments under license agreement"
}
}
},
"localname": "PaymentsUnderLicenseAgreement",
"nsuri": "http://achievelifesciences.com/20220630",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetail"
],
"xbrltype": "monetaryItemType"
},
"achv_PikeMember": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Pike.",
"label": "Pike [Member]",
"terseLabel": "Pike [Member]"
}
}
},
"localname": "PikeMember",
"nsuri": "http://achievelifesciences.com/20220630",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
],
"xbrltype": "domainItemType"
},
"achv_PreferredStockSharesDesignated": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Preferred stock shares designated.",
"label": "Preferred Stock Shares Designated",
"terseLabel": "Preferred stock, shares designated"
}
}
},
"localname": "PreferredStockSharesDesignated",
"nsuri": "http://achievelifesciences.com/20220630",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/StatementConsolidatedBalanceSheetsParentheticalUnaudited"
],
"xbrltype": "sharesItemType"
},
"achv_PrimeRateMinusOnePercentageMember": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Prime rate minus one percentage.",
"label": "Prime Rate Minus One Percentage [Member]",
"terseLabel": "Prime Rate Minus 1.0% [Member]"
}
}
},
"localname": "PrimeRateMinusOnePercentageMember",
"nsuri": "http://achievelifesciences.com/20220630",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureConvertibleDebtAdditionalInformationDetails"
],
"xbrltype": "domainItemType"
},
"achv_ProceedsFromAtMarketOffering": {
"auth_ref": [
],
"calculation": {
"http://achievelifesciences.com/20220630/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited": {
"order": 10050.0,
"parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Proceeds from At-the Market Offering.",
"label": "Proceeds From At Market Offering",
"terseLabel": "Proceeds from ATM, net of issuance costs [note 8[b]]"
}
}
},
"localname": "ProceedsFromAtMarketOffering",
"nsuri": "http://achievelifesciences.com/20220630",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited"
],
"xbrltype": "monetaryItemType"
},
"achv_ProceedsFromIssuanceOfCommonStockGross": {
"auth_ref": [
],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Proceeds from issuance of common stock gross.",
"label": "Proceeds From Issuance Of Common Stock Gross",
"terseLabel": "Gross proceeds"
}
}
},
"localname": "ProceedsFromIssuanceOfCommonStockGross",
"nsuri": "http://achievelifesciences.com/20220630",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureCommonStockIssuedAndOutstandingSharesAdditionalInformationDetail"
],
"xbrltype": "monetaryItemType"
},
"achv_ResearchAndDevelopmentExpensesIncreaseDecrease": {
"auth_ref": [
],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Research and development expenses increase (decrease).",
"label": "Research And Development Expenses Increase Decrease",
"negatedLabel": "Reduction in R&D expense"
}
}
},
"localname": "ResearchAndDevelopmentExpensesIncreaseDecrease",
"nsuri": "http://achievelifesciences.com/20220630",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureGovernmentGrantAdditionalInformationDetails"
],
"xbrltype": "monetaryItemType"
},
"achv_RestrictedCashMember": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Restricted cash.",
"label": "Restricted Cash [Member]",
"terseLabel": "Restricted cash [Member]"
}
}
},
"localname": "RestrictedCashMember",
"nsuri": "http://achievelifesciences.com/20220630",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAssetsMeasuredAtFairValueOnRecurringBasisDetail"
],
"xbrltype": "domainItemType"
},
"achv_RightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Right-of-use assets obtained in exchange for lease obligations.",
"label": "Right Of Use Assets Obtained In Exchange For Lease Obligations [Abstract]",
"terseLabel": "Right-of-use assets obtained in exchange for lease obligations:"
}
}
},
"localname": "RightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract",
"nsuri": "http://achievelifesciences.com/20220630",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfOtherInformationRelatedToLeasesDetail"
],
"xbrltype": "stringItemType"
},
"achv_ScheduleOfSupplementalCashFlowsInformationRelatedToLeasesTableTextBlock": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Schedule of supplemental cash flows information related to leases.",
"label": "Schedule Of Supplemental Cash Flows Information Related To Leases Table [Text Block]",
"terseLabel": "Summary of Other Information Related to Leases"
}
}
},
"localname": "ScheduleOfSupplementalCashFlowsInformationRelatedToLeasesTableTextBlock",
"nsuri": "http://achievelifesciences.com/20220630",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureCommitmentsAndContingenciesTables"
],
"xbrltype": "textBlockItemType"
},
"achv_SeattleOfficeOperatingLeaseMember": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Seattle office operating lease.",
"label": "Seattle Office Operating Lease [Member]",
"terseLabel": "Seattle Lease Arrangement [Member]"
}
}
},
"localname": "SeattleOfficeOperatingLeaseMember",
"nsuri": "http://achievelifesciences.com/20220630",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
],
"xbrltype": "domainItemType"
},
"achv_SeriesAConvertiblePreferredStockMember": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Series A convertible preferred stock.",
"label": "Series A Convertible Preferred Stock [Member]",
"terseLabel": "Series A Convertible Preferred Stock [Member]"
}
}
},
"localname": "SeriesAConvertiblePreferredStockMember",
"nsuri": "http://achievelifesciences.com/20220630",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/StatementConsolidatedBalanceSheetsParentheticalUnaudited",
"http://achievelifesciences.com/20220630/taxonomy/role/StatementConsolidatedBalanceSheetsUnaudited"
],
"xbrltype": "domainItemType"
},
"achv_SeriesBConvertiblePreferredStockMember": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Series A convertible preferred stock member.",
"label": "Series B Convertible Preferred Stock [Member]",
"terseLabel": "Series B Convertible Preferred Stock [Member]"
}
}
},
"localname": "SeriesBConvertiblePreferredStockMember",
"nsuri": "http://achievelifesciences.com/20220630",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/StatementConsolidatedBalanceSheetsParentheticalUnaudited",
"http://achievelifesciences.com/20220630/taxonomy/role/StatementConsolidatedBalanceSheetsUnaudited"
],
"xbrltype": "domainItemType"
},
"achv_ShareBasedCompensationMaximumNumberOfSharesAuthorizedToPurchased": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Share based compensation, maximum number of shares authorized to purchased.",
"label": "Share Based Compensation Maximum Number Of Shares Authorized To Purchased",
"terseLabel": "Maximum number of shares authorized to purchased"
}
}
},
"localname": "ShareBasedCompensationMaximumNumberOfSharesAuthorizedToPurchased",
"nsuri": "http://achievelifesciences.com/20220630",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureCommonStockEmployeeSharePurchasePlanAdditionalInformationDetail"
],
"xbrltype": "sharesItemType"
},
"achv_SharesIssuedAsSettlementWithTradeVendorAsNonMonetaryTransaction": {
"auth_ref": [
],
"calculation": {
"http://achievelifesciences.com/20220630/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited": {
"order": 10120.0,
"parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Shares issued as settlement with trade vendor as non-monetary transaction.",
"label": "Shares Issued As Settlement With Trade Vendor As Non Monetary Transaction",
"terseLabel": "Shares issued as settlement with trade vendor"
}
}
},
"localname": "SharesIssuedAsSettlementWithTradeVendorAsNonMonetaryTransaction",
"nsuri": "http://achievelifesciences.com/20220630",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited"
],
"xbrltype": "monetaryItemType"
},
"achv_SharesIssuedOnExerciseOfWarrants": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Shares issued on exercise of warrants.",
"label": "Shares Issued On Exercise Of Warrants",
"terseLabel": "Shares issued on exercise of warrants, Shares"
}
}
},
"localname": "SharesIssuedOnExerciseOfWarrants",
"nsuri": "http://achievelifesciences.com/20220630",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/StatementConsolidatedStatementsOfStockholderSEquityUnaudited"
],
"xbrltype": "sharesItemType"
},
"achv_SharesIssuedOnExerciseOfWarrantsValue": {
"auth_ref": [
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Shares issued on exercise of warrants value.",
"label": "Shares Issued On Exercise Of Warrants Value",
"terseLabel": "Shares issued on exercise of warrants"
}
}
},
"localname": "SharesIssuedOnExerciseOfWarrantsValue",
"nsuri": "http://achievelifesciences.com/20220630",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/StatementConsolidatedStatementsOfStockholderSEquityUnaudited"
],
"xbrltype": "monetaryItemType"
},
"achv_SiliconValleyBankAndSVBInnovationCreditFundVIIILPMember": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Silicon Valley Bank and SVB Innovation Credit Fund VIII, L.P.",
"label": "Silicon Valley Bank And S V B Innovation Credit Fund V I I I L P [Member]",
"terseLabel": "SVB [Member]"
}
}
},
"localname": "SiliconValleyBankAndSVBInnovationCreditFundVIIILPMember",
"nsuri": "http://achievelifesciences.com/20220630",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureConvertibleDebtAdditionalInformationDetails"
],
"xbrltype": "domainItemType"
},
"achv_StockIssuedDuringPeriodSharesRestrictedStockUnitSettlementWithheldAndRetiredToTreasury": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Stock issued during period shares restricted stock unit settlement withheld and retired to treasury.",
"label": "Stock Issued During Period Shares Restricted Stock Unit Settlement Withheld And Retired To Treasury",
"terseLabel": "Restricted stock unit settlements withheld and retired to treasury, Shares"
}
}
},
"localname": "StockIssuedDuringPeriodSharesRestrictedStockUnitSettlementWithheldAndRetiredToTreasury",
"nsuri": "http://achievelifesciences.com/20220630",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/StatementConsolidatedStatementsOfStockholderSEquityUnaudited"
],
"xbrltype": "sharesItemType"
},
"achv_StockIssuedDuringPeriodValueRestrictedStockUnitSettlementWithheldAndRetiredToTreasury": {
"auth_ref": [
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Stock issued during period value restricted stock unit settlement withheld and retired to treasury.",
"label": "Stock Issued During Period Value Restricted Stock Unit Settlement Withheld And Retired To Treasury",
"terseLabel": "Restricted stock unit settlements withheld and retired to treasury"
}
}
},
"localname": "StockIssuedDuringPeriodValueRestrictedStockUnitSettlementWithheldAndRetiredToTreasury",
"nsuri": "http://achievelifesciences.com/20220630",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/StatementConsolidatedStatementsOfStockholderSEquityUnaudited"
],
"xbrltype": "monetaryItemType"
},
"achv_TwoThousandAndEighteenEquityIncentivePlanMember": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Two thousand and eighteen equity incentive plan.",
"label": "Two Thousand And Eighteen Equity Incentive Plan [Member]",
"terseLabel": "2018 Equity Incentive Plan [Member]"
}
}
},
"localname": "TwoThousandAndEighteenEquityIncentivePlanMember",
"nsuri": "http://achievelifesciences.com/20220630",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureCommonStockStockOptionsAdditionalInformationDetail"
],
"xbrltype": "domainItemType"
},
"achv_TwoThousandsAndSeventeenEquityIncentivePlanMember": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Information pertaining to 2017 equity incentive plan.",
"label": "Two Thousands And Seventeen Equity Incentive Plan [Member]",
"terseLabel": "2017 Equity Incentive Plan [Member]"
}
}
},
"localname": "TwoThousandsAndSeventeenEquityIncentivePlanMember",
"nsuri": "http://achievelifesciences.com/20220630",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureCommonStockStockOptionsAdditionalInformationDetail"
],
"xbrltype": "domainItemType"
},
"achv_TwoThousandsAndTenPerformanceIncentivePlanMember": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Information pertaining to 2010 performance incentive plan.",
"label": "Two Thousands And Ten Performance Incentive Plan [Member]",
"terseLabel": "2010 Performance Incentive Plan [Member]"
}
}
},
"localname": "TwoThousandsAndTenPerformanceIncentivePlanMember",
"nsuri": "http://achievelifesciences.com/20220630",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureCommonStockStockOptionsAdditionalInformationDetail"
],
"xbrltype": "domainItemType"
},
"achv_UnderwritingDiscountsAndCommissionsAndOfferingExpenses": {
"auth_ref": [
],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Underwriting discounts and commissions and offering expenses.",
"label": "Underwriting Discounts And Commissions And Offering Expenses",
"terseLabel": "Underwriting discounts and commissions and offering expenses"
}
}
},
"localname": "UnderwritingDiscountsAndCommissionsAndOfferingExpenses",
"nsuri": "http://achievelifesciences.com/20220630",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureCommonStockIssuedAndOutstandingSharesAdditionalInformationDetail"
],
"xbrltype": "monetaryItemType"
},
"achv_UniversityOfBristolMember": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "University of Bristol.",
"label": "University Of Bristol [Member]",
"terseLabel": "University of Bristol [Member]"
}
}
},
"localname": "UniversityOfBristolMember",
"nsuri": "http://achievelifesciences.com/20220630",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetail"
],
"xbrltype": "domainItemType"
},
"achv_VancouverOfficeOperatingLeaseMember": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Vancouver office operating lease.",
"label": "Vancouver Office Operating Lease [Member]",
"terseLabel": "Vancouver Office Operating Lease [Member]",
"verboseLabel": "Vancouver Lease Arrangement [Member]"
}
}
},
"localname": "VancouverOfficeOperatingLeaseMember",
"nsuri": "http://achievelifesciences.com/20220630",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail",
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfContractualObligationsDetail",
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfFutureMinimumAnnualLeasePaymentsDetail",
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureCommitmentsAndContingenciesTables"
],
"xbrltype": "domainItemType"
},
"achv_WarrantsIssuedInAprilTwoThousandTwenty1Member": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Warrants issued in April two thousand twenty 1.",
"label": "Warrants Issued In April Two Thousand Twenty1 [Member]",
"terseLabel": "Warrants Issued in April 2020 [Member]"
}
}
},
"localname": "WarrantsIssuedInAprilTwoThousandTwenty1Member",
"nsuri": "http://achievelifesciences.com/20220630",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureCommonStockSummaryOfOutstandingWarrantsDetail"
],
"xbrltype": "domainItemType"
},
"achv_WarrantsIssuedInAprilTwoThousandTwenty2Member": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Warrants issued in April two thousand twenty 2.",
"label": "Warrants Issued In April Two Thousand Twenty2 [Member]",
"terseLabel": "Warrants Issued in April 2020 [Member]"
}
}
},
"localname": "WarrantsIssuedInAprilTwoThousandTwenty2Member",
"nsuri": "http://achievelifesciences.com/20220630",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureCommonStockSummaryOfOutstandingWarrantsDetail"
],
"xbrltype": "domainItemType"
},
"achv_WarrantsIssuedInAprilTwoThousandTwentyFinancingMember": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Warrants issued in April two thousand twenty financing.",
"label": "Warrants Issued In April Two Thousand Twenty Financing [Member]",
"terseLabel": "Warrants Issued in April 2020 [Member]"
}
}
},
"localname": "WarrantsIssuedInAprilTwoThousandTwentyFinancingMember",
"nsuri": "http://achievelifesciences.com/20220630",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureCommonStockCommonStockWarrantsAdditionalInformationDetail"
],
"xbrltype": "domainItemType"
},
"achv_WarrantsIssuedInAprilTwoThousandTwentyMember": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Warrants issued in April two thousand twenty.",
"label": "Warrants Issued In April Two Thousand Twenty [Member]",
"terseLabel": "Warrants Issued in April 2020 [Member]"
}
}
},
"localname": "WarrantsIssuedInAprilTwoThousandTwentyMember",
"nsuri": "http://achievelifesciences.com/20220630",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureCommonStockSummaryOfOutstandingWarrantsDetail"
],
"xbrltype": "domainItemType"
},
"achv_WarrantsIssuedInAugustTwoThousandTwentyMember": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Warrants issued in August two thousand twenty.",
"label": "Warrants Issued In August Two Thousand Twenty [Member]",
"terseLabel": "Pre-Funded Warrants Issued in August 2020 [Member]"
}
}
},
"localname": "WarrantsIssuedInAugustTwoThousandTwentyMember",
"nsuri": "http://achievelifesciences.com/20220630",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureCommonStockSummaryOfOutstandingWarrantsDetail"
],
"xbrltype": "domainItemType"
},
"achv_WarrantsIssuedInDecemberTwoThousandNineteenMember": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Warrants issued in december two thousand nineteen.",
"label": "Warrants Issued In December Two Thousand Nineteen [Member]",
"terseLabel": "Warrants Issued in December 2019 [Member]"
}
}
},
"localname": "WarrantsIssuedInDecemberTwoThousandNineteenMember",
"nsuri": "http://achievelifesciences.com/20220630",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureCommonStockCommonStockWarrantsAdditionalInformationDetail",
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureCommonStockSummaryOfOutstandingWarrantsDetail"
],
"xbrltype": "domainItemType"
},
"achv_WarrantsIssuedInDecemberTwoThousandTwentyMember": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Warrants issued In December two thousand twenty.",
"label": "Warrants Issued In December Two Thousand Twenty [Member]",
"terseLabel": "Warrants Issued in December 2020 [Member]"
}
}
},
"localname": "WarrantsIssuedInDecemberTwoThousandTwentyMember",
"nsuri": "http://achievelifesciences.com/20220630",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureCommonStockSummaryOfOutstandingWarrantsDetail"
],
"xbrltype": "domainItemType"
},
"achv_WarrantsIssuedInJuneTwoThousandEighteenMember": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Warrants issued in June two thousand eighteen.",
"label": "Warrants Issued In June Two Thousand Eighteen [Member]",
"terseLabel": "Warrants Issued in June 2018 [Member]"
}
}
},
"localname": "WarrantsIssuedInJuneTwoThousandEighteenMember",
"nsuri": "http://achievelifesciences.com/20220630",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureCommonStockSummaryOfOutstandingWarrantsDetail"
],
"xbrltype": "domainItemType"
},
"achv_WarrantsIssuedInMayTwoThousandNinteenMember": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "WarrantsIssuedInMayTwoThousandNinteenMember.",
"label": "Warrants Issued In May Two Thousand Ninteen [Member]",
"terseLabel": "Warrants Issued in May 2019 [Member]"
}
}
},
"localname": "WarrantsIssuedInMayTwoThousandNinteenMember",
"nsuri": "http://achievelifesciences.com/20220630",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureCommonStockSummaryOfOutstandingWarrantsDetail"
],
"xbrltype": "domainItemType"
},
"achv_WarrantsIssuedInOctoberTwoThousandEighteenMember": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Warrants issued in October two thousand eighteen.",
"label": "Warrants Issued In October Two Thousand Eighteen [Member]",
"terseLabel": "Warrants Issued in October 2018 [Member]"
}
}
},
"localname": "WarrantsIssuedInOctoberTwoThousandEighteenMember",
"nsuri": "http://achievelifesciences.com/20220630",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureCommonStockSummaryOfOutstandingWarrantsDetail"
],
"xbrltype": "domainItemType"
},
"achv_WarrantsIssuedInSeptemberTwoThousandSeventeenMember": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Warrants issued in September two thousand seventeen.",
"label": "Warrants Issued In September Two Thousand Seventeen [Member]",
"terseLabel": "Warrants Issued in September 2017 [Member]"
}
}
},
"localname": "WarrantsIssuedInSeptemberTwoThousandSeventeenMember",
"nsuri": "http://achievelifesciences.com/20220630",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureCommonStockSummaryOfOutstandingWarrantsDetail"
],
"xbrltype": "domainItemType"
},
"achv_WorkingCapitalBalance": {
"auth_ref": [
],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "The capital of a business which is used in its day-to-day trading operations, calculated as the current assets minus the current liabilities.",
"label": "Working Capital Balance",
"terseLabel": "Working capital"
}
}
},
"localname": "WorkingCapitalBalance",
"nsuri": "http://achievelifesciences.com/20220630",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureNatureOfBusinessBasisOfPresentationAndGoingConcernUncertaintyAdditionalInformationDetail"
],
"xbrltype": "monetaryItemType"
},
"dei_AmendmentFlag": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
"label": "Amendment Flag",
"terseLabel": "Amendment Flag"
}
}
},
"localname": "AmendmentFlag",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/DocumentDocumentAndEntityInformation"
],
"xbrltype": "booleanItemType"
},
"dei_CityAreaCode": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Area code of city",
"label": "City Area Code",
"terseLabel": "City Area Code"
}
}
},
"localname": "CityAreaCode",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/DocumentDocumentAndEntityInformation"
],
"xbrltype": "normalizedStringItemType"
},
"dei_CoverAbstract": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Cover page.",
"label": "Cover [Abstract]"
}
}
},
"localname": "CoverAbstract",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"xbrltype": "stringItemType"
},
"dei_CurrentFiscalYearEndDate": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "End date of current fiscal year in the format --MM-DD.",
"label": "Current Fiscal Year End Date",
"terseLabel": "Current Fiscal Year End Date"
}
}
},
"localname": "CurrentFiscalYearEndDate",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/DocumentDocumentAndEntityInformation"
],
"xbrltype": "gMonthDayItemType"
},
"dei_DocumentFiscalPeriodFocus": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
"label": "Document Fiscal Period Focus",
"terseLabel": "Document Fiscal Period Focus"
}
}
},
"localname": "DocumentFiscalPeriodFocus",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/DocumentDocumentAndEntityInformation"
],
"xbrltype": "fiscalPeriodItemType"
},
"dei_DocumentFiscalYearFocus": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
"label": "Document Fiscal Year Focus",
"terseLabel": "Document Fiscal Year Focus"
}
}
},
"localname": "DocumentFiscalYearFocus",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/DocumentDocumentAndEntityInformation"
],
"xbrltype": "gYearItemType"
},
"dei_DocumentPeriodEndDate": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.",
"label": "Document Period End Date",
"terseLabel": "Document Period End Date"
}
}
},
"localname": "DocumentPeriodEndDate",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/DocumentDocumentAndEntityInformation"
],
"xbrltype": "dateItemType"
},
"dei_DocumentQuarterlyReport": {
"auth_ref": [
"r405"
],
"lang": {
"en-us": {
"role": {
"documentation": "Boolean flag that is true only for a form used as an quarterly report.",
"label": "Document Quarterly Report",
"terseLabel": "Document Quarterly Report"
}
}
},
"localname": "DocumentQuarterlyReport",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/DocumentDocumentAndEntityInformation"
],
"xbrltype": "booleanItemType"
},
"dei_DocumentTransitionReport": {
"auth_ref": [
"r406"
],
"lang": {
"en-us": {
"role": {
"documentation": "Boolean flag that is true only for a form used as a transition report.",
"label": "Document Transition Report",
"terseLabel": "Document Transition Report"
}
}
},
"localname": "DocumentTransitionReport",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/DocumentDocumentAndEntityInformation"
],
"xbrltype": "booleanItemType"
},
"dei_DocumentType": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
"label": "Document Type",
"terseLabel": "Document Type"
}
}
},
"localname": "DocumentType",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/DocumentDocumentAndEntityInformation"
],
"xbrltype": "submissionTypeItemType"
},
"dei_EntityAddressAddressLine1": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Address Line 1 such as Attn, Building Name, Street Name",
"label": "Entity Address Address Line1",
"terseLabel": "Entity Address, Address Line One"
}
}
},
"localname": "EntityAddressAddressLine1",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/DocumentDocumentAndEntityInformation"
],
"xbrltype": "normalizedStringItemType"
},
"dei_EntityAddressAddressLine2": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Address Line 2 such as Street or Suite number",
"label": "Entity Address Address Line2",
"terseLabel": "Entity Address, Address Line Two"
}
}
},
"localname": "EntityAddressAddressLine2",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/DocumentDocumentAndEntityInformation"
],
"xbrltype": "normalizedStringItemType"
},
"dei_EntityAddressCityOrTown": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Name of the City or Town",
"label": "Entity Address City Or Town",
"terseLabel": "Entity Address, City or Town"
}
}
},
"localname": "EntityAddressCityOrTown",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/DocumentDocumentAndEntityInformation"
],
"xbrltype": "normalizedStringItemType"
},
"dei_EntityAddressCountry": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "ISO 3166-1 alpha-2 country code.",
"label": "Entity Address Country",
"terseLabel": "Entity Address, Country"
}
}
},
"localname": "EntityAddressCountry",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/DocumentDocumentAndEntityInformation"
],
"xbrltype": "countryCodeItemType"
},
"dei_EntityAddressPostalZipCode": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Code for the postal or zip code",
"label": "Entity Address Postal Zip Code",
"terseLabel": "Entity Address, Postal Zip Code"
}
}
},
"localname": "EntityAddressPostalZipCode",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/DocumentDocumentAndEntityInformation"
],
"xbrltype": "normalizedStringItemType"
},
"dei_EntityAddressStateOrProvince": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Name of the state or province.",
"label": "Entity Address State Or Province",
"terseLabel": "Entity Address, State or Province"
}
}
},
"localname": "EntityAddressStateOrProvince",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/DocumentDocumentAndEntityInformation"
],
"xbrltype": "stateOrProvinceItemType"
},
"dei_EntityCentralIndexKey": {
"auth_ref": [
"r403"
],
"lang": {
"en-us": {
"role": {
"documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
"label": "Entity Central Index Key",
"terseLabel": "Entity Central Index Key"
}
}
},
"localname": "EntityCentralIndexKey",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/DocumentDocumentAndEntityInformation"
],
"xbrltype": "centralIndexKeyItemType"
},
"dei_EntityCommonStockSharesOutstanding": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
"label": "Entity Common Stock Shares Outstanding",
"terseLabel": "Entity Common Stock, Shares Outstanding"
}
}
},
"localname": "EntityCommonStockSharesOutstanding",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/DocumentDocumentAndEntityInformation"
],
"xbrltype": "sharesItemType"
},
"dei_EntityCurrentReportingStatus": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
"label": "Entity Current Reporting Status",
"terseLabel": "Entity Current Reporting Status"
}
}
},
"localname": "EntityCurrentReportingStatus",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/DocumentDocumentAndEntityInformation"
],
"xbrltype": "yesNoItemType"
},
"dei_EntityEmergingGrowthCompany": {
"auth_ref": [
"r403"
],
"lang": {
"en-us": {
"role": {
"documentation": "Indicate if registrant meets the emerging growth company criteria.",
"label": "Entity Emerging Growth Company",
"terseLabel": "Entity Emerging Growth Company"
}
}
},
"localname": "EntityEmergingGrowthCompany",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/DocumentDocumentAndEntityInformation"
],
"xbrltype": "booleanItemType"
},
"dei_EntityFileNumber": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
"label": "Entity File Number",
"terseLabel": "Entity File Number"
}
}
},
"localname": "EntityFileNumber",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/DocumentDocumentAndEntityInformation"
],
"xbrltype": "fileNumberItemType"
},
"dei_EntityFilerCategory": {
"auth_ref": [
"r403"
],
"lang": {
"en-us": {
"role": {
"documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
"label": "Entity Filer Category",
"terseLabel": "Entity Filer Category"
}
}
},
"localname": "EntityFilerCategory",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/DocumentDocumentAndEntityInformation"
],
"xbrltype": "filerCategoryItemType"
},
"dei_EntityIncorporationStateCountryCode": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Two-character EDGAR code representing the state or country of incorporation.",
"label": "Entity Incorporation State Country Code",
"terseLabel": "Entity Incorporation, State or Country Code"
}
}
},
"localname": "EntityIncorporationStateCountryCode",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/DocumentDocumentAndEntityInformation"
],
"xbrltype": "edgarStateCountryItemType"
},
"dei_EntityInteractiveDataCurrent": {
"auth_ref": [
"r409"
],
"lang": {
"en-us": {
"role": {
"documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
"label": "Entity Interactive Data Current",
"terseLabel": "Entity Interactive Data Current"
}
}
},
"localname": "EntityInteractiveDataCurrent",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/DocumentDocumentAndEntityInformation"
],
"xbrltype": "yesNoItemType"
},
"dei_EntityRegistrantName": {
"auth_ref": [
"r403"
],
"lang": {
"en-us": {
"role": {
"documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
"label": "Entity Registrant Name",
"terseLabel": "Entity Registrant Name"
}
}
},
"localname": "EntityRegistrantName",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/DocumentDocumentAndEntityInformation"
],
"xbrltype": "normalizedStringItemType"
},
"dei_EntityShellCompany": {
"auth_ref": [
"r403"
],
"lang": {
"en-us": {
"role": {
"documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
"label": "Entity Shell Company",
"terseLabel": "Entity Shell Company"
}
}
},
"localname": "EntityShellCompany",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/DocumentDocumentAndEntityInformation"
],
"xbrltype": "booleanItemType"
},
"dei_EntitySmallBusiness": {
"auth_ref": [
"r403"
],
"lang": {
"en-us": {
"role": {
"documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
"label": "Entity Small Business",
"terseLabel": "Entity Small Business"
}
}
},
"localname": "EntitySmallBusiness",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/DocumentDocumentAndEntityInformation"
],
"xbrltype": "booleanItemType"
},
"dei_EntityTaxIdentificationNumber": {
"auth_ref": [
"r403"
],
"lang": {
"en-us": {
"role": {
"documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
"label": "Entity Tax Identification Number",
"terseLabel": "Entity Tax Identification Number"
}
}
},
"localname": "EntityTaxIdentificationNumber",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/DocumentDocumentAndEntityInformation"
],
"xbrltype": "employerIdItemType"
},
"dei_LocalPhoneNumber": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Local phone number for entity.",
"label": "Local Phone Number",
"terseLabel": "Local Phone Number"
}
}
},
"localname": "LocalPhoneNumber",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/DocumentDocumentAndEntityInformation"
],
"xbrltype": "normalizedStringItemType"
},
"dei_Security12bTitle": {
"auth_ref": [
"r402"
],
"lang": {
"en-us": {
"role": {
"documentation": "Title of a 12(b) registered security.",
"label": "Security12b Title",
"terseLabel": "Title of 12(b) Security"
}
}
},
"localname": "Security12bTitle",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/DocumentDocumentAndEntityInformation"
],
"xbrltype": "securityTitleItemType"
},
"dei_SecurityExchangeName": {
"auth_ref": [
"r404"
],
"lang": {
"en-us": {
"role": {
"documentation": "Name of the Exchange on which a security is registered.",
"label": "Security Exchange Name",
"terseLabel": "Security Exchange Name"
}
}
},
"localname": "SecurityExchangeName",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/DocumentDocumentAndEntityInformation"
],
"xbrltype": "edgarExchangeCodeItemType"
},
"dei_TradingSymbol": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Trading symbol of an instrument as listed on an exchange.",
"label": "Trading Symbol",
"terseLabel": "Trading Symbol"
}
}
},
"localname": "TradingSymbol",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/DocumentDocumentAndEntityInformation"
],
"xbrltype": "tradingSymbolItemType"
},
"srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock": {
"auth_ref": [
"r408"
],
"lang": {
"en-us": {
"role": {
"documentation": "Tabular disclosure of contractual obligation by timing of payment due. Includes, but is not limited to, long-term debt obligation, lease obligation, and purchase obligation.",
"label": "Contractual Obligation Fiscal Year Maturity Schedule Table [Text Block]",
"terseLabel": "Summary of Contractual Obligations"
}
}
},
"localname": "ContractualObligationFiscalYearMaturityScheduleTableTextBlock",
"nsuri": "http://fasb.org/srt/2022",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureCommitmentsAndContingenciesTables"
],
"xbrltype": "textBlockItemType"
},
"srt_CounterpartyNameAxis": {
"auth_ref": [
"r37",
"r39",
"r76",
"r77",
"r171",
"r203",
"r420"
],
"lang": {
"en-us": {
"role": {
"documentation": "Information by name of counterparty. A counterparty is the other party that participates in a financial transaction. Examples include, but not limited to, the name of the financial institution.",
"label": "Counterparty Name [Axis]",
"terseLabel": "Counterparty Name"
}
}
},
"localname": "CounterpartyNameAxis",
"nsuri": "http://fasb.org/srt/2022",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail",
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetail"
],
"xbrltype": "stringItemType"
},
"srt_MaximumMember": {
"auth_ref": [
"r148",
"r149",
"r150",
"r151",
"r170",
"r202",
"r233",
"r234",
"r343",
"r344",
"r345",
"r346",
"r347",
"r348",
"r349",
"r379",
"r381",
"r399",
"r400"
],
"lang": {
"en-us": {
"role": {
"documentation": "Upper limit of the provided range.",
"label": "Maximum [Member]",
"terseLabel": "Maximum [Member]"
}
}
},
"localname": "MaximumMember",
"nsuri": "http://fasb.org/srt/2022",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureCommonStockStockOptionsAdditionalInformationDetail",
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureConvertibleDebtAdditionalInformationDetails",
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetail"
],
"xbrltype": "domainItemType"
},
"srt_MinimumMember": {
"auth_ref": [
"r148",
"r149",
"r150",
"r151",
"r170",
"r202",
"r233",
"r234",
"r343",
"r344",
"r345",
"r346",
"r347",
"r348",
"r349",
"r379",
"r381",
"r399",
"r400"
],
"lang": {
"en-us": {
"role": {
"documentation": "Lower limit of the provided range.",
"label": "Minimum [Member]",
"terseLabel": "Minimum [Member]"
}
}
},
"localname": "MinimumMember",
"nsuri": "http://fasb.org/srt/2022",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureCommonStockStockOptionsAdditionalInformationDetail",
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureConvertibleDebtAdditionalInformationDetails",
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetail"
],
"xbrltype": "domainItemType"
},
"srt_RangeAxis": {
"auth_ref": [
"r143",
"r148",
"r149",
"r150",
"r151",
"r170",
"r202",
"r224",
"r233",
"r234",
"r263",
"r264",
"r265",
"r343",
"r344",
"r345",
"r346",
"r347",
"r348",
"r349",
"r379",
"r381",
"r399",
"r400"
],
"lang": {
"en-us": {
"role": {
"documentation": "Information by statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median.",
"label": "Range [Axis]",
"terseLabel": "Statistical Measurement"
}
}
},
"localname": "RangeAxis",
"nsuri": "http://fasb.org/srt/2022",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureCommonStockStockOptionsAdditionalInformationDetail",
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureConvertibleDebtAdditionalInformationDetails",
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetail"
],
"xbrltype": "stringItemType"
},
"srt_RangeMember": {
"auth_ref": [
"r143",
"r148",
"r149",
"r150",
"r151",
"r170",
"r202",
"r224",
"r233",
"r234",
"r263",
"r264",
"r265",
"r343",
"r344",
"r345",
"r346",
"r347",
"r348",
"r349",
"r379",
"r381",
"r399",
"r400"
],
"lang": {
"en-us": {
"role": {
"documentation": "Statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median.",
"label": "Range [Member]",
"terseLabel": "Statistical Measurement"
}
}
},
"localname": "RangeMember",
"nsuri": "http://fasb.org/srt/2022",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureCommonStockStockOptionsAdditionalInformationDetail",
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureConvertibleDebtAdditionalInformationDetails",
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetail"
],
"xbrltype": "domainItemType"
},
"srt_RepurchaseAgreementCounterpartyNameDomain": {
"auth_ref": [
"r38",
"r39",
"r76",
"r77",
"r171",
"r203"
],
"lang": {
"en-us": {
"role": {
"documentation": "Named other party that participates in a financial transaction. Examples include, but not limited to, the name of the financial institution.",
"label": "Repurchase Agreement Counterparty Name [Domain]",
"terseLabel": "Counterparty Name"
}
}
},
"localname": "RepurchaseAgreementCounterpartyNameDomain",
"nsuri": "http://fasb.org/srt/2022",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail",
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetail"
],
"xbrltype": "domainItemType"
},
"srt_SegmentGeographicalDomain": {
"auth_ref": [
"r120",
"r121",
"r222",
"r223",
"r380",
"r390",
"r391",
"r392",
"r393",
"r394",
"r395",
"r396",
"r397",
"r398",
"r410",
"r412",
"r413",
"r414",
"r415",
"r416",
"r417",
"r418",
"r419"
],
"lang": {
"en-us": {
"role": {
"documentation": "Geographical area.",
"label": "Segment Geographical [Domain]",
"terseLabel": "Geographical"
}
}
},
"localname": "SegmentGeographicalDomain",
"nsuri": "http://fasb.org/srt/2022",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
],
"xbrltype": "domainItemType"
},
"srt_StatementGeographicalAxis": {
"auth_ref": [
"r120",
"r121",
"r222",
"r223",
"r380",
"r388",
"r390",
"r391",
"r392",
"r393",
"r394",
"r395",
"r396",
"r397",
"r398",
"r410",
"r411"
],
"lang": {
"en-us": {
"role": {
"documentation": "Information by geographical components.",
"label": "Statement Geographical [Axis]",
"terseLabel": "Geographical"
}
}
},
"localname": "StatementGeographicalAxis",
"nsuri": "http://fasb.org/srt/2022",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
],
"xbrltype": "stringItemType"
},
"srt_TitleOfIndividualAxis": {
"auth_ref": [
"r122",
"r336"
],
"lang": {
"en-us": {
"role": {
"documentation": "Information by title of individual or nature of relationship to individual or group of individuals.",
"label": "Title Of Individual [Axis]",
"terseLabel": "Title of Individual"
}
}
},
"localname": "TitleOfIndividualAxis",
"nsuri": "http://fasb.org/srt/2022",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureCommonStockStockOptionsAdditionalInformationDetail"
],
"xbrltype": "stringItemType"
},
"srt_TitleOfIndividualWithRelationshipToEntityDomain": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Title of individual, or nature of relationship to individual or group of individuals.",
"label": "Title Of Individual With Relationship To Entity [Domain]",
"terseLabel": "Title of Individual"
}
}
},
"localname": "TitleOfIndividualWithRelationshipToEntityDomain",
"nsuri": "http://fasb.org/srt/2022",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureCommonStockStockOptionsAdditionalInformationDetail"
],
"xbrltype": "domainItemType"
},
"stpr_CA-BC": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "BRITISH COLUMBIA",
"terseLabel": "Vancouver, British Columbia [Member]"
}
}
},
"localname": "CA-BC",
"nsuri": "http://xbrl.sec.gov/stpr/2022",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
],
"xbrltype": "domainItemType"
},
"us-gaap_AccountingPoliciesAbstract": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Accounting Policies [Abstract]"
}
}
},
"localname": "AccountingPoliciesAbstract",
"nsuri": "http://fasb.org/us-gaap/2022",
"xbrltype": "stringItemType"
},
"us-gaap_AccountsPayableCurrent": {
"auth_ref": [
"r25",
"r339"
],
"calculation": {
"http://achievelifesciences.com/20220630/taxonomy/role/StatementConsolidatedBalanceSheetsUnaudited": {
"order": 10130.0,
"parentTag": "us-gaap_LiabilitiesCurrent",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
"label": "Accounts Payable Current",
"terseLabel": "Accounts payable"
}
}
},
"localname": "AccountsPayableCurrent",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/StatementConsolidatedBalanceSheetsUnaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
"auth_ref": [
"r20",
"r41",
"r42",
"r43",
"r372",
"r386",
"r387"
],
"calculation": {
"http://achievelifesciences.com/20220630/taxonomy/role/StatementConsolidatedBalanceSheetsUnaudited": {
"order": 10090.0,
"parentTag": "us-gaap_StockholdersEquity",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
"label": "Accumulated Other Comprehensive Income Loss Net Of Tax",
"terseLabel": "Accumulated other comprehensive income"
}
}
},
"localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/StatementConsolidatedBalanceSheetsUnaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
"auth_ref": [
"r40",
"r43",
"r46",
"r47",
"r48",
"r80",
"r81",
"r82",
"r291",
"r335",
"r382",
"r383"
],
"lang": {
"en-us": {
"role": {
"documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
"label": "Accumulated Other Comprehensive Income [Member]",
"terseLabel": "Accumulated other comprehensive income (loss) [Member]"
}
}
},
"localname": "AccumulatedOtherComprehensiveIncomeMember",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/StatementConsolidatedStatementsOfStockholderSEquityUnaudited"
],
"xbrltype": "domainItemType"
},
"us-gaap_AdditionalPaidInCapitalCommonStock": {
"auth_ref": [
"r18"
],
"calculation": {
"http://achievelifesciences.com/20220630/taxonomy/role/StatementConsolidatedBalanceSheetsUnaudited": {
"order": 10070.0,
"parentTag": "us-gaap_StockholdersEquity",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.",
"label": "Additional Paid In Capital Common Stock",
"terseLabel": "Additional paid-in capital"
}
}
},
"localname": "AdditionalPaidInCapitalCommonStock",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/StatementConsolidatedBalanceSheetsUnaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Adjustments Noncash Items To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract]",
"terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
}
}
},
"localname": "AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited"
],
"xbrltype": "stringItemType"
},
"us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
"auth_ref": [
"r236",
"r276",
"r277"
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
"label": "Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value",
"terseLabel": "Stock-based compensation expense"
}
}
},
"localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/StatementConsolidatedStatementsOfStockholderSEquityUnaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_AllocatedShareBasedCompensationExpense": {
"auth_ref": [
"r268"
],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
"label": "Allocated Share Based Compensation Expense",
"terseLabel": "Stock based compensation expense"
}
}
},
"localname": "AllocatedShareBasedCompensationExpense",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureCommonStockRestrictedStockUnitAwardsAdditionalInformationDetail"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_AmortizationOfIntangibleAssets": {
"auth_ref": [
"r66",
"r131",
"r136"
],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.",
"label": "Amortization Of Intangible Assets",
"terseLabel": "License agreement amortization expense"
}
}
},
"localname": "AmortizationOfIntangibleAssets",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureIntangiblesAdditionalInformationDetail"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
"auth_ref": [
"r102"
],
"lang": {
"en-us": {
"role": {
"documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
"label": "Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount",
"terseLabel": "Anti-dilutive securities excluded from earning per share computation"
}
}
},
"localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureCommonStockStockOptionsAdditionalInformationDetail"
],
"xbrltype": "sharesItemType"
},
"us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
"auth_ref": [
"r102"
],
"lang": {
"en-us": {
"role": {
"documentation": "Information by type of antidilutive security.",
"label": "Antidilutive Securities Excluded From Computation Of Earnings Per Share By Antidilutive Securities [Axis]",
"terseLabel": "Antidilutive Securities"
}
}
},
"localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureCommonStockStockOptionsAdditionalInformationDetail"
],
"xbrltype": "stringItemType"
},
"us-gaap_AntidilutiveSecuritiesNameDomain": {
"auth_ref": [
"r102"
],
"lang": {
"en-us": {
"role": {
"documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
"label": "Antidilutive Securities Name [Domain]",
"terseLabel": "Antidilutive Securities, Name"
}
}
},
"localname": "AntidilutiveSecuritiesNameDomain",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureCommonStockStockOptionsAdditionalInformationDetail"
],
"xbrltype": "domainItemType"
},
"us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
"label": "Arrangements And Nonarrangement Transactions [Member]",
"terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative"
}
}
},
"localname": "ArrangementsAndNonarrangementTransactionsMember",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail",
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfContractualObligationsDetail",
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfFutureMinimumAnnualLeasePaymentsDetail",
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureCommitmentsAndContingenciesTables",
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetail"
],
"xbrltype": "domainItemType"
},
"us-gaap_Assets": {
"auth_ref": [
"r10",
"r75",
"r112",
"r114",
"r118",
"r125",
"r155",
"r156",
"r157",
"r158",
"r159",
"r160",
"r161",
"r162",
"r163",
"r164",
"r165",
"r287",
"r292",
"r310",
"r337",
"r339",
"r356",
"r369"
],
"calculation": {
"http://achievelifesciences.com/20220630/taxonomy/role/StatementConsolidatedBalanceSheetsUnaudited": {
"order": null,
"parentTag": null,
"root": true,
"weight": null
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
"label": "Assets",
"totalLabel": "Total assets"
}
}
},
"localname": "Assets",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/StatementConsolidatedBalanceSheetsUnaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_AssetsAbstract": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Assets [Abstract]",
"terseLabel": "ASSETS"
}
}
},
"localname": "AssetsAbstract",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/StatementConsolidatedBalanceSheetsUnaudited"
],
"xbrltype": "stringItemType"
},
"us-gaap_AssetsCurrent": {
"auth_ref": [
"r4",
"r24",
"r75",
"r125",
"r155",
"r156",
"r157",
"r158",
"r159",
"r160",
"r161",
"r162",
"r163",
"r164",
"r165",
"r287",
"r292",
"r310",
"r337",
"r339"
],
"calculation": {
"http://achievelifesciences.com/20220630/taxonomy/role/StatementConsolidatedBalanceSheetsUnaudited": {
"order": 10180.0,
"parentTag": "us-gaap_Assets",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
"label": "Assets Current",
"totalLabel": "Total current assets"
}
}
},
"localname": "AssetsCurrent",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/StatementConsolidatedBalanceSheetsUnaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_AssetsCurrentAbstract": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Assets Current [Abstract]",
"terseLabel": "Current assets:"
}
}
},
"localname": "AssetsCurrentAbstract",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/StatementConsolidatedBalanceSheetsUnaudited"
],
"xbrltype": "stringItemType"
},
"us-gaap_AssetsFairValueDisclosure": {
"auth_ref": [
"r300"
],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
"label": "Assets Fair Value Disclosure",
"terseLabel": "Total assets"
}
}
},
"localname": "AssetsFairValueDisclosure",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAssetsMeasuredAtFairValueOnRecurringBasisDetail"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_AssetsFairValueDisclosureAbstract": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Assets Fair Value Disclosure [Abstract]",
"terseLabel": "Assets"
}
}
},
"localname": "AssetsFairValueDisclosureAbstract",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAssetsMeasuredAtFairValueOnRecurringBasisDetail"
],
"xbrltype": "stringItemType"
},
"us-gaap_AwardTypeAxis": {
"auth_ref": [
"r239",
"r240",
"r241",
"r243",
"r244",
"r245",
"r246",
"r247",
"r248",
"r249",
"r250",
"r251",
"r252",
"r253",
"r254",
"r255",
"r256",
"r257",
"r258",
"r259",
"r260",
"r262",
"r263",
"r264",
"r265",
"r266"
],
"lang": {
"en-us": {
"role": {
"documentation": "Information by type of award under share-based payment arrangement.",
"label": "Award Type [Axis]",
"terseLabel": "Award Type"
}
}
},
"localname": "AwardTypeAxis",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureCommonStockRestrictedStockUnitAwardsAdditionalInformationDetail",
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureCommonStockStockOptionsAdditionalInformationDetail",
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureCommonStockSummaryOfRestrictedStockUnitAwardActivityDetail"
],
"xbrltype": "stringItemType"
},
"us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": {
"auth_ref": [
"r2",
"r79",
"r109"
],
"lang": {
"en-us": {
"role": {
"documentation": "The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
"label": "Business Description And Basis Of Presentation [Text Block]",
"terseLabel": "Nature of Business, Basis of Presentation and Going Concern Uncertainty"
}
}
},
"localname": "BusinessDescriptionAndBasisOfPresentationTextBlock",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureNatureOfBusinessBasisOfPresentationAndGoingConcernUncertainty"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_CashAndCashEquivalentsAtCarryingValue": {
"auth_ref": [
"r3",
"r6",
"r68"
],
"calculation": {
"http://achievelifesciences.com/20220630/taxonomy/role/StatementConsolidatedBalanceSheetsUnaudited": {
"order": 10230.0,
"parentTag": "us-gaap_AssetsCurrent",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
"label": "Cash And Cash Equivalents At Carrying Value",
"positiveLabel": "Cash and cash equivalents",
"terseLabel": "Cash and cash equivalents [note 6]"
}
}
},
"localname": "CashAndCashEquivalentsAtCarryingValue",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureNatureOfBusinessBasisOfPresentationAndGoingConcernUncertaintyAdditionalInformationDetail",
"http://achievelifesciences.com/20220630/taxonomy/role/StatementConsolidatedBalanceSheetsUnaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
"auth_ref": [
"r63",
"r68",
"r69"
],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
"label": "Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations",
"periodEndLabel": "Cash, cash equivalents and restricted cash at end of the period",
"periodStartLabel": "Cash, cash equivalents and restricted cash at beginning of the period"
}
}
},
"localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
"auth_ref": [
"r63",
"r311"
],
"calculation": {
"http://achievelifesciences.com/20220630/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited": {
"order": null,
"parentTag": null,
"root": true,
"weight": null
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
"label": "Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect",
"totalLabel": "Net decrease in cash, cash equivalents and restricted cash"
}
}
},
"localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_CashEquivalentsAtCarryingValue": {
"auth_ref": [
"r6"
],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
"label": "Cash Equivalents At Carrying Value",
"terseLabel": "Cash equivalents, amortized cost and estimated fair value"
}
}
},
"localname": "CashEquivalentsAtCarryingValue",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfCashEquivalentsDetail"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_CashFlowOperatingActivitiesLesseeAbstract": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Cash Flow Operating Activities Lessee [Abstract]",
"terseLabel": "Cash paid for amounts included in the measurement of lease liabilities:"
}
}
},
"localname": "CashFlowOperatingActivitiesLesseeAbstract",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfOtherInformationRelatedToLeasesDetail"
],
"xbrltype": "stringItemType"
},
"us-gaap_ClassOfStockDomain": {
"auth_ref": [
"r14",
"r15",
"r16",
"r72",
"r75",
"r95",
"r96",
"r97",
"r99",
"r101",
"r106",
"r107",
"r108",
"r125",
"r155",
"r159",
"r160",
"r161",
"r164",
"r165",
"r200",
"r201",
"r205",
"r209",
"r215",
"r310",
"r407"
],
"lang": {
"en-us": {
"role": {
"documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
"label": "Class Of Stock [Domain]",
"terseLabel": "Class of Stock"
}
}
},
"localname": "ClassOfStockDomain",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/StatementConsolidatedBalanceSheetsParentheticalUnaudited",
"http://achievelifesciences.com/20220630/taxonomy/role/StatementConsolidatedBalanceSheetsUnaudited"
],
"xbrltype": "domainItemType"
},
"us-gaap_ClassOfWarrantOrRightAxis": {
"auth_ref": [
"r220",
"r238"
],
"lang": {
"en-us": {
"role": {
"documentation": "Information by type of warrant or right issued.",
"label": "Class Of Warrant Or Right [Axis]",
"terseLabel": "Class of Warrant or Right"
}
}
},
"localname": "ClassOfWarrantOrRightAxis",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureCommonStockCommonStockWarrantsAdditionalInformationDetail",
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureCommonStockSummaryOfOutstandingWarrantsDetail"
],
"xbrltype": "stringItemType"
},
"us-gaap_ClassOfWarrantOrRightDomain": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months.",
"label": "Class Of Warrant Or Right [Domain]",
"terseLabel": "Class of Warrant or Right"
}
}
},
"localname": "ClassOfWarrantOrRightDomain",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureCommonStockCommonStockWarrantsAdditionalInformationDetail",
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureCommonStockSummaryOfOutstandingWarrantsDetail"
],
"xbrltype": "domainItemType"
},
"us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
"auth_ref": [
"r216"
],
"lang": {
"en-us": {
"role": {
"documentation": "Exercise price per share or per unit of warrants or rights outstanding.",
"label": "Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1",
"terseLabel": "Exercise price per share of warrant",
"verboseLabel": "Exercise price per Share"
}
}
},
"localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureCommonStockCommonStockWarrantsAdditionalInformationDetail",
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureCommonStockSummaryOfOutstandingWarrantsDetail"
],
"xbrltype": "perShareItemType"
},
"us-gaap_ClassOfWarrantOrRightLineItems": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
"label": "Class Of Warrant Or Right [Line Items]",
"terseLabel": "Class of Warrant or Right [Line Items]"
}
}
},
"localname": "ClassOfWarrantOrRightLineItems",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureCommonStockCommonStockWarrantsAdditionalInformationDetail",
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureCommonStockSummaryOfOutstandingWarrantsDetail"
],
"xbrltype": "stringItemType"
},
"us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
"auth_ref": [
"r216"
],
"lang": {
"en-us": {
"role": {
"documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.",
"label": "Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights",
"terseLabel": "Warrants to purchase common stock"
}
}
},
"localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureCommonStockCommonStockWarrantsAdditionalInformationDetail"
],
"xbrltype": "sharesItemType"
},
"us-gaap_ClassOfWarrantOrRightOutstanding": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Number of warrants or rights outstanding.",
"label": "Class Of Warrant Or Right Outstanding",
"verboseLabel": "Total Outstanding and Exercisable"
}
}
},
"localname": "ClassOfWarrantOrRightOutstanding",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureCommonStockSummaryOfOutstandingWarrantsDetail"
],
"xbrltype": "sharesItemType"
},
"us-gaap_ClassOfWarrantOrRightTable": {
"auth_ref": [
"r220",
"r238"
],
"lang": {
"en-us": {
"role": {
"documentation": "Disclosure for warrants or rights issued, which includes the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.",
"label": "Class Of Warrant Or Right [Table]",
"terseLabel": "Class Of Warrant Or Right [Table]"
}
}
},
"localname": "ClassOfWarrantOrRightTable",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureCommonStockCommonStockWarrantsAdditionalInformationDetail",
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureCommonStockSummaryOfOutstandingWarrantsDetail"
],
"xbrltype": "stringItemType"
},
"us-gaap_CollaborativeArrangementDisclosureTextBlock": {
"auth_ref": [
"r282",
"r283",
"r285"
],
"lang": {
"en-us": {
"role": {
"documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.",
"label": "Collaborative Arrangement Disclosure [Text Block]",
"terseLabel": "License Agreements"
}
}
},
"localname": "CollaborativeArrangementDisclosureTextBlock",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureLicenseAgreements"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
"label": "Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]",
"terseLabel": "Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]"
}
}
},
"localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetail"
],
"xbrltype": "stringItemType"
},
"us-gaap_CommitmentsAndContingencies": {
"auth_ref": [
"r35",
"r361",
"r375"
],
"calculation": {
"http://achievelifesciences.com/20220630/taxonomy/role/StatementConsolidatedBalanceSheetsUnaudited": {
"order": 10020.0,
"parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
"label": "Commitments And Contingencies",
"terseLabel": "Commitments and contingencies [note 9]"
}
}
},
"localname": "CommitmentsAndContingencies",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/StatementConsolidatedBalanceSheetsUnaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Commitments And Contingencies Disclosure [Abstract]"
}
}
},
"localname": "CommitmentsAndContingenciesDisclosureAbstract",
"nsuri": "http://fasb.org/us-gaap/2022",
"xbrltype": "stringItemType"
},
"us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
"auth_ref": [
"r145",
"r146",
"r147",
"r152",
"r389"
],
"lang": {
"en-us": {
"role": {
"documentation": "The entire disclosure for commitments and contingencies.",
"label": "Commitments And Contingencies Disclosure [Text Block]",
"terseLabel": "Commitments and Contingencies"
}
}
},
"localname": "CommitmentsAndContingenciesDisclosureTextBlock",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureCommitmentsAndContingencies"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_CommonStockIncludingAdditionalPaidInCapitalMember": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Common stock held by shareholders with par value plus amounts in excess of par value or issuance value (in cases of no-par value stock).",
"label": "Common Stock Including Additional Paid In Capital [Member]",
"terseLabel": "Additional paid-in capital [Member]"
}
}
},
"localname": "CommonStockIncludingAdditionalPaidInCapitalMember",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/StatementConsolidatedStatementsOfStockholderSEquityUnaudited"
],
"xbrltype": "domainItemType"
},
"us-gaap_CommonStockMember": {
"auth_ref": [
"r80",
"r81",
"r297"
],
"lang": {
"en-us": {
"role": {
"documentation": "Stock that is subordinate to all other stock of the issuer.",
"label": "Common Stock [Member]",
"terseLabel": "Common stock [Member]"
}
}
},
"localname": "CommonStockMember",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureCommonStockIssuedAndOutstandingSharesAdditionalInformationDetail",
"http://achievelifesciences.com/20220630/taxonomy/role/StatementConsolidatedStatementsOfStockholderSEquityUnaudited"
],
"xbrltype": "domainItemType"
},
"us-gaap_CommonStockParOrStatedValuePerShare": {
"auth_ref": [
"r16"
],
"lang": {
"en-us": {
"role": {
"documentation": "Face amount or stated value per share of common stock.",
"label": "Common Stock Par Or Stated Value Per Share",
"terseLabel": "Common stock, par value"
}
}
},
"localname": "CommonStockParOrStatedValuePerShare",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureCommonStockAuthorizedAdditionalInformationDetail",
"http://achievelifesciences.com/20220630/taxonomy/role/StatementConsolidatedBalanceSheetsParentheticalUnaudited"
],
"xbrltype": "perShareItemType"
},
"us-gaap_CommonStockSharesAuthorized": {
"auth_ref": [
"r16"
],
"lang": {
"en-us": {
"role": {
"documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
"label": "Common Stock Shares Authorized",
"terseLabel": "Common stock, shares authorized"
}
}
},
"localname": "CommonStockSharesAuthorized",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureCommonStockAuthorizedAdditionalInformationDetail",
"http://achievelifesciences.com/20220630/taxonomy/role/StatementConsolidatedBalanceSheetsParentheticalUnaudited"
],
"xbrltype": "sharesItemType"
},
"us-gaap_CommonStockSharesIssued": {
"auth_ref": [
"r16"
],
"lang": {
"en-us": {
"role": {
"documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
"label": "Common Stock Shares Issued",
"terseLabel": "Common stock, shares issued"
}
}
},
"localname": "CommonStockSharesIssued",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/StatementConsolidatedBalanceSheetsParentheticalUnaudited"
],
"xbrltype": "sharesItemType"
},
"us-gaap_CommonStockSharesOutstanding": {
"auth_ref": [
"r16",
"r215"
],
"lang": {
"en-us": {
"role": {
"documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
"label": "Common Stock Shares Outstanding",
"terseLabel": "Common stock, shares outstanding"
}
}
},
"localname": "CommonStockSharesOutstanding",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/StatementConsolidatedBalanceSheetsParentheticalUnaudited"
],
"xbrltype": "sharesItemType"
},
"us-gaap_CommonStockValue": {
"auth_ref": [
"r16",
"r339"
],
"calculation": {
"http://achievelifesciences.com/20220630/taxonomy/role/StatementConsolidatedBalanceSheetsUnaudited": {
"order": 10060.0,
"parentTag": "us-gaap_StockholdersEquity",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
"label": "Common Stock Value",
"terseLabel": "Common stock, $0.001 par value, 150,000,000 shares authorized, 9,681,855 issued and outstanding at June 30, 2022 and 9,453,542 issued and outstanding at December 31, 2021"
}
}
},
"localname": "CommonStockValue",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/StatementConsolidatedBalanceSheetsUnaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_ContractualObligation": {
"auth_ref": [
],
"calculation": {
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfContractualObligationsDetail": {
"order": null,
"parentTag": null,
"root": true,
"weight": null
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of contractual obligation, including but not limited to, long-term debt, capital lease obligations, operating lease obligations, purchase obligations, and other commitments.",
"label": "Contractual Obligation",
"totalLabel": "Total"
}
}
},
"localname": "ContractualObligation",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfContractualObligationsDetail"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_ContractualObligationDueAfterFifthYear": {
"auth_ref": [
],
"calculation": {
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfContractualObligationsDetail": {
"order": 10040.0,
"parentTag": "us-gaap_ContractualObligation",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of contractual obligation to be paid after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
"label": "Contractual Obligation Due After Fifth Year",
"terseLabel": "More than 5 years"
}
}
},
"localname": "ContractualObligationDueAfterFifthYear",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfContractualObligationsDetail"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_ContractualObligationDueInFourthAndFifthYear": {
"auth_ref": [
],
"calculation": {
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfContractualObligationsDetail": {
"order": 10030.0,
"parentTag": "us-gaap_ContractualObligation",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of contractual obligation to be paid in fourth and fifth fiscal years following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
"label": "Contractual Obligation Due In Fourth And Fifth Year",
"terseLabel": "3-5 years"
}
}
},
"localname": "ContractualObligationDueInFourthAndFifthYear",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfContractualObligationsDetail"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_ContractualObligationDueInNextTwelveMonths": {
"auth_ref": [
],
"calculation": {
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfContractualObligationsDetail": {
"order": 10010.0,
"parentTag": "us-gaap_ContractualObligation",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of contractual obligation to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
"label": "Contractual Obligation Due In Next Twelve Months",
"terseLabel": "Less than 1 year"
}
}
},
"localname": "ContractualObligationDueInNextTwelveMonths",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfContractualObligationsDetail"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_ContractualObligationDueInSecondAndThirdYear": {
"auth_ref": [
],
"calculation": {
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfContractualObligationsDetail": {
"order": 10020.0,
"parentTag": "us-gaap_ContractualObligation",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of contractual obligation to be paid in second and third fiscal years following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
"label": "Contractual Obligation Due In Second And Third Year",
"terseLabel": "1-3 years"
}
}
},
"localname": "ContractualObligationDueInSecondAndThirdYear",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfContractualObligationsDetail"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_ConvertibleDebt": {
"auth_ref": [
"r13",
"r358",
"r370"
],
"calculation": {
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureConvertibleDebtScheduleOfConvertibleDebtBalanceDetails": {
"order": null,
"parentTag": null,
"root": true,
"weight": null
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Including the current and noncurrent portions, carrying amount of debt identified as being convertible into another form of financial instrument (typically the entity's common stock) as of the balance sheet date, which originally required full repayment more than twelve months after issuance or greater than the normal operating cycle of the company.",
"label": "Convertible Debt",
"terseLabel": "Convertible Debt, Carrying Value",
"totalLabel": "Convertible debt"
}
}
},
"localname": "ConvertibleDebt",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureConvertibleDebtScheduleOfConvertibleDebtBalanceDetails",
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfAggregateFairValueOfPrincipalAmountOfConvertibleDebtDetail"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_ConvertibleDebtFairValueDisclosures": {
"auth_ref": [
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Fair value portion of borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.",
"label": "Convertible Debt Fair Value Disclosures",
"terseLabel": "Convertible Debt, Fair Value"
}
}
},
"localname": "ConvertibleDebtFairValueDisclosures",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfAggregateFairValueOfPrincipalAmountOfConvertibleDebtDetail"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_ConvertibleDebtMember": {
"auth_ref": [
"r166",
"r167",
"r168",
"r170",
"r180",
"r181",
"r182",
"r186",
"r187",
"r188",
"r189",
"r190",
"r195",
"r196",
"r197",
"r198"
],
"lang": {
"en-us": {
"role": {
"documentation": "Borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.",
"label": "Convertible Debt [Member]",
"terseLabel": "Convertible Indebtedness [Member]"
}
}
},
"localname": "ConvertibleDebtMember",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureConvertibleDebtAdditionalInformationDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_ConvertibleDebtNoncurrent": {
"auth_ref": [
"r34"
],
"calculation": {
"http://achievelifesciences.com/20220630/taxonomy/role/StatementConsolidatedBalanceSheetsUnaudited": {
"order": 10110.0,
"parentTag": "us-gaap_Liabilities",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Carrying amount of long-term convertible debt as of the balance sheet date, net of the amount due in the next twelve months or greater than the normal operating cycle, if longer. The debt is convertible into another form of financial instrument, typically the entity's common stock.",
"label": "Convertible Debt Noncurrent",
"terseLabel": "Convertible debt [note 7]"
}
}
},
"localname": "ConvertibleDebtNoncurrent",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/StatementConsolidatedBalanceSheetsUnaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_ConvertibleDebtTableTextBlock": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Tabular disclosure of convertible debt instrument. Includes, but is not limited to, principal amount and amortized premium or discount.",
"label": "Convertible Debt Table [Text Block]",
"terseLabel": "Schedule of Aggregate Fair Value of Principal Amount of Convertible Debt"
}
}
},
"localname": "ConvertibleDebtTableTextBlock",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureConvertibleDebtTables",
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureFairValueMeasurementsTables"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_CostsAndExpenses": {
"auth_ref": [
"r53"
],
"calculation": {
"http://achievelifesciences.com/20220630/taxonomy/role/StatementConsolidatedStatementsOfLossAndComprehensiveLossUnaudited": {
"order": 10010.0,
"parentTag": "us-gaap_NetIncomeLoss",
"weight": -1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Total costs of sales and operating expenses for the period.",
"label": "Costs And Expenses",
"totalLabel": "Total operating expenses"
}
}
},
"localname": "CostsAndExpenses",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/StatementConsolidatedStatementsOfLossAndComprehensiveLossUnaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_CostsAndExpensesAbstract": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Costs And Expenses [Abstract]",
"terseLabel": "EXPENSES"
}
}
},
"localname": "CostsAndExpensesAbstract",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/StatementConsolidatedStatementsOfLossAndComprehensiveLossUnaudited"
],
"xbrltype": "stringItemType"
},
"us-gaap_DebtDisclosureAbstract": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Debt Disclosure [Abstract]"
}
}
},
"localname": "DebtDisclosureAbstract",
"nsuri": "http://fasb.org/us-gaap/2022",
"xbrltype": "stringItemType"
},
"us-gaap_DebtDisclosureTextBlock": {
"auth_ref": [
"r71",
"r173",
"r174",
"r175",
"r176",
"r177",
"r178",
"r179",
"r184",
"r191",
"r192",
"r193",
"r199"
],
"lang": {
"en-us": {
"role": {
"documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
"label": "Debt Disclosure [Text Block]",
"terseLabel": "Convertible Debt"
}
}
},
"localname": "DebtDisclosureTextBlock",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureConvertibleDebt"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_DebtInstrumentAxis": {
"auth_ref": [
"r11",
"r12",
"r13",
"r74",
"r78",
"r167",
"r168",
"r169",
"r170",
"r171",
"r172",
"r174",
"r180",
"r181",
"r182",
"r183",
"r185",
"r186",
"r187",
"r188",
"r189",
"r190",
"r195",
"r196",
"r197",
"r198",
"r321",
"r357",
"r358",
"r368"
],
"lang": {
"en-us": {
"role": {
"documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
"label": "Debt Instrument [Axis]",
"terseLabel": "Debt Instrument"
}
}
},
"localname": "DebtInstrumentAxis",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureConvertibleDebtAdditionalInformationDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.",
"label": "Debt Instrument Basis Spread On Variable Rate1",
"terseLabel": "Convertible debt, interest rate"
}
}
},
"localname": "DebtInstrumentBasisSpreadOnVariableRate1",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureConvertibleDebtAdditionalInformationDetails"
],
"xbrltype": "percentItemType"
},
"us-gaap_DebtInstrumentConvertibleConversionPrice1": {
"auth_ref": [
"r169",
"r194"
],
"lang": {
"en-us": {
"role": {
"documentation": "The price per share of the conversion feature embedded in the debt instrument.",
"label": "Debt Instrument Convertible Conversion Price1",
"terseLabel": "Conversion price per share"
}
}
},
"localname": "DebtInstrumentConvertibleConversionPrice1",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureConvertibleDebtAdditionalInformationDetails"
],
"xbrltype": "perShareItemType"
},
"us-gaap_DebtInstrumentConvertibleConversionRatio1": {
"auth_ref": [
"r33",
"r169",
"r216",
"r217",
"r218"
],
"lang": {
"en-us": {
"role": {
"documentation": "Ratio applied to the conversion of debt instrument into equity with equity shares divided by debt principal amount.",
"label": "Debt Instrument Convertible Conversion Ratio1",
"terseLabel": "Debt instrument, liquidity ratio"
}
}
},
"localname": "DebtInstrumentConvertibleConversionRatio1",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureConvertibleDebtAdditionalInformationDetails"
],
"xbrltype": "pureItemType"
},
"us-gaap_DebtInstrumentConvertibleStockPriceTrigger": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Price of the entity's common stock which would be required to be attained for the conversion feature embedded in the debt instrument to become effective.",
"label": "Debt Instrument Convertible Stock Price Trigger",
"terseLabel": "Stock price trigger"
}
}
},
"localname": "DebtInstrumentConvertibleStockPriceTrigger",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureConvertibleDebtAdditionalInformationDetails"
],
"xbrltype": "perShareItemType"
},
"us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Threshold period of specified consecutive trading days within which common stock price to conversion price of convertible debt instrument must exceed threshold percentage for specified number of trading days to trigger conversion feature.",
"label": "Debt Instrument Convertible Threshold Consecutive Trading Days1",
"terseLabel": "Threshold consecutive trading days"
}
}
},
"localname": "DebtInstrumentConvertibleThresholdConsecutiveTradingDays1",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureConvertibleDebtAdditionalInformationDetails"
],
"xbrltype": "integerItemType"
},
"us-gaap_DebtInstrumentFaceAmount": {
"auth_ref": [
"r167",
"r195",
"r196",
"r319",
"r321",
"r322"
],
"calculation": {
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureConvertibleDebtScheduleOfConvertibleDebtBalanceDetails": {
"order": 10010.0,
"parentTag": "us-gaap_ConvertibleDebt",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Face (par) amount of debt instrument at time of issuance.",
"label": "Debt Instrument Face Amount",
"terseLabel": "Convertible Debt, Principal Amount",
"verboseLabel": "Convertible debt principal amount"
}
}
},
"localname": "DebtInstrumentFaceAmount",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureConvertibleDebtAdditionalInformationDetails",
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureConvertibleDebtScheduleOfConvertibleDebtBalanceDetails",
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfAggregateFairValueOfPrincipalAmountOfConvertibleDebtDetail"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_DebtInstrumentInterestRateStatedPercentage": {
"auth_ref": [
"r30",
"r168"
],
"lang": {
"en-us": {
"role": {
"documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
"label": "Debt Instrument Interest Rate Stated Percentage",
"terseLabel": "Convertible debt compound interest"
}
}
},
"localname": "DebtInstrumentInterestRateStatedPercentage",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureConvertibleDebtAdditionalInformationDetails"
],
"xbrltype": "percentItemType"
},
"us-gaap_DebtInstrumentMaturityDate": {
"auth_ref": [
"r31",
"r170",
"r303"
],
"lang": {
"en-us": {
"role": {
"documentation": "Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format.",
"label": "Debt Instrument Maturity Date",
"terseLabel": "Maturity date"
}
}
},
"localname": "DebtInstrumentMaturityDate",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureConvertibleDebtAdditionalInformationDetails"
],
"xbrltype": "dateItemType"
},
"us-gaap_DebtInstrumentNameDomain": {
"auth_ref": [
"r34",
"r74",
"r78",
"r167",
"r168",
"r169",
"r170",
"r171",
"r172",
"r174",
"r180",
"r181",
"r182",
"r183",
"r185",
"r186",
"r187",
"r188",
"r189",
"r190",
"r195",
"r196",
"r197",
"r198",
"r321"
],
"lang": {
"en-us": {
"role": {
"documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
"label": "Debt Instrument Name [Domain]",
"terseLabel": "Debt Instrument, Name"
}
}
},
"localname": "DebtInstrumentNameDomain",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureConvertibleDebtAdditionalInformationDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_DebtInstrumentPaymentTerms": {
"auth_ref": [
"r32",
"r366"
],
"lang": {
"en-us": {
"role": {
"documentation": "Description of the payment terms of the debt instrument (for example, whether periodic payments include principal and frequency of payments) and discussion about any contingencies associated with the payment.",
"label": "Debt Instrument Payment Terms",
"terseLabel": "Debt instrument, repayment terms"
}
}
},
"localname": "DebtInstrumentPaymentTerms",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureConvertibleDebtAdditionalInformationDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_DebtInstrumentRedemptionPeriodAxis": {
"auth_ref": [
"r367"
],
"lang": {
"en-us": {
"role": {
"documentation": "Information about timing of debt redemption features under terms of the debt agreement.",
"label": "Debt Instrument Redemption Period [Axis]",
"terseLabel": "Debt Instrument, Redemption, Period"
}
}
},
"localname": "DebtInstrumentRedemptionPeriodAxis",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureConvertibleDebtAdditionalInformationDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_DebtInstrumentRedemptionPeriodDomain": {
"auth_ref": [
"r367"
],
"lang": {
"en-us": {
"role": {
"documentation": "Period as defined under terms of the debt agreement for debt redemption features.",
"label": "Debt Instrument Redemption Period [Domain]",
"terseLabel": "Debt Instrument, Redemption, Period"
}
}
},
"localname": "DebtInstrumentRedemptionPeriodDomain",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureConvertibleDebtAdditionalInformationDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Percentage of principal amount of debt redeemed.",
"label": "Debt Instrument Redemption Price Percentage Of Principal Amount Redeemed",
"terseLabel": "Percentage of principal amount to be repaid"
}
}
},
"localname": "DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureConvertibleDebtAdditionalInformationDetails"
],
"xbrltype": "percentItemType"
},
"us-gaap_DeferredFinanceCostsNet": {
"auth_ref": [
"r180",
"r320"
],
"calculation": {
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureConvertibleDebtScheduleOfConvertibleDebtBalanceDetails": {
"order": 10020.0,
"parentTag": "us-gaap_ConvertibleDebt",
"weight": -1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.",
"label": "Deferred Finance Costs Net",
"negatedLabel": "Transaction Costs"
}
}
},
"localname": "DeferredFinanceCostsNet",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureConvertibleDebtScheduleOfConvertibleDebtBalanceDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_DepreciationAndAmortization": {
"auth_ref": [
"r66",
"r141"
],
"calculation": {
"http://achievelifesciences.com/20220630/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited": {
"order": 10100.0,
"parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.",
"label": "Depreciation And Amortization",
"terseLabel": "Depreciation and amortization [note 4]"
}
}
},
"localname": "DepreciationAndAmortization",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]"
}
}
},
"localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
"nsuri": "http://fasb.org/us-gaap/2022",
"xbrltype": "stringItemType"
},
"us-gaap_EarningsPerShareBasic": {
"auth_ref": [
"r51",
"r85",
"r86",
"r87",
"r88",
"r89",
"r93",
"r95",
"r99",
"r100",
"r101",
"r103",
"r104",
"r298",
"r299",
"r363",
"r378"
],
"lang": {
"en-us": {
"role": {
"documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
"label": "Earnings Per Share Basic",
"terseLabel": "Basic net loss per common share [note 8[d]]"
}
}
},
"localname": "EarningsPerShareBasic",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/StatementConsolidatedStatementsOfLossAndComprehensiveLossUnaudited"
],
"xbrltype": "perShareItemType"
},
"us-gaap_EarningsPerShareDiluted": {
"auth_ref": [
"r51",
"r85",
"r86",
"r87",
"r88",
"r89",
"r95",
"r99",
"r100",
"r101",
"r103",
"r104",
"r298",
"r299",
"r363",
"r378"
],
"lang": {
"en-us": {
"role": {
"documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
"label": "Earnings Per Share Diluted",
"terseLabel": "Diluted net loss per common share [note 8[d]]"
}
}
},
"localname": "EarningsPerShareDiluted",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/StatementConsolidatedStatementsOfLossAndComprehensiveLossUnaudited"
],
"xbrltype": "perShareItemType"
},
"us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
"auth_ref": [
"r311"
],
"calculation": {
"http://achievelifesciences.com/20220630/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited": {
"order": 10030.0,
"parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
"label": "Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations",
"terseLabel": "Effect of exchange rate changes on cash"
}
}
},
"localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_EmployeeRelatedLiabilitiesCurrent": {
"auth_ref": [
"r28"
],
"calculation": {
"http://achievelifesciences.com/20220630/taxonomy/role/StatementConsolidatedBalanceSheetsUnaudited": {
"order": 10160.0,
"parentTag": "us-gaap_LiabilitiesCurrent",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
"label": "Employee Related Liabilities Current",
"terseLabel": "Accrued compensation"
}
}
},
"localname": "EmployeeRelatedLiabilitiesCurrent",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/StatementConsolidatedBalanceSheetsUnaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
"label": "Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]",
"terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]"
}
}
},
"localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureCommonStockSummaryOfShareBasedCompensationExpenseForStockOptionsRestrictedStockAndEmployeeSharePurchasePlanDetail"
],
"xbrltype": "stringItemType"
},
"us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
"auth_ref": [
"r269"
],
"lang": {
"en-us": {
"role": {
"documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
"label": "Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1",
"terseLabel": "Weighted-average period, restricted stock awards"
}
}
},
"localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureCommonStockRestrictedStockUnitAwardsAdditionalInformationDetail",
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureCommonStockStockOptionsAdditionalInformationDetail"
],
"xbrltype": "durationItemType"
},
"us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": {
"auth_ref": [
"r269"
],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.",
"label": "Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Share Based Awards Other Than Options",
"terseLabel": "Total unrecognized compensation expense related to the Company's restricted stock unit awards"
}
}
},
"localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureCommonStockRestrictedStockUnitAwardsAdditionalInformationDetail"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
"auth_ref": [
"r269"
],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of cost to be recognized for option under share-based payment arrangement.",
"label": "Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options",
"terseLabel": "Unrecognized compensation expense related to stock options granted"
}
}
},
"localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureCommonStockStockOptionsAdditionalInformationDetail"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_EmployeeStockMember": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock.",
"label": "Employee Stock [Member]",
"terseLabel": "Employee Share Purchase Plan"
}
}
},
"localname": "EmployeeStockMember",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureCommonStockEmployeeSharePurchasePlanAdditionalInformationDetail"
],
"xbrltype": "domainItemType"
},
"us-gaap_EmployeeStockOptionMember": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
"label": "Employee Stock Option [Member]",
"terseLabel": "Stock Options [Member]"
}
}
},
"localname": "EmployeeStockOptionMember",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureCommonStockStockOptionsAdditionalInformationDetail"
],
"xbrltype": "domainItemType"
},
"us-gaap_EquityAbstract": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Equity [Abstract]"
}
}
},
"localname": "EquityAbstract",
"nsuri": "http://fasb.org/us-gaap/2022",
"xbrltype": "stringItemType"
},
"us-gaap_EquityComponentDomain": {
"auth_ref": [
"r0",
"r46",
"r47",
"r48",
"r80",
"r81",
"r82",
"r84",
"r90",
"r92",
"r105",
"r126",
"r215",
"r219",
"r272",
"r273",
"r274",
"r279",
"r280",
"r297",
"r312",
"r313",
"r314",
"r315",
"r316",
"r317",
"r335",
"r382",
"r383",
"r384"
],
"lang": {
"en-us": {
"role": {
"documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
"label": "Equity Component [Domain]",
"terseLabel": "Equity Component"
}
}
},
"localname": "EquityComponentDomain",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureCommonStockIssuedAndOutstandingSharesAdditionalInformationDetail",
"http://achievelifesciences.com/20220630/taxonomy/role/StatementConsolidatedStatementsOfStockholderSEquityUnaudited"
],
"xbrltype": "domainItemType"
},
"us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
"label": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]",
"terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]"
}
}
},
"localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAssetsMeasuredAtFairValueOnRecurringBasisDetail"
],
"xbrltype": "stringItemType"
},
"us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
"auth_ref": [
"r300",
"r301",
"r306"
],
"lang": {
"en-us": {
"role": {
"documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
"label": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]",
"terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]"
}
}
},
"localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAssetsMeasuredAtFairValueOnRecurringBasisDetail"
],
"xbrltype": "stringItemType"
},
"us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": {
"auth_ref": [
"r304"
],
"lang": {
"en-us": {
"role": {
"documentation": "Class of asset.",
"label": "Fair Value Assets Measured On Recurring Basis Unobservable Input Reconciliation By Asset Class [Domain]",
"terseLabel": "Asset Class"
}
}
},
"localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAssetsMeasuredAtFairValueOnRecurringBasisDetail",
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfCashEquivalentsDetail"
],
"xbrltype": "domainItemType"
},
"us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
"label": "Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]",
"terseLabel": "Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]"
}
}
},
"localname": "FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfCashEquivalentsDetail"
],
"xbrltype": "stringItemType"
},
"us-gaap_FairValueByAssetClassAxis": {
"auth_ref": [
"r300",
"r306"
],
"lang": {
"en-us": {
"role": {
"documentation": "Information by class of asset.",
"label": "Fair Value By Asset Class [Axis]",
"terseLabel": "Asset Class"
}
}
},
"localname": "FairValueByAssetClassAxis",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAssetsMeasuredAtFairValueOnRecurringBasisDetail",
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfCashEquivalentsDetail"
],
"xbrltype": "stringItemType"
},
"us-gaap_FairValueByBalanceSheetGroupingTable": {
"auth_ref": [
"r300",
"r308",
"r309"
],
"lang": {
"en-us": {
"role": {
"documentation": "Disclosure of information about the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.",
"label": "Fair Value By Balance Sheet Grouping [Table]",
"terseLabel": "Fair Value By Balance Sheet Grouping [Table]"
}
}
},
"localname": "FairValueByBalanceSheetGroupingTable",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfCashEquivalentsDetail"
],
"xbrltype": "stringItemType"
},
"us-gaap_FairValueByFairValueHierarchyLevelAxis": {
"auth_ref": [
"r182",
"r195",
"r196",
"r225",
"r226",
"r227",
"r228",
"r229",
"r230",
"r231",
"r232",
"r301",
"r340",
"r341",
"r342"
],
"lang": {
"en-us": {
"role": {
"documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
"label": "Fair Value By Fair Value Hierarchy Level [Axis]",
"terseLabel": "Fair Value Hierarchy and NAV"
}
}
},
"localname": "FairValueByFairValueHierarchyLevelAxis",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAssetsMeasuredAtFairValueOnRecurringBasisDetail"
],
"xbrltype": "stringItemType"
},
"us-gaap_FairValueByMeasurementFrequencyAxis": {
"auth_ref": [
"r300",
"r301",
"r302",
"r303",
"r307"
],
"lang": {
"en-us": {
"role": {
"documentation": "Information by measurement frequency.",
"label": "Fair Value By Measurement Frequency [Axis]",
"terseLabel": "Measurement Frequency"
}
}
},
"localname": "FairValueByMeasurementFrequencyAxis",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAssetsMeasuredAtFairValueOnRecurringBasisDetail"
],
"xbrltype": "stringItemType"
},
"us-gaap_FairValueDisclosuresAbstract": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Fair Value Disclosures [Abstract]"
}
}
},
"localname": "FairValueDisclosuresAbstract",
"nsuri": "http://fasb.org/us-gaap/2022",
"xbrltype": "stringItemType"
},
"us-gaap_FairValueDisclosuresTextBlock": {
"auth_ref": [
"r305"
],
"lang": {
"en-us": {
"role": {
"documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
"label": "Fair Value Disclosures [Text Block]",
"terseLabel": "Fair Value Measurements"
}
}
},
"localname": "FairValueDisclosuresTextBlock",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureFairValueMeasurements"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_FairValueInputsLevel1Member": {
"auth_ref": [
"r182",
"r225",
"r226",
"r231",
"r232",
"r301",
"r340"
],
"lang": {
"en-us": {
"role": {
"documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
"label": "Fair Value Inputs Level1 [Member]",
"terseLabel": "Level 1 [Member]"
}
}
},
"localname": "FairValueInputsLevel1Member",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAssetsMeasuredAtFairValueOnRecurringBasisDetail"
],
"xbrltype": "domainItemType"
},
"us-gaap_FairValueInputsLevel2Member": {
"auth_ref": [
"r182",
"r195",
"r196",
"r225",
"r226",
"r231",
"r232",
"r301",
"r341"
],
"lang": {
"en-us": {
"role": {
"documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
"label": "Fair Value Inputs Level2 [Member]",
"terseLabel": "Level 2 [Member]"
}
}
},
"localname": "FairValueInputsLevel2Member",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAssetsMeasuredAtFairValueOnRecurringBasisDetail"
],
"xbrltype": "domainItemType"
},
"us-gaap_FairValueInputsLevel3Member": {
"auth_ref": [
"r182",
"r195",
"r196",
"r225",
"r226",
"r227",
"r228",
"r229",
"r230",
"r231",
"r232",
"r301",
"r342"
],
"lang": {
"en-us": {
"role": {
"documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
"label": "Fair Value Inputs Level3 [Member]",
"terseLabel": "Level 3 [Member]"
}
}
},
"localname": "FairValueInputsLevel3Member",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAssetsMeasuredAtFairValueOnRecurringBasisDetail"
],
"xbrltype": "domainItemType"
},
"us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
"label": "Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]",
"terseLabel": "Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]"
}
}
},
"localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetail"
],
"xbrltype": "stringItemType"
},
"us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable": {
"auth_ref": [
"r304",
"r306"
],
"lang": {
"en-us": {
"role": {
"documentation": "Schedule of information required and determined to be provided for purposes of reconciling beginning and ending balances of fair value measurements of liabilities using significant unobservable inputs (level 3). Separately presenting changes during the period, attributable to: (1) total gains or losses for the period (realized and unrealized) and location reported in the statement of income (or activities); (2) purchases, sales, issuances, and settlements (net); (3) transfers in and/or out of Level 3.",
"label": "Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Table]",
"terseLabel": "Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Table]"
}
}
},
"localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetail"
],
"xbrltype": "stringItemType"
},
"us-gaap_FairValueMeasurementFrequencyDomain": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Measurement frequency.",
"label": "Fair Value Measurement Frequency [Domain]",
"terseLabel": "Measurement Frequency"
}
}
},
"localname": "FairValueMeasurementFrequencyDomain",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAssetsMeasuredAtFairValueOnRecurringBasisDetail"
],
"xbrltype": "domainItemType"
},
"us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
"auth_ref": [
"r182",
"r195",
"r196",
"r225",
"r226",
"r227",
"r228",
"r229",
"r230",
"r231",
"r232",
"r340",
"r341",
"r342"
],
"lang": {
"en-us": {
"role": {
"documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
"label": "Fair Value Measurements Fair Value Hierarchy [Domain]",
"terseLabel": "Fair Value Hierarchy and NAV"
}
}
},
"localname": "FairValueMeasurementsFairValueHierarchyDomain",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAssetsMeasuredAtFairValueOnRecurringBasisDetail"
],
"xbrltype": "domainItemType"
},
"us-gaap_FairValueMeasurementsRecurringMember": {
"auth_ref": [
"r305",
"r307"
],
"lang": {
"en-us": {
"role": {
"documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
"label": "Fair Value Measurements Recurring [Member]",
"terseLabel": "Fair Value, Measurements, Recurring [Member]"
}
}
},
"localname": "FairValueMeasurementsRecurringMember",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAssetsMeasuredAtFairValueOnRecurringBasisDetail"
],
"xbrltype": "domainItemType"
},
"us-gaap_FiniteLivedIntangibleAssetUsefulLife": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
"label": "Finite Lived Intangible Asset Useful Life",
"terseLabel": "Intangible assets, Useful life"
}
}
},
"localname": "FiniteLivedIntangibleAssetUsefulLife",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureIntangiblesAdditionalInformationDetail"
],
"xbrltype": "durationItemType"
},
"us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
"auth_ref": [
"r8",
"r135"
],
"calculation": {
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureIntangiblesComponentsOfIntangibleAssetsDetail": {
"order": 10020.0,
"parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
"weight": -1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
"label": "Finite Lived Intangible Assets Accumulated Amortization",
"negatedLabel": "Intangible assets, Accumulated Amortization"
}
}
},
"localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureIntangiblesComponentsOfIntangibleAssetsDetail"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
"auth_ref": [
"r137"
],
"calculation": {
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureIntangiblesEstimatedFutureAmortizationExpenseRelatedToIntangibleAssetsDetail": {
"order": 10020.0,
"parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
"label": "Finite Lived Intangible Assets Amortization Expense Next Twelve Months",
"terseLabel": "2023"
}
}
},
"localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureIntangiblesEstimatedFutureAmortizationExpenseRelatedToIntangibleAssetsDetail"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear": {
"auth_ref": [
],
"calculation": {
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureIntangiblesEstimatedFutureAmortizationExpenseRelatedToIntangibleAssetsDetail": {
"order": 10010.0,
"parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year.",
"label": "Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year",
"terseLabel": "2022"
}
}
},
"localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureIntangiblesEstimatedFutureAmortizationExpenseRelatedToIntangibleAssetsDetail"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
"auth_ref": [
"r137"
],
"calculation": {
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureIntangiblesEstimatedFutureAmortizationExpenseRelatedToIntangibleAssetsDetail": {
"order": 10030.0,
"parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
"label": "Finite Lived Intangible Assets Amortization Expense Year Two",
"terseLabel": "2024"
}
}
},
"localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureIntangiblesEstimatedFutureAmortizationExpenseRelatedToIntangibleAssetsDetail"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
"auth_ref": [
"r132",
"r133",
"r135",
"r138",
"r352",
"r353"
],
"lang": {
"en-us": {
"role": {
"documentation": "Information by major type or class of finite-lived intangible assets.",
"label": "Finite Lived Intangible Assets By Major Class [Axis]",
"terseLabel": "Finite-Lived Intangible Assets by Major Class"
}
}
},
"localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureIntangiblesComponentsOfIntangibleAssetsDetail"
],
"xbrltype": "stringItemType"
},
"us-gaap_FiniteLivedIntangibleAssetsFairValueDisclosure": {
"auth_ref": [
"r300"
],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Fair value portion of assets, excluding financial assets, that lack physical substance, having a limited useful life.",
"label": "Finite Lived Intangible Assets Fair Value Disclosure",
"terseLabel": "Intangible assets, Fair Value"
}
}
},
"localname": "FiniteLivedIntangibleAssetsFairValueDisclosure",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureIntangiblesAdditionalInformationDetail"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseCurrentAndFiveSucceedingFiscalYearsAbstract": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Finite Lived Intangible Assets Future Amortization Expense Current And Five Succeeding Fiscal Years [Abstract]",
"terseLabel": "Finite-Lived Intangible Assets, Amortization Expense, Maturity Schedule [Abstract]"
}
}
},
"localname": "FiniteLivedIntangibleAssetsFutureAmortizationExpenseCurrentAndFiveSucceedingFiscalYearsAbstract",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureIntangiblesEstimatedFutureAmortizationExpenseRelatedToIntangibleAssetsDetail"
],
"xbrltype": "stringItemType"
},
"us-gaap_FiniteLivedIntangibleAssetsGross": {
"auth_ref": [
"r135",
"r353"
],
"calculation": {
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureIntangiblesComponentsOfIntangibleAssetsDetail": {
"order": 10010.0,
"parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
"label": "Finite Lived Intangible Assets Gross",
"terseLabel": "Intangible assets, Gross Carrying Value"
}
}
},
"localname": "FiniteLivedIntangibleAssetsGross",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureIntangiblesComponentsOfIntangibleAssetsDetail"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_FiniteLivedIntangibleAssetsLineItems": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
"label": "Finite Lived Intangible Assets [Line Items]",
"terseLabel": "Finite Lived Intangible Assets [Line Items]"
}
}
},
"localname": "FiniteLivedIntangibleAssetsLineItems",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureIntangiblesComponentsOfIntangibleAssetsDetail"
],
"xbrltype": "stringItemType"
},
"us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
"auth_ref": [
"r132",
"r134"
],
"lang": {
"en-us": {
"role": {
"documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.",
"label": "Finite Lived Intangible Assets Major Class Name [Domain]",
"terseLabel": "Finite-Lived Intangible Assets, Major Class Name"
}
}
},
"localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureIntangiblesComponentsOfIntangibleAssetsDetail"
],
"xbrltype": "domainItemType"
},
"us-gaap_FiniteLivedIntangibleAssetsNet": {
"auth_ref": [
"r135",
"r352"
],
"calculation": {
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureIntangiblesComponentsOfIntangibleAssetsDetail": {
"order": null,
"parentTag": null,
"root": true,
"weight": null
},
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureIntangiblesEstimatedFutureAmortizationExpenseRelatedToIntangibleAssetsDetail": {
"order": null,
"parentTag": null,
"root": true,
"weight": null
},
"http://achievelifesciences.com/20220630/taxonomy/role/StatementConsolidatedBalanceSheetsUnaudited": {
"order": 10210.0,
"parentTag": "us-gaap_Assets",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
"label": "Finite Lived Intangible Assets Net",
"terseLabel": "License agreement [note 4 and 5]",
"totalLabel": "Intangible assets, Net Carrying Value"
}
}
},
"localname": "FiniteLivedIntangibleAssetsNet",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureIntangiblesComponentsOfIntangibleAssetsDetail",
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureIntangiblesEstimatedFutureAmortizationExpenseRelatedToIntangibleAssetsDetail",
"http://achievelifesciences.com/20220630/taxonomy/role/StatementConsolidatedBalanceSheetsUnaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_GeneralAndAdministrativeExpense": {
"auth_ref": [
"r54"
],
"calculation": {
"http://achievelifesciences.com/20220630/taxonomy/role/StatementConsolidatedStatementsOfLossAndComprehensiveLossUnaudited": {
"order": 10070.0,
"parentTag": "us-gaap_CostsAndExpenses",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
"label": "General And Administrative Expense",
"terseLabel": "General and administrative"
}
}
},
"localname": "GeneralAndAdministrativeExpense",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/StatementConsolidatedStatementsOfLossAndComprehensiveLossUnaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_GeneralAndAdministrativeExpenseMember": {
"auth_ref": [
"r52"
],
"lang": {
"en-us": {
"role": {
"documentation": "Primary financial statement caption encompassing general and administrative expense.",
"label": "General And Administrative Expense [Member]",
"terseLabel": "General and administrative [Member]"
}
}
},
"localname": "GeneralAndAdministrativeExpenseMember",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureCommonStockSummaryOfShareBasedCompensationExpenseForStockOptionsRestrictedStockAndEmployeeSharePurchasePlanDetail"
],
"xbrltype": "domainItemType"
},
"us-gaap_Goodwill": {
"auth_ref": [
"r7",
"r127",
"r128",
"r129",
"r130",
"r339",
"r355"
],
"calculation": {
"http://achievelifesciences.com/20220630/taxonomy/role/StatementConsolidatedBalanceSheetsUnaudited": {
"order": 10220.0,
"parentTag": "us-gaap_Assets",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
"label": "Goodwill",
"terseLabel": "Goodwill [note 5]"
}
}
},
"localname": "Goodwill",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/StatementConsolidatedBalanceSheetsUnaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Goodwill And Intangible Assets Disclosure [Abstract]"
}
}
},
"localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
"nsuri": "http://fasb.org/us-gaap/2022",
"xbrltype": "stringItemType"
},
"us-gaap_GrantsReceivableCurrent": {
"auth_ref": [
"r17"
],
"calculation": {
"http://achievelifesciences.com/20220630/taxonomy/role/StatementConsolidatedBalanceSheetsUnaudited": {
"order": 10240.0,
"parentTag": "us-gaap_AssetsCurrent",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Carrying amount as of the balance sheet date of amounts due under the terms of governmental, corporate, or foundation grants. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.",
"label": "Grants Receivable Current",
"terseLabel": "Grant receivable [note 3]",
"verboseLabel": "Grant receivable"
}
}
},
"localname": "GrantsReceivableCurrent",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureGovernmentGrantAdditionalInformationDetails",
"http://achievelifesciences.com/20220630/taxonomy/role/StatementConsolidatedBalanceSheetsUnaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_GuaranteeObligationsCurrentCarryingValue": {
"auth_ref": [
"r153"
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "The current carrying amount of the liability for the freestanding or embedded guarantor's obligations under the guarantee or each group of similar guarantees.",
"label": "Guarantee Obligations Current Carrying Value",
"terseLabel": "Indemnification obligations"
}
}
},
"localname": "GuaranteeObligationsCurrentCarryingValue",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_ImpairmentOfIntangibleAssetsFinitelived": {
"auth_ref": [
"r66",
"r139"
],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value.",
"label": "Impairment Of Intangible Assets Finitelived",
"terseLabel": "Impairment of intangible assets"
}
}
},
"localname": "ImpairmentOfIntangibleAssetsFinitelived",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureIntangiblesAdditionalInformationDetail"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_IncomeStatementLocationAxis": {
"auth_ref": [
"r142",
"r144"
],
"lang": {
"en-us": {
"role": {
"documentation": "Information by location in the income statement.",
"label": "Income Statement Location [Axis]",
"terseLabel": "Income Statement Location"
}
}
},
"localname": "IncomeStatementLocationAxis",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureCommonStockSummaryOfShareBasedCompensationExpenseForStockOptionsRestrictedStockAndEmployeeSharePurchasePlanDetail"
],
"xbrltype": "stringItemType"
},
"us-gaap_IncomeStatementLocationDomain": {
"auth_ref": [
"r144"
],
"lang": {
"en-us": {
"role": {
"documentation": "Location in the income statement.",
"label": "Income Statement Location [Domain]",
"terseLabel": "Income Statement Location"
}
}
},
"localname": "IncomeStatementLocationDomain",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureCommonStockSummaryOfShareBasedCompensationExpenseForStockOptionsRestrictedStockAndEmployeeSharePurchasePlanDetail"
],
"xbrltype": "domainItemType"
},
"us-gaap_IncreaseDecreaseInAccountsPayableTrade": {
"auth_ref": [
"r65"
],
"calculation": {
"http://achievelifesciences.com/20220630/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited": {
"order": 10160.0,
"parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Change in recurring obligations of a business that arise from the acquisition of merchandise, materials, supplies and services used in the production and sale of goods and services.",
"label": "Increase Decrease In Accounts Payable Trade",
"terseLabel": "Accounts payable"
}
}
},
"localname": "IncreaseDecreaseInAccountsPayableTrade",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities": {
"auth_ref": [
"r65"
],
"calculation": {
"http://achievelifesciences.com/20220630/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited": {
"order": 10190.0,
"parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.",
"label": "Increase Decrease In Employee Related Liabilities",
"terseLabel": "Accrued compensation"
}
}
},
"localname": "IncreaseDecreaseInEmployeeRelatedLiabilities",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Increase Decrease In Operating Capital [Abstract]",
"terseLabel": "Changes in operating assets and liabilities:"
}
}
},
"localname": "IncreaseDecreaseInOperatingCapitalAbstract",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited"
],
"xbrltype": "stringItemType"
},
"us-gaap_IncreaseDecreaseInOtherAccruedLiabilities": {
"auth_ref": [
"r65"
],
"calculation": {
"http://achievelifesciences.com/20220630/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited": {
"order": 10170.0,
"parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "The increase (decrease) during the reporting period in other expenses incurred but not yet paid.",
"label": "Increase Decrease In Other Accrued Liabilities",
"terseLabel": "Accrued liabilities other"
}
}
},
"localname": "IncreaseDecreaseInOtherAccruedLiabilities",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
"auth_ref": [
"r65"
],
"calculation": {
"http://achievelifesciences.com/20220630/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited": {
"order": 10150.0,
"parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
"weight": -1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
"label": "Increase Decrease In Prepaid Deferred Expense And Other Assets",
"negatedLabel": "Prepaid expenses and other assets"
}
}
},
"localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_IntangibleAssetsDisclosureTextBlock": {
"auth_ref": [
"r140"
],
"lang": {
"en-us": {
"role": {
"documentation": "The entire disclosure for all or part of the information related to intangible assets.",
"label": "Intangible Assets Disclosure [Text Block]",
"terseLabel": "Intangibles"
}
}
},
"localname": "IntangibleAssetsDisclosureTextBlock",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureIntangibles"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_InterestExpense": {
"auth_ref": [
"r49",
"r111",
"r318",
"r320",
"r364"
],
"calculation": {
"http://achievelifesciences.com/20220630/taxonomy/role/StatementConsolidatedStatementsOfLossAndComprehensiveLossUnaudited": {
"order": 10040.0,
"parentTag": "us-gaap_NonoperatingIncomeExpense",
"weight": -1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
"label": "Interest Expense",
"negatedLabel": "Interest expense [note 7]"
}
}
},
"localname": "InterestExpense",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/StatementConsolidatedStatementsOfLossAndComprehensiveLossUnaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_InterestPayableCurrentAndNoncurrent": {
"auth_ref": [
"r360",
"r376"
],
"calculation": {
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureConvertibleDebtScheduleOfConvertibleDebtBalanceDetails": {
"order": 10030.0,
"parentTag": "us-gaap_ConvertibleDebt",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of interest payable on debt, including, but not limited to, trade payables.",
"label": "Interest Payable Current And Noncurrent",
"terseLabel": "Accrued paid-in-kind interest"
}
}
},
"localname": "InterestPayableCurrentAndNoncurrent",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureConvertibleDebtScheduleOfConvertibleDebtBalanceDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_InvestmentIncomeInterest": {
"auth_ref": [
"r55",
"r110"
],
"calculation": {
"http://achievelifesciences.com/20220630/taxonomy/role/StatementConsolidatedStatementsOfLossAndComprehensiveLossUnaudited": {
"order": 10030.0,
"parentTag": "us-gaap_NonoperatingIncomeExpense",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.",
"label": "Investment Income Interest",
"terseLabel": "Interest income"
}
}
},
"localname": "InvestmentIncomeInterest",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/StatementConsolidatedStatementsOfLossAndComprehensiveLossUnaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_LeaseExpirationDate1": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Date which lease or group of leases is set to expire, in YYYY-MM-DD format.",
"label": "Lease Expiration Date1",
"terseLabel": "Initial term of lease expiration date"
}
}
},
"localname": "LeaseExpirationDate1",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
],
"xbrltype": "dateItemType"
},
"us-gaap_LesseeOperatingLeaseDescription": {
"auth_ref": [
"r327"
],
"lang": {
"en-us": {
"role": {
"documentation": "Description of lessee's operating lease.",
"label": "Lessee Operating Lease Description",
"terseLabel": "Lease agreement"
}
}
},
"localname": "LesseeOperatingLeaseDescription",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
],
"xbrltype": "stringItemType"
},
"us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend": {
"auth_ref": [
"r328"
],
"lang": {
"en-us": {
"role": {
"documentation": "Indicates (true false) whether lessee has option to extend operating lease.",
"label": "Lessee Operating Lease Existence Of Option To Extend",
"terseLabel": "Lessee, Operating Lease, Existence of Option to Extend [true false]"
}
}
},
"localname": "LesseeOperatingLeaseExistenceOfOptionToExtend",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
],
"xbrltype": "booleanItemType"
},
"us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
"auth_ref": [
"r333"
],
"lang": {
"en-us": {
"role": {
"documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
"label": "Lessee Operating Lease Liability Maturity Table [Text Block]",
"terseLabel": "Summary of Future Minimum Annual Lease Payments"
}
}
},
"localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureCommitmentsAndContingenciesTables"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
"auth_ref": [
"r333"
],
"calculation": {
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfFutureMinimumAnnualLeasePaymentsDetail": {
"order": null,
"parentTag": null,
"root": true,
"weight": null
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
"label": "Lessee Operating Lease Liability Payments Due",
"totalLabel": "Total"
}
}
},
"localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfFutureMinimumAnnualLeasePaymentsDetail"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
"auth_ref": [
"r333"
],
"calculation": {
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfFutureMinimumAnnualLeasePaymentsDetail": {
"order": 10020.0,
"parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
"label": "Lessee Operating Lease Liability Payments Due Next Twelve Months",
"terseLabel": "2023"
}
}
},
"localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfFutureMinimumAnnualLeasePaymentsDetail"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": {
"auth_ref": [
"r333"
],
"calculation": {
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfFutureMinimumAnnualLeasePaymentsDetail": {
"order": 10010.0,
"parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.",
"label": "Lessee Operating Lease Liability Payments Remainder Of Fiscal Year",
"terseLabel": "2022"
}
}
},
"localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfFutureMinimumAnnualLeasePaymentsDetail"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_LesseeOperatingLeaseOptionToExtend": {
"auth_ref": [
"r328"
],
"lang": {
"en-us": {
"role": {
"documentation": "Description of terms and conditions of option to extend lessee's operating lease. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability.",
"label": "Lessee Operating Lease Option To Extend",
"terseLabel": "Operating lease, option to extend, description"
}
}
},
"localname": "LesseeOperatingLeaseOptionToExtend",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
],
"xbrltype": "stringItemType"
},
"us-gaap_LesseeOperatingLeaseTermOfContract": {
"auth_ref": [
"r328"
],
"lang": {
"en-us": {
"role": {
"documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
"label": "Lessee Operating Lease Term Of Contract",
"terseLabel": "Operating lease, term of contract"
}
}
},
"localname": "LesseeOperatingLeaseTermOfContract",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
],
"xbrltype": "durationItemType"
},
"us-gaap_Liabilities": {
"auth_ref": [
"r27",
"r75",
"r115",
"r125",
"r155",
"r156",
"r157",
"r159",
"r160",
"r161",
"r162",
"r163",
"r164",
"r165",
"r288",
"r292",
"r293",
"r310",
"r337",
"r338"
],
"calculation": {
"http://achievelifesciences.com/20220630/taxonomy/role/StatementConsolidatedBalanceSheetsUnaudited": {
"order": 10010.0,
"parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
"label": "Liabilities",
"totalLabel": "Total liabilities"
}
}
},
"localname": "Liabilities",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/StatementConsolidatedBalanceSheetsUnaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_LiabilitiesAndStockholdersEquity": {
"auth_ref": [
"r23",
"r75",
"r125",
"r310",
"r339",
"r359",
"r374"
],
"calculation": {
"http://achievelifesciences.com/20220630/taxonomy/role/StatementConsolidatedBalanceSheetsUnaudited": {
"order": null,
"parentTag": null,
"root": true,
"weight": null
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
"label": "Liabilities And Stockholders Equity",
"totalLabel": "Total liabilities and stockholders' equity"
}
}
},
"localname": "LiabilitiesAndStockholdersEquity",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/StatementConsolidatedBalanceSheetsUnaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Liabilities And Stockholders Equity [Abstract]",
"terseLabel": "LIABILITIES AND STOCKHOLDERS\u2019 EQUITY"
}
}
},
"localname": "LiabilitiesAndStockholdersEquityAbstract",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/StatementConsolidatedBalanceSheetsUnaudited"
],
"xbrltype": "stringItemType"
},
"us-gaap_LiabilitiesCurrent": {
"auth_ref": [
"r5",
"r29",
"r75",
"r125",
"r155",
"r156",
"r157",
"r159",
"r160",
"r161",
"r162",
"r163",
"r164",
"r165",
"r288",
"r292",
"r293",
"r310",
"r337",
"r338",
"r339"
],
"calculation": {
"http://achievelifesciences.com/20220630/taxonomy/role/StatementConsolidatedBalanceSheetsUnaudited": {
"order": 10100.0,
"parentTag": "us-gaap_Liabilities",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
"label": "Liabilities Current",
"totalLabel": "Total current liabilities"
}
}
},
"localname": "LiabilitiesCurrent",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/StatementConsolidatedBalanceSheetsUnaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_LiabilitiesCurrentAbstract": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Liabilities Current [Abstract]",
"terseLabel": "Current liabilities:"
}
}
},
"localname": "LiabilitiesCurrentAbstract",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/StatementConsolidatedBalanceSheetsUnaudited"
],
"xbrltype": "stringItemType"
},
"us-gaap_LicensingAgreementsMember": {
"auth_ref": [
"r281"
],
"lang": {
"en-us": {
"role": {
"documentation": "Rights, generally of limited duration, under a license arrangement (for example, to sell or otherwise utilize specified products or processes in a specified territory).",
"label": "Licensing Agreements [Member]",
"terseLabel": "License Agreements [Member]"
}
}
},
"localname": "LicensingAgreementsMember",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureIntangiblesComponentsOfIntangibleAssetsDetail"
],
"xbrltype": "domainItemType"
},
"us-gaap_LineOfCreditFacilityAxis": {
"auth_ref": [
"r26",
"r74"
],
"lang": {
"en-us": {
"role": {
"documentation": "Information by name of lender, which may be a single entity (for example, but not limited to, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit.",
"label": "Line Of Credit Facility [Axis]",
"terseLabel": "Lender Name"
}
}
},
"localname": "LineOfCreditFacilityAxis",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureConvertibleDebtAdditionalInformationDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_LineOfCreditFacilityLenderDomain": {
"auth_ref": [
"r26",
"r74"
],
"lang": {
"en-us": {
"role": {
"documentation": "Identification of the lender, which may be a single entity (for example, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit, including a letter of credit facility.",
"label": "Line Of Credit Facility Lender [Domain]",
"terseLabel": "Line of Credit Facility, Lender"
}
}
},
"localname": "LineOfCreditFacilityLenderDomain",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureConvertibleDebtAdditionalInformationDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Longterm Convertible Debt Current And Noncurrent [Abstract]",
"terseLabel": "Convertible Debt Information"
}
}
},
"localname": "LongtermConvertibleDebtCurrentAndNoncurrentAbstract",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureConvertibleDebtScheduleOfConvertibleDebtBalanceDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_LongtermDebtTypeAxis": {
"auth_ref": [
"r34"
],
"lang": {
"en-us": {
"role": {
"documentation": "Information by type of long-term debt.",
"label": "Longterm Debt Type [Axis]",
"terseLabel": "Long-Term Debt, Type"
}
}
},
"localname": "LongtermDebtTypeAxis",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureConvertibleDebtAdditionalInformationDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_LongtermDebtTypeDomain": {
"auth_ref": [
"r34",
"r154"
],
"lang": {
"en-us": {
"role": {
"documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
"label": "Longterm Debt Type [Domain]",
"terseLabel": "Long-Term Debt, Type"
}
}
},
"localname": "LongtermDebtTypeDomain",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureConvertibleDebtAdditionalInformationDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_MoneyMarketFundsMember": {
"auth_ref": [
"r225"
],
"lang": {
"en-us": {
"role": {
"documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
"label": "Money Market Funds [Member]",
"terseLabel": "Money market securities (cash equivalents) [Member]",
"verboseLabel": "Money market securities [Member]"
}
}
},
"localname": "MoneyMarketFundsMember",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAssetsMeasuredAtFairValueOnRecurringBasisDetail",
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfCashEquivalentsDetail"
],
"xbrltype": "domainItemType"
},
"us-gaap_NetCashProvidedByUsedInFinancingActivities": {
"auth_ref": [
"r63"
],
"calculation": {
"http://achievelifesciences.com/20220630/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited": {
"order": 10020.0,
"parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
"label": "Net Cash Provided By Used In Financing Activities",
"totalLabel": "Net cash provided by financing activities"
}
}
},
"localname": "NetCashProvidedByUsedInFinancingActivities",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Net Cash Provided By Used In Financing Activities [Abstract]",
"terseLabel": "Financing Activities:"
}
}
},
"localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited"
],
"xbrltype": "stringItemType"
},
"us-gaap_NetCashProvidedByUsedInOperatingActivities": {
"auth_ref": [
"r63",
"r64",
"r67"
],
"calculation": {
"http://achievelifesciences.com/20220630/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited": {
"order": 10010.0,
"parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
"weight": 1.0
}
},
"lang": {
"en-us": {
"role": {
"documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
"label": "Net Cash Provided By Used In Operating Activities",
"negatedLabel": "Net cash used in operating activities",
"totalLabel": "Net cash used in operating activities"
}
}
},
"localname": "NetCashProvidedByUsedInOperatingActivities",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureNatureOfBusinessBasisOfPresentationAndGoingConcernUncertaintyAdditionalInformationDetail",
"http://achievelifesciences.com/20220630/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Net Cash Provided By Used In Operating Activities [Abstract]",
"terseLabel": "Operating Activities:"
}
}
},
"localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited"
],
"xbrltype": "stringItemType"
},
"us-gaap_NetIncomeLoss": {
"auth_ref": [
"r1",
"r44",
"r45",
"r48",
"r50",
"r67",
"r75",
"r83",
"r85",
"r86",
"r87",
"r88",
"r91",
"r92",
"r98",
"r112",
"r113",
"r116",
"r117",
"r119",
"r125",
"r155",
"r156",
"r157",
"r159",
"r160",
"r161",
"r162",
"r163",
"r164",
"r165",
"r299",
"r310",
"r362",
"r377"
],
"calculation": {
"http://achievelifesciences.com/20220630/taxonomy/role/StatementConsolidatedStatementsOfLossAndComprehensiveLossUnaudited": {
"order": null,
"parentTag": null,
"root": true,
"weight": null
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
"label": "Net Income Loss",
"terseLabel": "Net loss",
"totalLabel": "Net loss and comprehensive loss"
}
}
},
"localname": "NetIncomeLoss",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureNatureOfBusinessBasisOfPresentationAndGoingConcernUncertaintyAdditionalInformationDetail",
"http://achievelifesciences.com/20220630/taxonomy/role/StatementConsolidatedStatementsOfLossAndComprehensiveLossUnaudited",
"http://achievelifesciences.com/20220630/taxonomy/role/StatementConsolidatedStatementsOfStockholderSEquityUnaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_NonoperatingIncomeExpense": {
"auth_ref": [
"r56"
],
"calculation": {
"http://achievelifesciences.com/20220630/taxonomy/role/StatementConsolidatedStatementsOfLossAndComprehensiveLossUnaudited": {
"order": 10020.0,
"parentTag": "us-gaap_NetIncomeLoss",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
"label": "Nonoperating Income Expense",
"totalLabel": "Total other (expense)"
}
}
},
"localname": "NonoperatingIncomeExpense",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/StatementConsolidatedStatementsOfLossAndComprehensiveLossUnaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_NonoperatingIncomeExpenseAbstract": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Nonoperating Income Expense [Abstract]",
"terseLabel": "OTHER INCOME (EXPENSE)"
}
}
},
"localname": "NonoperatingIncomeExpenseAbstract",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/StatementConsolidatedStatementsOfLossAndComprehensiveLossUnaudited"
],
"xbrltype": "stringItemType"
},
"us-gaap_OperatingLeaseExpense": {
"auth_ref": [
"r325"
],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of operating lease expense. Excludes sublease income.",
"label": "Operating Lease Expense",
"terseLabel": "Consolidated rent expense"
}
}
},
"localname": "OperatingLeaseExpense",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_OperatingLeaseLiabilityCurrent": {
"auth_ref": [
"r324"
],
"calculation": {
"http://achievelifesciences.com/20220630/taxonomy/role/StatementConsolidatedBalanceSheetsUnaudited": {
"order": 10170.0,
"parentTag": "us-gaap_LiabilitiesCurrent",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
"label": "Operating Lease Liability Current",
"terseLabel": "Current portion of long-term obligations [note 9]"
}
}
},
"localname": "OperatingLeaseLiabilityCurrent",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/StatementConsolidatedBalanceSheetsUnaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_OperatingLeaseLiabilityNoncurrent": {
"auth_ref": [
"r324"
],
"calculation": {
"http://achievelifesciences.com/20220630/taxonomy/role/StatementConsolidatedBalanceSheetsUnaudited": {
"order": 10120.0,
"parentTag": "us-gaap_Liabilities",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
"label": "Operating Lease Liability Noncurrent",
"terseLabel": "Long-term obligations [note 9]"
}
}
},
"localname": "OperatingLeaseLiabilityNoncurrent",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/StatementConsolidatedBalanceSheetsUnaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_OperatingLeasePayments": {
"auth_ref": [
"r326",
"r329"
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
"label": "Operating Lease Payments",
"terseLabel": "Operating cash flows to operating leases"
}
}
},
"localname": "OperatingLeasePayments",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfOtherInformationRelatedToLeasesDetail"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_OperatingLeaseRightOfUseAsset": {
"auth_ref": [
"r323"
],
"calculation": {
"http://achievelifesciences.com/20220630/taxonomy/role/StatementConsolidatedBalanceSheetsUnaudited": {
"order": 10190.0,
"parentTag": "us-gaap_Assets",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of lessee's right to use underlying asset under operating lease.",
"label": "Operating Lease Right Of Use Asset",
"terseLabel": "Right-of-use assets [note 9]"
}
}
},
"localname": "OperatingLeaseRightOfUseAsset",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/StatementConsolidatedBalanceSheetsUnaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
"auth_ref": [
"r332",
"r334"
],
"lang": {
"en-us": {
"role": {
"documentation": "Weighted average discount rate for operating lease calculated at point in time.",
"label": "Operating Lease Weighted Average Discount Rate Percent",
"terseLabel": "Weighted Average Discount Rate Operating leases"
}
}
},
"localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfOtherInformationRelatedToLeasesDetail"
],
"xbrltype": "percentItemType"
},
"us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
"auth_ref": [
"r331",
"r334"
],
"lang": {
"en-us": {
"role": {
"documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
"label": "Operating Lease Weighted Average Remaining Lease Term1",
"terseLabel": "Weighted Average Remaining Lease Term Operating leases"
}
}
},
"localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfOtherInformationRelatedToLeasesDetail"
],
"xbrltype": "durationItemType"
},
"us-gaap_OperatingLeasedAssetsLineItems": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
"label": "Operating Leased Assets [Line Items]",
"terseLabel": "Operating Leased Assets [Line Items]"
}
}
},
"localname": "OperatingLeasedAssetsLineItems",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfFutureMinimumAnnualLeasePaymentsDetail",
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureCommitmentsAndContingenciesTables"
],
"xbrltype": "stringItemType"
},
"us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Organization Consolidation And Presentation Of Financial Statements [Abstract]"
}
}
},
"localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
"nsuri": "http://fasb.org/us-gaap/2022",
"xbrltype": "stringItemType"
},
"us-gaap_OtherAccruedLiabilitiesCurrent": {
"auth_ref": [
"r28"
],
"calculation": {
"http://achievelifesciences.com/20220630/taxonomy/role/StatementConsolidatedBalanceSheetsUnaudited": {
"order": 10140.0,
"parentTag": "us-gaap_LiabilitiesCurrent",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
"label": "Other Accrued Liabilities Current",
"terseLabel": "Accrued liabilities other"
}
}
},
"localname": "OtherAccruedLiabilitiesCurrent",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/StatementConsolidatedBalanceSheetsUnaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_OtherCommitmentsLineItems": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
"label": "Other Commitments [Line Items]",
"terseLabel": "Other Commitments [Line Items]"
}
}
},
"localname": "OtherCommitmentsLineItems",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
],
"xbrltype": "stringItemType"
},
"us-gaap_OtherCommitmentsTable": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Disclosure of information about obligations resulting from other commitments.",
"label": "Other Commitments [Table]",
"terseLabel": "Other Commitments [Table]"
}
}
},
"localname": "OtherCommitmentsTable",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
],
"xbrltype": "stringItemType"
},
"us-gaap_OtherNonoperatingIncomeExpense": {
"auth_ref": [
"r57"
],
"calculation": {
"http://achievelifesciences.com/20220630/taxonomy/role/StatementConsolidatedStatementsOfLossAndComprehensiveLossUnaudited": {
"order": 10050.0,
"parentTag": "us-gaap_NonoperatingIncomeExpense",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
"label": "Other Nonoperating Income Expense",
"terseLabel": "Other income (expense)"
}
}
},
"localname": "OtherNonoperatingIncomeExpense",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/StatementConsolidatedStatementsOfLossAndComprehensiveLossUnaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_OverAllotmentOptionMember": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Right given to the underwriter to sell additional shares over the initial allotment.",
"label": "Over Allotment Option [Member]",
"terseLabel": "Underwriters Over-Allotment Option Exercise [Member]"
}
}
},
"localname": "OverAllotmentOptionMember",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureCommonStockIssuedAndOutstandingSharesAdditionalInformationDetail"
],
"xbrltype": "domainItemType"
},
"us-gaap_PaymentsOfFinancingCosts": {
"auth_ref": [
"r60"
],
"calculation": {
"http://achievelifesciences.com/20220630/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited": {
"order": 10060.0,
"parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
"weight": -1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "The cash outflow for loan and debt issuance costs.",
"label": "Payments Of Financing Costs",
"negatedLabel": "Financing costs relating to convertible debt with SVB [note 7]"
}
}
},
"localname": "PaymentsOfFinancingCosts",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": {
"auth_ref": [
"r59"
],
"calculation": {
"http://achievelifesciences.com/20220630/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited": {
"order": 10080.0,
"parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
"weight": -1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.",
"label": "Payments Related To Tax Withholding For Share Based Compensation",
"negatedLabel": "Taxes paid related to net share settlement of equity awards"
}
}
},
"localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_PlanNameAxis": {
"auth_ref": [
"r239",
"r240",
"r241",
"r243",
"r244",
"r245",
"r246",
"r247",
"r248",
"r249",
"r250",
"r251",
"r252",
"r253",
"r254",
"r255",
"r256",
"r257",
"r258",
"r259",
"r260",
"r262",
"r263",
"r264",
"r265",
"r266"
],
"lang": {
"en-us": {
"role": {
"documentation": "Information by plan name for share-based payment arrangement.",
"label": "Plan Name [Axis]",
"terseLabel": "Plan Name"
}
}
},
"localname": "PlanNameAxis",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureCommonStockStockOptionsAdditionalInformationDetail"
],
"xbrltype": "stringItemType"
},
"us-gaap_PlanNameDomain": {
"auth_ref": [
"r239",
"r240",
"r241",
"r243",
"r244",
"r245",
"r246",
"r247",
"r248",
"r249",
"r250",
"r251",
"r252",
"r253",
"r254",
"r255",
"r256",
"r257",
"r258",
"r259",
"r260",
"r262",
"r263",
"r264",
"r265",
"r266"
],
"lang": {
"en-us": {
"role": {
"documentation": "Plan name for share-based payment arrangement.",
"label": "Plan Name [Domain]",
"terseLabel": "Plan Name"
}
}
},
"localname": "PlanNameDomain",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureCommonStockStockOptionsAdditionalInformationDetail"
],
"xbrltype": "domainItemType"
},
"us-gaap_PreferredStockMember": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company.",
"label": "Preferred Stock [Member]",
"terseLabel": "Preferred stock [Member]"
}
}
},
"localname": "PreferredStockMember",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/StatementConsolidatedStatementsOfStockholderSEquityUnaudited"
],
"xbrltype": "domainItemType"
},
"us-gaap_PreferredStockParOrStatedValuePerShare": {
"auth_ref": [
"r15",
"r200"
],
"lang": {
"en-us": {
"role": {
"documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
"label": "Preferred Stock Par Or Stated Value Per Share",
"terseLabel": "Preferred stock, par value"
}
}
},
"localname": "PreferredStockParOrStatedValuePerShare",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureCommonStockAuthorizedAdditionalInformationDetail",
"http://achievelifesciences.com/20220630/taxonomy/role/StatementConsolidatedBalanceSheetsParentheticalUnaudited"
],
"xbrltype": "perShareItemType"
},
"us-gaap_PreferredStockSharesAuthorized": {
"auth_ref": [
"r15"
],
"lang": {
"en-us": {
"role": {
"documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
"label": "Preferred Stock Shares Authorized",
"terseLabel": "Preferred stock, shares authorized"
}
}
},
"localname": "PreferredStockSharesAuthorized",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureCommonStockAuthorizedAdditionalInformationDetail"
],
"xbrltype": "sharesItemType"
},
"us-gaap_PreferredStockSharesIssued": {
"auth_ref": [
"r15",
"r200"
],
"lang": {
"en-us": {
"role": {
"documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
"label": "Preferred Stock Shares Issued",
"terseLabel": "Preferred stock, shares issued"
}
}
},
"localname": "PreferredStockSharesIssued",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/StatementConsolidatedBalanceSheetsParentheticalUnaudited"
],
"xbrltype": "sharesItemType"
},
"us-gaap_PreferredStockSharesOutstanding": {
"auth_ref": [
"r15"
],
"lang": {
"en-us": {
"role": {
"documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
"label": "Preferred Stock Shares Outstanding",
"terseLabel": "Preferred stock, shares outstanding"
}
}
},
"localname": "PreferredStockSharesOutstanding",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/StatementConsolidatedBalanceSheetsParentheticalUnaudited"
],
"xbrltype": "sharesItemType"
},
"us-gaap_PreferredStockValue": {
"auth_ref": [
"r15",
"r339"
],
"calculation": {
"http://achievelifesciences.com/20220630/taxonomy/role/StatementConsolidatedBalanceSheetsUnaudited": {
"order": 10040.0,
"parentTag": "us-gaap_StockholdersEquity",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
"label": "Preferred Stock Value",
"terseLabel": "Convertible preferred stock, value"
}
}
},
"localname": "PreferredStockValue",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/StatementConsolidatedBalanceSheetsUnaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
"auth_ref": [
"r24"
],
"calculation": {
"http://achievelifesciences.com/20220630/taxonomy/role/StatementConsolidatedBalanceSheetsUnaudited": {
"order": 10250.0,
"parentTag": "us-gaap_AssetsCurrent",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
"label": "Prepaid Expense And Other Assets Current",
"terseLabel": "Prepaid expenses and other assets"
}
}
},
"localname": "PrepaidExpenseAndOtherAssetsCurrent",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/StatementConsolidatedBalanceSheetsUnaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_ProceedsFromIssuanceOfCommonStock": {
"auth_ref": [
"r58"
],
"calculation": {
"http://achievelifesciences.com/20220630/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited": {
"order": 10070.0,
"parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "The cash inflow from the additional capital contribution to the entity.",
"label": "Proceeds From Issuance Of Common Stock",
"terseLabel": "Proceeds from the May 2021 public offering, net of issuance costs",
"verboseLabel": "Proceeds from issuance of common stock"
}
}
},
"localname": "ProceedsFromIssuanceOfCommonStock",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureCommonStockIssuedAndOutstandingSharesAdditionalInformationDetail",
"http://achievelifesciences.com/20220630/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_ProceedsFromSaleOfEquitySecuritiesFvNi": {
"auth_ref": [
"r61",
"r124"
],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of cash inflow from sale of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as investing activity.",
"label": "Proceeds From Sale Of Equity Securities Fv Ni",
"terseLabel": "Net cash proceeds from the issuance and sale of equity securities"
}
}
},
"localname": "ProceedsFromSaleOfEquitySecuritiesFvNi",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureConvertibleDebtAdditionalInformationDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_ProceedsFromWarrantExercises": {
"auth_ref": [
"r58"
],
"calculation": {
"http://achievelifesciences.com/20220630/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited": {
"order": 10040.0,
"parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants.",
"label": "Proceeds From Warrant Exercises",
"terseLabel": "Proceeds from exercise of warrants",
"verboseLabel": "Proceeds from exercise of warrants"
}
}
},
"localname": "ProceedsFromWarrantExercises",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureCommonStockCommonStockWarrantsAdditionalInformationDetail",
"http://achievelifesciences.com/20220630/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_ProfitLoss": {
"auth_ref": [
"r1",
"r44",
"r45",
"r48",
"r62",
"r75",
"r83",
"r91",
"r92",
"r112",
"r113",
"r116",
"r117",
"r119",
"r125",
"r155",
"r156",
"r157",
"r159",
"r160",
"r161",
"r162",
"r163",
"r164",
"r165",
"r286",
"r289",
"r290",
"r294",
"r295",
"r299",
"r310",
"r365"
],
"calculation": {
"http://achievelifesciences.com/20220630/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited": {
"order": 10090.0,
"parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
"label": "Profit Loss",
"terseLabel": "Net loss"
}
}
},
"localname": "ProfitLoss",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_ReceivablesAbstract": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Receivables [Abstract]"
}
}
},
"localname": "ReceivablesAbstract",
"nsuri": "http://fasb.org/us-gaap/2022",
"xbrltype": "stringItemType"
},
"us-gaap_RegulatoryAgencyAxis": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Information by name of regulatory agency.",
"label": "Regulatory Agency [Axis]",
"terseLabel": "Regulatory Agency"
}
}
},
"localname": "RegulatoryAgencyAxis",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureGovernmentGrantAdditionalInformationDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_RegulatoryAgencyDomain": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Organization that establishes and ensures compliance with rules or regulations.",
"label": "Regulatory Agency [Domain]",
"terseLabel": "Regulatory Agency"
}
}
},
"localname": "RegulatoryAgencyDomain",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureGovernmentGrantAdditionalInformationDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_ResearchAndDevelopmentExpense": {
"auth_ref": [
"r278",
"r350",
"r401"
],
"calculation": {
"http://achievelifesciences.com/20220630/taxonomy/role/StatementConsolidatedStatementsOfLossAndComprehensiveLossUnaudited": {
"order": 10060.0,
"parentTag": "us-gaap_CostsAndExpenses",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
"label": "Research And Development Expense",
"terseLabel": "Research and development"
}
}
},
"localname": "ResearchAndDevelopmentExpense",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/StatementConsolidatedStatementsOfLossAndComprehensiveLossUnaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_ResearchAndDevelopmentExpenseMember": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
"label": "Research And Development Expense [Member]",
"terseLabel": "Research and development [Member]"
}
}
},
"localname": "ResearchAndDevelopmentExpenseMember",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureCommonStockSummaryOfShareBasedCompensationExpenseForStockOptionsRestrictedStockAndEmployeeSharePurchasePlanDetail"
],
"xbrltype": "domainItemType"
},
"us-gaap_RestrictedCashAndCashEquivalents": {
"auth_ref": [
"r6",
"r68",
"r69",
"r354",
"r371"
],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
"label": "Restricted Cash And Cash Equivalents",
"verboseLabel": "Restricted cash, amortized cost and estimated fair value"
}
}
},
"localname": "RestrictedCashAndCashEquivalents",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfCashEquivalentsDetail"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_RestrictedStockUnitsRSUMember": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
"label": "Restricted Stock Units R S U [Member]",
"terseLabel": "Restricted Stock Unit [Member]"
}
}
},
"localname": "RestrictedStockUnitsRSUMember",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureCommonStockRestrictedStockUnitAwardsAdditionalInformationDetail",
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureCommonStockStockOptionsAdditionalInformationDetail",
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureCommonStockSummaryOfRestrictedStockUnitAwardActivityDetail"
],
"xbrltype": "domainItemType"
},
"us-gaap_RetainedEarningsAccumulatedDeficit": {
"auth_ref": [
"r19",
"r219",
"r339",
"r373",
"r385",
"r387"
],
"calculation": {
"http://achievelifesciences.com/20220630/taxonomy/role/StatementConsolidatedBalanceSheetsUnaudited": {
"order": 10080.0,
"parentTag": "us-gaap_StockholdersEquity",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
"label": "Retained Earnings Accumulated Deficit",
"terseLabel": "Accumulated deficit"
}
}
},
"localname": "RetainedEarningsAccumulatedDeficit",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureNatureOfBusinessBasisOfPresentationAndGoingConcernUncertaintyAdditionalInformationDetail",
"http://achievelifesciences.com/20220630/taxonomy/role/StatementConsolidatedBalanceSheetsUnaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_RetainedEarningsMember": {
"auth_ref": [
"r0",
"r80",
"r81",
"r82",
"r84",
"r90",
"r92",
"r126",
"r272",
"r273",
"r274",
"r279",
"r280",
"r297",
"r382",
"r384"
],
"lang": {
"en-us": {
"role": {
"documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
"label": "Retained Earnings [Member]",
"terseLabel": "Accumulated deficit [Member]"
}
}
},
"localname": "RetainedEarningsMember",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/StatementConsolidatedStatementsOfStockholderSEquityUnaudited"
],
"xbrltype": "domainItemType"
},
"us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
"auth_ref": [
"r330",
"r334"
],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
"label": "Right Of Use Asset Obtained In Exchange For Operating Lease Liability",
"terseLabel": "Operating leases"
}
}
},
"localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfOtherInformationRelatedToLeasesDetail"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_SaleOfStockNameOfTransactionDomain": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
"label": "Sale Of Stock Name Of Transaction [Domain]",
"terseLabel": "Sale of Stock"
}
}
},
"localname": "SaleOfStockNameOfTransactionDomain",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureCommonStockEmployeeSharePurchasePlanAdditionalInformationDetail",
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureCommonStockIssuedAndOutstandingSharesAdditionalInformationDetail",
"http://achievelifesciences.com/20220630/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited",
"http://achievelifesciences.com/20220630/taxonomy/role/StatementConsolidatedStatementsOfStockholderSEquityUnaudited"
],
"xbrltype": "domainItemType"
},
"us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Tabular disclosure of the components of cash, cash equivalents, and investments.",
"label": "Schedule Of Cash Cash Equivalents And Short Term Investments Table [Text Block]",
"terseLabel": "Summary of Cash Equivalents"
}
}
},
"localname": "ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureFairValueMeasurementsTables"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
"auth_ref": [
"r284"
],
"lang": {
"en-us": {
"role": {
"documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
"label": "Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table]",
"terseLabel": "Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table]"
}
}
},
"localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetail"
],
"xbrltype": "stringItemType"
},
"us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
"auth_ref": [
"r267",
"r275"
],
"lang": {
"en-us": {
"role": {
"documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.",
"label": "Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]",
"terseLabel": "Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]"
}
}
},
"localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureCommonStockSummaryOfShareBasedCompensationExpenseForStockOptionsRestrictedStockAndEmployeeSharePurchasePlanDetail"
],
"xbrltype": "stringItemType"
},
"us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
"auth_ref": [
"r267"
],
"lang": {
"en-us": {
"role": {
"documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
"label": "Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Text Block]",
"terseLabel": "Summary of Share-Based Compensation Expense"
}
}
},
"localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureCommonStockTables"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
"auth_ref": [
"r300",
"r301"
],
"lang": {
"en-us": {
"role": {
"documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
"label": "Schedule Of Fair Value Assets And Liabilities Measured On Recurring Basis Table [Text Block]",
"terseLabel": "Summary of Assets Measured at Fair Value on Recurring Basis"
}
}
},
"localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureFairValueMeasurementsTables"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": {
"auth_ref": [
"r132",
"r134",
"r352"
],
"lang": {
"en-us": {
"role": {
"documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
"label": "Schedule Of Finite Lived Intangible Assets [Table]",
"terseLabel": "Schedule Of Finite Lived Intangible Assets [Table]"
}
}
},
"localname": "ScheduleOfFiniteLivedIntangibleAssetsTable",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureIntangiblesComponentsOfIntangibleAssetsDetail"
],
"xbrltype": "stringItemType"
},
"us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": {
"auth_ref": [
"r132",
"r134"
],
"lang": {
"en-us": {
"role": {
"documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.",
"label": "Schedule Of Finite Lived Intangible Assets Table [Text Block]",
"terseLabel": "Components of Intangible Assets"
}
}
},
"localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureIntangiblesTables"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_ScheduleOfOperatingLeasedAssetsTable": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Schedule of long-lived, depreciable assets that are subject to a operating lease agreements and are used in the normal conduct of business to produce goods and services. Examples may include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
"label": "Schedule Of Operating Leased Assets [Table]",
"terseLabel": "Schedule Of Operating Leased Assets [Table]"
}
}
},
"localname": "ScheduleOfOperatingLeasedAssetsTable",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfFutureMinimumAnnualLeasePaymentsDetail",
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureCommitmentsAndContingenciesTables"
],
"xbrltype": "stringItemType"
},
"us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
"auth_ref": [
"r235",
"r237",
"r239",
"r240",
"r241",
"r243",
"r244",
"r245",
"r246",
"r247",
"r248",
"r249",
"r250",
"r251",
"r252",
"r253",
"r254",
"r255",
"r256",
"r257",
"r258",
"r259",
"r260",
"r262",
"r263",
"r264",
"r265",
"r266"
],
"lang": {
"en-us": {
"role": {
"documentation": "Disclosure of information about share-based payment arrangement.",
"label": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]",
"terseLabel": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]"
}
}
},
"localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureCommonStockEmployeeSharePurchasePlanAdditionalInformationDetail",
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureCommonStockIssuedAndOutstandingSharesAdditionalInformationDetail",
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureCommonStockRestrictedStockUnitAwardsAdditionalInformationDetail",
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureCommonStockStockOptionsAdditionalInformationDetail",
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureCommonStockSummaryOfRestrictedStockUnitAwardActivityDetail"
],
"xbrltype": "stringItemType"
},
"us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": {
"auth_ref": [
"r242"
],
"lang": {
"en-us": {
"role": {
"documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.",
"label": "Schedule Of Share Based Compensation Restricted Stock Units Award Activity Table [Text Block]",
"terseLabel": "Summary of Restricted Stock Unit Award Activity"
}
}
},
"localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureCommonStockTables"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
"auth_ref": [
"r261"
],
"lang": {
"en-us": {
"role": {
"documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
"label": "Schedule Of Share Based Payment Award Stock Options Valuation Assumptions Table [Text Block]",
"terseLabel": "Summary of Fair Value of Each Stock Award for Employees and Directors"
}
}
},
"localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureCommonStockTables"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Tabular disclosure of the change in stock options.",
"label": "Schedule Of Stock Options Roll Forward Table [Text Block]",
"terseLabel": "Summary of Stock Options Activity"
}
}
},
"localname": "ScheduleOfStockOptionsRollForwardTableTextBlock",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureCommonStockTables"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": {
"auth_ref": [
"r220",
"r238"
],
"lang": {
"en-us": {
"role": {
"documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.",
"label": "Schedule Of Stockholders Equity Note Warrants Or Rights [Text Block]",
"terseLabel": "Summary of Outstanding Warrants"
}
}
},
"localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureCommonStockTables"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": {
"auth_ref": [
"r134"
],
"lang": {
"en-us": {
"role": {
"documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.",
"label": "Scheduleof Finite Lived Intangible Assets Future Amortization Expense Table [Text Block]",
"terseLabel": "Estimated Future Amortization Expense Related to Intangible Assets"
}
}
},
"localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureIntangiblesTables"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_SecurityDeposit": {
"auth_ref": [
"r9"
],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease.",
"label": "Security Deposit",
"terseLabel": "Security deposit"
}
}
},
"localname": "SecurityDeposit",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_ShareBasedCompensation": {
"auth_ref": [
"r65"
],
"calculation": {
"http://achievelifesciences.com/20220630/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited": {
"order": 10110.0,
"parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of noncash expense for share-based payment arrangement.",
"label": "Share Based Compensation",
"terseLabel": "Stock-based compensation [note 8[c], note 8[e], note 8[f] and note 8[g]]",
"verboseLabel": "Total stock-based compensation"
}
}
},
"localname": "ShareBasedCompensation",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureCommonStockSummaryOfShareBasedCompensationExpenseForStockOptionsRestrictedStockAndEmployeeSharePurchasePlanDetail",
"http://achievelifesciences.com/20220630/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
"auth_ref": [
"r239"
],
"lang": {
"en-us": {
"role": {
"documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
"label": "Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1",
"terseLabel": "Award vesting period"
}
}
},
"localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureCommonStockRestrictedStockUnitAwardsAdditionalInformationDetail",
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureCommonStockStockOptionsAdditionalInformationDetail"
],
"xbrltype": "durationItemType"
},
"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
"auth_ref": [
"r254"
],
"lang": {
"en-us": {
"role": {
"documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
"label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period",
"terseLabel": "Number of Shares, Granted"
}
}
},
"localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureCommonStockSummaryOfRestrictedStockUnitAwardActivityDetail"
],
"xbrltype": "sharesItemType"
},
"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
"auth_ref": [
"r254"
],
"lang": {
"en-us": {
"role": {
"documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
"label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value",
"terseLabel": "Weighted-Average Grant Date Fair Value, Granted"
}
}
},
"localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureCommonStockSummaryOfRestrictedStockUnitAwardActivityDetail"
],
"xbrltype": "perShareItemType"
},
"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
"auth_ref": [
"r251",
"r252"
],
"lang": {
"en-us": {
"role": {
"documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
"label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number",
"periodEndLabel": "Number of Shares, Ending Balance",
"periodStartLabel": "Number of Shares, Beginning Balance",
"terseLabel": "Common shares reserved for awards currently outstanding"
}
}
},
"localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureCommonStockStockOptionsAdditionalInformationDetail",
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureCommonStockSummaryOfRestrictedStockUnitAwardActivityDetail"
],
"xbrltype": "sharesItemType"
},
"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
"auth_ref": [
"r251",
"r252"
],
"lang": {
"en-us": {
"role": {
"documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
"label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value",
"periodEndLabel": "Weighted-Average Grant Date Fair Value, Released",
"periodStartLabel": "Weighted-Average Grant Date Fair Value, Beginning Balance"
}
}
},
"localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureCommonStockSummaryOfRestrictedStockUnitAwardActivityDetail"
],
"xbrltype": "perShareItemType"
},
"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
"auth_ref": [
"r255"
],
"lang": {
"en-us": {
"role": {
"documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
"label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period",
"negatedLabel": "Number of Shares, Released"
}
}
},
"localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureCommonStockSummaryOfRestrictedStockUnitAwardActivityDetail"
],
"xbrltype": "sharesItemType"
},
"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
"auth_ref": [
"r255"
],
"lang": {
"en-us": {
"role": {
"documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.",
"label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value",
"terseLabel": "Weighted-Average Grant Date Fair Value, Released"
}
}
},
"localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureCommonStockSummaryOfRestrictedStockUnitAwardActivityDetail"
],
"xbrltype": "perShareItemType"
},
"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
"auth_ref": [
"r264"
],
"lang": {
"en-us": {
"role": {
"documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
"label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate",
"terseLabel": "Expected dividend yield"
}
}
},
"localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureCommonStockSummaryOfFairValueOfEachStockAwardForEmployeesAndDirectorsDetail"
],
"xbrltype": "percentItemType"
},
"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
"auth_ref": [
"r263"
],
"lang": {
"en-us": {
"role": {
"documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
"label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate",
"terseLabel": "Expected volatility"
}
}
},
"localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureCommonStockSummaryOfFairValueOfEachStockAwardForEmployeesAndDirectorsDetail"
],
"xbrltype": "percentItemType"
},
"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
"auth_ref": [
"r265"
],
"lang": {
"en-us": {
"role": {
"documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
"label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate",
"terseLabel": "Risk-free interest rates"
}
}
},
"localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureCommonStockSummaryOfFairValueOfEachStockAwardForEmployeesAndDirectorsDetail"
],
"xbrltype": "percentItemType"
},
"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
"label": "Share Based Compensation Arrangement By Share Based Payment Award [Line Items]",
"terseLabel": "Share Based Compensation Arrangement By Share Based Payment Award [Line Items]"
}
}
},
"localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureCommonStockEmployeeSharePurchasePlanAdditionalInformationDetail",
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureCommonStockIssuedAndOutstandingSharesAdditionalInformationDetail",
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureCommonStockRestrictedStockUnitAwardsAdditionalInformationDetail",
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureCommonStockStockOptionsAdditionalInformationDetail",
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureCommonStockSummaryOfRestrictedStockUnitAwardActivityDetail"
],
"xbrltype": "stringItemType"
},
"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber": {
"auth_ref": [
"r243",
"r244"
],
"lang": {
"en-us": {
"role": {
"documentation": "Number of equity instruments other than options outstanding, including both vested and non-vested instruments.",
"label": "Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number",
"terseLabel": "Restricted shares reserved for issuance under incentive plan"
}
}
},
"localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureCommonStockStockOptionsAdditionalInformationDetail"
],
"xbrltype": "sharesItemType"
},
"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
"auth_ref": [
"r271"
],
"lang": {
"en-us": {
"role": {
"documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
"label": "Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant",
"terseLabel": "Common shares reserved for issuance under incentive plan"
}
}
},
"localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureCommonStockStockOptionsAdditionalInformationDetail"
],
"xbrltype": "sharesItemType"
},
"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": {
"auth_ref": [
"r250"
],
"lang": {
"en-us": {
"role": {
"documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.",
"label": "Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period",
"negatedLabel": "Number of Optioned Common Shares, Expired"
}
}
},
"localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureCommonStockSummaryOfStockOptionsActivityDetail"
],
"xbrltype": "sharesItemType"
},
"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
"auth_ref": [
"r247"
],
"lang": {
"en-us": {
"role": {
"documentation": "Gross number of share options (or share units) granted during the period.",
"label": "Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross",
"terseLabel": "Number of shares granted"
}
}
},
"localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureCommonStockStockOptionsAdditionalInformationDetail",
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureCommonStockSummaryOfStockOptionsActivityDetail"
],
"xbrltype": "sharesItemType"
},
"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
"auth_ref": [
"r243",
"r244"
],
"lang": {
"en-us": {
"role": {
"documentation": "Number of options outstanding, including both vested and non-vested options.",
"label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number",
"periodEndLabel": "Number of Optioned Common Shares, Ending Balance",
"periodStartLabel": "Number of Optioned Common Shares, Beginning Balance",
"terseLabel": "Common shares reserved for options currently outstanding"
}
}
},
"localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureCommonStockStockOptionsAdditionalInformationDetail",
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureCommonStockSummaryOfStockOptionsActivityDetail"
],
"xbrltype": "sharesItemType"
},
"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
"auth_ref": [
"r243",
"r244"
],
"lang": {
"en-us": {
"role": {
"documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
"label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price",
"periodEndLabel": "Weighted Average Exercise Price, Ending Balance",
"periodStartLabel": "Weighted Average Exercise Price, Beginning Balance"
}
}
},
"localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureCommonStockSummaryOfStockOptionsActivityDetail"
],
"xbrltype": "perShareItemType"
},
"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward": {
"auth_ref": [
"r270"
],
"lang": {
"en-us": {
"role": {
"documentation": "Number of shares purchased for issuance under share-based payment arrangement.",
"label": "Share Based Compensation Arrangement By Share Based Payment Award Shares Purchased For Award",
"terseLabel": "Number of shares purchased"
}
}
},
"localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureCommonStockEmployeeSharePurchasePlanAdditionalInformationDetail"
],
"xbrltype": "sharesItemType"
},
"us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
"auth_ref": [
"r239",
"r240",
"r241",
"r243",
"r244",
"r245",
"r246",
"r247",
"r248",
"r249",
"r250",
"r251",
"r252",
"r253",
"r254",
"r255",
"r256",
"r257",
"r258",
"r259",
"r260",
"r262",
"r263",
"r264",
"r265",
"r266"
],
"lang": {
"en-us": {
"role": {
"documentation": "Award under share-based payment arrangement.",
"label": "Share Based Compensation Arrangements By Share Based Payment Award Award Type And Plan Name [Domain]",
"terseLabel": "Award Type"
}
}
},
"localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureCommonStockRestrictedStockUnitAwardsAdditionalInformationDetail",
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureCommonStockStockOptionsAdditionalInformationDetail",
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureCommonStockSummaryOfRestrictedStockUnitAwardActivityDetail"
],
"xbrltype": "domainItemType"
},
"us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": {
"auth_ref": [
"r250"
],
"lang": {
"en-us": {
"role": {
"documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.",
"label": "Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price",
"terseLabel": "Weighted Average Exercise Price, Expired"
}
}
},
"localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureCommonStockSummaryOfStockOptionsActivityDetail"
],
"xbrltype": "perShareItemType"
},
"us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
"auth_ref": [
"r247"
],
"lang": {
"en-us": {
"role": {
"documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
"label": "Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price",
"terseLabel": "Weighted Average Exercise Price, Granted"
}
}
},
"localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureCommonStockSummaryOfStockOptionsActivityDetail"
],
"xbrltype": "perShareItemType"
},
"us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
"auth_ref": [
"r240"
],
"lang": {
"en-us": {
"role": {
"documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
"label": "Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period",
"terseLabel": "Award expiration period"
}
}
},
"localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureCommonStockStockOptionsAdditionalInformationDetail"
],
"xbrltype": "durationItemType"
},
"us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
"auth_ref": [
"r262"
],
"lang": {
"en-us": {
"role": {
"documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
"label": "Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1",
"terseLabel": "Expected life"
}
}
},
"localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureCommonStockSummaryOfFairValueOfEachStockAwardForEmployeesAndDirectorsDetail"
],
"xbrltype": "durationItemType"
},
"us-gaap_SharesIssued": {
"auth_ref": [
"r215"
],
"lang": {
"en-us": {
"role": {
"documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.",
"label": "Shares Issued",
"periodEndLabel": "Ending Balance, Shares",
"periodStartLabel": "Beginning Balance, Shares"
}
}
},
"localname": "SharesIssued",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/StatementConsolidatedStatementsOfStockholderSEquityUnaudited"
],
"xbrltype": "sharesItemType"
},
"us-gaap_SharesIssuedPricePerShare": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Per share or per unit amount of equity securities issued.",
"label": "Shares Issued Price Per Share",
"terseLabel": "Common stock, price per share"
}
}
},
"localname": "SharesIssuedPricePerShare",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureCommonStockIssuedAndOutstandingSharesAdditionalInformationDetail"
],
"xbrltype": "perShareItemType"
},
"us-gaap_SignificantAccountingPoliciesTextBlock": {
"auth_ref": [
"r70",
"r79"
],
"lang": {
"en-us": {
"role": {
"documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
"label": "Significant Accounting Policies [Text Block]",
"terseLabel": "Accounting Policies"
}
}
},
"localname": "SignificantAccountingPoliciesTextBlock",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureAccountingPolicies"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_StatementClassOfStockAxis": {
"auth_ref": [
"r14",
"r15",
"r16",
"r72",
"r75",
"r95",
"r96",
"r97",
"r99",
"r101",
"r106",
"r107",
"r108",
"r125",
"r155",
"r159",
"r160",
"r161",
"r164",
"r165",
"r200",
"r201",
"r205",
"r209",
"r215",
"r310",
"r407"
],
"lang": {
"en-us": {
"role": {
"documentation": "Information by the different classes of stock of the entity.",
"label": "Statement Class Of Stock [Axis]",
"terseLabel": "Class of Stock"
}
}
},
"localname": "StatementClassOfStockAxis",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/StatementConsolidatedBalanceSheetsParentheticalUnaudited",
"http://achievelifesciences.com/20220630/taxonomy/role/StatementConsolidatedBalanceSheetsUnaudited"
],
"xbrltype": "stringItemType"
},
"us-gaap_StatementEquityComponentsAxis": {
"auth_ref": [
"r0",
"r36",
"r46",
"r47",
"r48",
"r80",
"r81",
"r82",
"r84",
"r90",
"r92",
"r105",
"r126",
"r215",
"r219",
"r272",
"r273",
"r274",
"r279",
"r280",
"r297",
"r312",
"r313",
"r314",
"r315",
"r316",
"r317",
"r335",
"r382",
"r383",
"r384"
],
"lang": {
"en-us": {
"role": {
"documentation": "Information by component of equity.",
"label": "Statement Equity Components [Axis]",
"terseLabel": "Equity Components"
}
}
},
"localname": "StatementEquityComponentsAxis",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureCommonStockIssuedAndOutstandingSharesAdditionalInformationDetail",
"http://achievelifesciences.com/20220630/taxonomy/role/StatementConsolidatedStatementsOfStockholderSEquityUnaudited"
],
"xbrltype": "stringItemType"
},
"us-gaap_StatementLineItems": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
"label": "Statement [Line Items]",
"terseLabel": "Statement [Line Items]"
}
}
},
"localname": "StatementLineItems",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/StatementConsolidatedBalanceSheetsParentheticalUnaudited",
"http://achievelifesciences.com/20220630/taxonomy/role/StatementConsolidatedBalanceSheetsUnaudited",
"http://achievelifesciences.com/20220630/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited",
"http://achievelifesciences.com/20220630/taxonomy/role/StatementConsolidatedStatementsOfStockholderSEquityUnaudited"
],
"xbrltype": "stringItemType"
},
"us-gaap_StatementOfCashFlowsAbstract": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Statement Of Cash Flows [Abstract]"
}
}
},
"localname": "StatementOfCashFlowsAbstract",
"nsuri": "http://fasb.org/us-gaap/2022",
"xbrltype": "stringItemType"
},
"us-gaap_StatementOfFinancialPositionAbstract": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Statement Of Financial Position [Abstract]"
}
}
},
"localname": "StatementOfFinancialPositionAbstract",
"nsuri": "http://fasb.org/us-gaap/2022",
"xbrltype": "stringItemType"
},
"us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Statement Of Income And Comprehensive Income [Abstract]"
}
}
},
"localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
"nsuri": "http://fasb.org/us-gaap/2022",
"xbrltype": "stringItemType"
},
"us-gaap_StatementOfStockholdersEquityAbstract": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Statement Of Stockholders Equity [Abstract]"
}
}
},
"localname": "StatementOfStockholdersEquityAbstract",
"nsuri": "http://fasb.org/us-gaap/2022",
"xbrltype": "stringItemType"
},
"us-gaap_StatementTable": {
"auth_ref": [
"r80",
"r81",
"r82",
"r105",
"r351"
],
"lang": {
"en-us": {
"role": {
"documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
"label": "Statement [Table]",
"terseLabel": "Statement [Table]"
}
}
},
"localname": "StatementTable",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/StatementConsolidatedBalanceSheetsParentheticalUnaudited",
"http://achievelifesciences.com/20220630/taxonomy/role/StatementConsolidatedBalanceSheetsUnaudited",
"http://achievelifesciences.com/20220630/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited",
"http://achievelifesciences.com/20220630/taxonomy/role/StatementConsolidatedStatementsOfStockholderSEquityUnaudited"
],
"xbrltype": "stringItemType"
},
"us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
"auth_ref": [
"r15",
"r16",
"r215",
"r219"
],
"lang": {
"en-us": {
"role": {
"documentation": "Number of new stock issued during the period.",
"label": "Stock Issued During Period Shares New Issues",
"terseLabel": "Shares issued, Shares",
"verboseLabel": "Common stock, shares issued"
}
}
},
"localname": "StockIssuedDuringPeriodSharesNewIssues",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureCommonStockIssuedAndOutstandingSharesAdditionalInformationDetail",
"http://achievelifesciences.com/20220630/taxonomy/role/StatementConsolidatedStatementsOfStockholderSEquityUnaudited"
],
"xbrltype": "sharesItemType"
},
"us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures": {
"auth_ref": [
"r15",
"r16",
"r215",
"r219"
],
"lang": {
"en-us": {
"role": {
"documentation": "Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.",
"label": "Stock Issued During Period Shares Restricted Stock Award Net Of Forfeitures",
"terseLabel": "Restricted stock unit settlements",
"verboseLabel": "Restricted stock unit settlements"
}
}
},
"localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureCommonStockIssuedAndOutstandingSharesAdditionalInformationDetail",
"http://achievelifesciences.com/20220630/taxonomy/role/StatementConsolidatedStatementsOfStockholderSEquityUnaudited"
],
"xbrltype": "sharesItemType"
},
"us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
"auth_ref": [
"r15",
"r16",
"r215",
"r219",
"r248"
],
"lang": {
"en-us": {
"role": {
"documentation": "Number of share options (or share units) exercised during the current period.",
"label": "Stock Issued During Period Shares Stock Options Exercised",
"terseLabel": "Stock option exercises, Shares"
}
}
},
"localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureCommonStockIssuedAndOutstandingSharesAdditionalInformationDetail"
],
"xbrltype": "sharesItemType"
},
"us-gaap_StockIssuedDuringPeriodValueNewIssues": {
"auth_ref": [
"r15",
"r16",
"r215",
"r219"
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
"label": "Stock Issued During Period Value New Issues",
"terseLabel": "Shares issued"
}
}
},
"localname": "StockIssuedDuringPeriodValueNewIssues",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/StatementConsolidatedStatementsOfStockholderSEquityUnaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_StockholdersEquity": {
"auth_ref": [
"r16",
"r21",
"r22",
"r75",
"r123",
"r125",
"r310",
"r339"
],
"calculation": {
"http://achievelifesciences.com/20220630/taxonomy/role/StatementConsolidatedBalanceSheetsUnaudited": {
"order": 10030.0,
"parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
"label": "Stockholders Equity",
"periodEndLabel": "Ending Balance",
"periodStartLabel": "Beginning Balance",
"totalLabel": "Total stockholders' equity"
}
}
},
"localname": "StockholdersEquity",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/StatementConsolidatedBalanceSheetsUnaudited",
"http://achievelifesciences.com/20220630/taxonomy/role/StatementConsolidatedStatementsOfStockholderSEquityUnaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_StockholdersEquityAbstract": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Stockholders Equity [Abstract]",
"terseLabel": "Stockholders' equity:"
}
}
},
"localname": "StockholdersEquityAbstract",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/StatementConsolidatedBalanceSheetsUnaudited"
],
"xbrltype": "stringItemType"
},
"us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
"auth_ref": [
"r73",
"r201",
"r204",
"r205",
"r206",
"r207",
"r208",
"r209",
"r210",
"r211",
"r212",
"r213",
"r214",
"r219",
"r221",
"r296"
],
"lang": {
"en-us": {
"role": {
"documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
"label": "Stockholders Equity Note Disclosure [Text Block]",
"terseLabel": "Common Stock"
}
}
},
"localname": "StockholdersEquityNoteDisclosureTextBlock",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureCommonStock"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_SubsidiarySaleOfStockAxis": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Information by type of sale of the entity's stock.",
"label": "Subsidiary Sale Of Stock [Axis]",
"terseLabel": "Sale of Stock"
}
}
},
"localname": "SubsidiarySaleOfStockAxis",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureCommonStockEmployeeSharePurchasePlanAdditionalInformationDetail",
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureCommonStockIssuedAndOutstandingSharesAdditionalInformationDetail",
"http://achievelifesciences.com/20220630/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited",
"http://achievelifesciences.com/20220630/taxonomy/role/StatementConsolidatedStatementsOfStockholderSEquityUnaudited"
],
"xbrltype": "stringItemType"
},
"us-gaap_TypeOfArrangementAxis": {
"auth_ref": [
"r284"
],
"lang": {
"en-us": {
"role": {
"documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
"label": "Type Of Arrangement [Axis]",
"terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative"
}
}
},
"localname": "TypeOfArrangementAxis",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail",
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfContractualObligationsDetail",
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfFutureMinimumAnnualLeasePaymentsDetail",
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureCommitmentsAndContingenciesTables",
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetail"
],
"xbrltype": "stringItemType"
},
"us-gaap_VariableRateAxis": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Information by type of variable rate.",
"label": "Variable Rate [Axis]",
"terseLabel": "Variable Rate"
}
}
},
"localname": "VariableRateAxis",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureConvertibleDebtAdditionalInformationDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_VariableRateDomain": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.",
"label": "Variable Rate [Domain]",
"terseLabel": "Variable Rate"
}
}
},
"localname": "VariableRateDomain",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureConvertibleDebtAdditionalInformationDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_WarrantMember": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.",
"label": "Warrant [Member]",
"verboseLabel": "Warrant [Member]"
}
}
},
"localname": "WarrantMember",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/DisclosureCommonStockStockOptionsAdditionalInformationDetail"
],
"xbrltype": "domainItemType"
},
"us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
"auth_ref": [
"r94",
"r101"
],
"lang": {
"en-us": {
"role": {
"documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
"label": "Weighted Average Number Of Diluted Shares Outstanding",
"verboseLabel": "Weighted average shares used in computation of diluted net loss per common share [note 8[d]]"
}
}
},
"localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/StatementConsolidatedStatementsOfLossAndComprehensiveLossUnaudited"
],
"xbrltype": "sharesItemType"
},
"us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
"auth_ref": [
"r93",
"r101"
],
"lang": {
"en-us": {
"role": {
"documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
"label": "Weighted Average Number Of Shares Outstanding Basic",
"terseLabel": "Weighted average shares used in computation of basic net loss per common share [note 8[d]]"
}
}
},
"localname": "WeightedAverageNumberOfSharesOutstandingBasic",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://achievelifesciences.com/20220630/taxonomy/role/StatementConsolidatedStatementsOfLossAndComprehensiveLossUnaudited"
],
"xbrltype": "sharesItemType"
}
},
"unitCount": 6
}
},
"std_ref": {
"r0": {
"Name": "Accounting Standards Codification",
"Paragraph": "6",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "10",
"Subparagraph": "(c)",
"Topic": "105",
"URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695"
},
"r1": {
"Name": "Accounting Standards Codification",
"Paragraph": "7",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Topic": "205",
"URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
},
"r10": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(18))",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r100": {
"Name": "Accounting Standards Codification",
"Paragraph": "7",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "260",
"URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256"
},
"r101": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "260",
"URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
},
"r102": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)",
"Topic": "260",
"URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
},
"r103": {
"Name": "Accounting Standards Codification",
"Paragraph": "15",
"Publisher": "FASB",
"Section": "55",
"SubTopic": "10",
"Topic": "260",
"URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258"
},
"r104": {
"Name": "Accounting Standards Codification",
"Paragraph": "52",
"Publisher": "FASB",
"Section": "55",
"SubTopic": "10",
"Topic": "260",
"URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258"
},
"r105": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "272",
"URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
},
"r106": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "272",
"URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054"
},
"r107": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "272",
"URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
},
"r108": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "272",
"URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055"
},
"r109": {
"Name": "Accounting Standards Codification",
"Publisher": "FASB",
"Topic": "275",
"URI": "https://asc.fasb.org/topic&trid=2134479"
},
"r11": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(19))",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r110": {
"Name": "Accounting Standards Codification",
"Paragraph": "22",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)",
"Topic": "280",
"URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
},
"r111": {
"Name": "Accounting Standards Codification",
"Paragraph": "22",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(d)",
"Topic": "280",
"URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
},
"r112": {
"Name": "Accounting Standards Codification",
"Paragraph": "22",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "280",
"URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
},
"r113": {
"Name": "Accounting Standards Codification",
"Paragraph": "30",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "280",
"URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
},
"r114": {
"Name": "Accounting Standards Codification",
"Paragraph": "30",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)",
"Topic": "280",
"URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
},
"r115": {
"Name": "Accounting Standards Codification",
"Paragraph": "30",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(d)",
"Topic": "280",
"URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
},
"r116": {
"Name": "Accounting Standards Codification",
"Paragraph": "31",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "280",
"URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599"
},
"r117": {
"Name": "Accounting Standards Codification",
"Paragraph": "32",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)",
"Topic": "280",
"URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
},
"r118": {
"Name": "Accounting Standards Codification",
"Paragraph": "32",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(d)",
"Topic": "280",
"URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
},
"r119": {
"Name": "Accounting Standards Codification",
"Paragraph": "32",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(f)",
"Topic": "280",
"URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
},
"r12": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(20))",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r120": {
"Name": "Accounting Standards Codification",
"Paragraph": "41",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "280",
"URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599"
},
"r121": {
"Name": "Accounting Standards Codification",
"Paragraph": "41",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "280",
"URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599"
},
"r122": {
"Name": "Accounting Standards Codification",
"Paragraph": "13",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "310",
"URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522"
},
"r123": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SAB Topic 4.E)",
"Topic": "310",
"URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
},
"r124": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "321",
"URI": "https://asc.fasb.org/extlink&oid=123583714&loc=SL75117360-209713"
},
"r125": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)",
"Topic": "323",
"URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
},
"r126": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "10",
"Subparagraph": "(d)",
"Topic": "326",
"URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
},
"r127": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "20",
"Topic": "350",
"URI": "https://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266"
},
"r128": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(a)",
"Topic": "350",
"URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
},
"r129": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(h)",
"Topic": "350",
"URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
},
"r13": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(22))",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r130": {
"Name": "Accounting Standards Codification",
"Paragraph": "24",
"Publisher": "FASB",
"Section": "55",
"SubTopic": "20",
"Topic": "350",
"URI": "https://asc.fasb.org/extlink&oid=122137925&loc=d3e14258-109268"
},
"r131": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "30",
"Topic": "350",
"URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274"
},
"r132": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "30",
"Subparagraph": "(a)",
"Topic": "350",
"URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
},
"r133": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "30",
"Subparagraph": "(d)",
"Topic": "350",
"URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
},
"r134": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "30",
"Subparagraph": "(a)",
"Topic": "350",
"URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
},
"r135": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "30",
"Subparagraph": "(a)(1)",
"Topic": "350",
"URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
},
"r136": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "30",
"Subparagraph": "(a)(2)",
"Topic": "350",
"URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
},
"r137": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "30",
"Subparagraph": "(a)(3)",
"Topic": "350",
"URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
},
"r138": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "30",
"Subparagraph": "(d)",
"Topic": "350",
"URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
},
"r139": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "30",
"Subparagraph": "(b)",
"Topic": "350",
"URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275"
},
"r14": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(27)(b))",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r140": {
"Name": "Accounting Standards Codification",
"Publisher": "FASB",
"SubTopic": "30",
"Topic": "350",
"URI": "https://asc.fasb.org/subtopic&trid=2144471"
},
"r141": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "360",
"URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
},
"r142": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(d)",
"Topic": "360",
"URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
},
"r143": {
"Name": "Accounting Standards Codification",
"Paragraph": "10",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "30",
"Subparagraph": "(c)",
"Topic": "410",
"URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859"
},
"r144": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)",
"Topic": "420",
"URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
},
"r145": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "440",
"URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
},
"r146": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)",
"Topic": "440",
"URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
},
"r147": {
"Name": "Accounting Standards Codification",
"Publisher": "FASB",
"Topic": "440",
"URI": "https://asc.fasb.org/topic&trid=2144648"
},
"r148": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(b)",
"Topic": "450",
"URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349"
},
"r149": {
"Name": "Accounting Standards Codification",
"Paragraph": "9",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(b)",
"Topic": "450",
"URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349"
},
"r15": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(28))",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r150": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "20",
"Subparagraph": "(SAB Topic 5.Y.Q2)",
"Topic": "450",
"URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751"
},
"r151": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "20",
"Subparagraph": "(SAB Topic 5.Y.Q4)",
"Topic": "450",
"URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751"
},
"r152": {
"Name": "Accounting Standards Codification",
"Publisher": "FASB",
"Topic": "450",
"URI": "https://asc.fasb.org/topic&trid=2127136"
},
"r153": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)",
"Topic": "460",
"URI": "https://asc.fasb.org/extlink&oid=124440162&loc=d3e12069-110248"
},
"r154": {
"Name": "Accounting Standards Codification",
"Paragraph": "5",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=123465755&loc=SL6230698-112601"
},
"r155": {
"Name": "Accounting Standards Codification",
"Paragraph": "1A",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.13-01(a)(4)(i))",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
},
"r156": {
"Name": "Accounting Standards Codification",
"Paragraph": "1A",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.13-01(a)(4)(ii))",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
},
"r157": {
"Name": "Accounting Standards Codification",
"Paragraph": "1A",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
},
"r158": {
"Name": "Accounting Standards Codification",
"Paragraph": "1A",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.13-01(a)(4)(iii))",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
},
"r159": {
"Name": "Accounting Standards Codification",
"Paragraph": "1A",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.13-01(a)(4)(iv))",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
},
"r16": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(29))",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r160": {
"Name": "Accounting Standards Codification",
"Paragraph": "1A",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.13-01(a)(5))",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
},
"r161": {
"Name": "Accounting Standards Codification",
"Paragraph": "1B",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.13-02(a)(4)(i))",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
},
"r162": {
"Name": "Accounting Standards Codification",
"Paragraph": "1B",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
},
"r163": {
"Name": "Accounting Standards Codification",
"Paragraph": "1B",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
},
"r164": {
"Name": "Accounting Standards Codification",
"Paragraph": "1B",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.13-02(a)(4)(iv))",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
},
"r165": {
"Name": "Accounting Standards Codification",
"Paragraph": "1B",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.13-02(a)(5))",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
},
"r166": {
"Name": "Accounting Standards Codification",
"Paragraph": "10",
"Publisher": "FASB",
"Section": "25",
"SubTopic": "20",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=123466302&loc=d3e4852-112606"
},
"r167": {
"Name": "Accounting Standards Codification",
"Paragraph": "1B",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(a)",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
},
"r168": {
"Name": "Accounting Standards Codification",
"Paragraph": "1B",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(b)",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
},
"r169": {
"Name": "Accounting Standards Codification",
"Paragraph": "1B",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(c)",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
},
"r17": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(3)(a)(4))",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r170": {
"Name": "Accounting Standards Codification",
"Paragraph": "1B",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(d)",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
},
"r171": {
"Name": "Accounting Standards Codification",
"Paragraph": "1B",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(e)",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
},
"r172": {
"Name": "Accounting Standards Codification",
"Paragraph": "1B",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(f)",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
},
"r173": {
"Name": "Accounting Standards Codification",
"Paragraph": "1B",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(g)",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
},
"r174": {
"Name": "Accounting Standards Codification",
"Paragraph": "1B",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(h)",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
},
"r175": {
"Name": "Accounting Standards Codification",
"Paragraph": "1B",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(i)",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
},
"r176": {
"Name": "Accounting Standards Codification",
"Paragraph": "1B",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
},
"r177": {
"Name": "Accounting Standards Codification",
"Paragraph": "1C",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(a)",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
},
"r178": {
"Name": "Accounting Standards Codification",
"Paragraph": "1C",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(b)",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
},
"r179": {
"Name": "Accounting Standards Codification",
"Paragraph": "1C",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(c)",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
},
"r18": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(30)(a)(1))",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r180": {
"Name": "Accounting Standards Codification",
"Paragraph": "1D",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(a)",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
},
"r181": {
"Name": "Accounting Standards Codification",
"Paragraph": "1D",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(b)",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
},
"r182": {
"Name": "Accounting Standards Codification",
"Paragraph": "1D",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(c)",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
},
"r183": {
"Name": "Accounting Standards Codification",
"Paragraph": "1E",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(a)",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
},
"r184": {
"Name": "Accounting Standards Codification",
"Paragraph": "1E",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(b)",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
},
"r185": {
"Name": "Accounting Standards Codification",
"Paragraph": "1E",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(c)",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
},
"r186": {
"Name": "Accounting Standards Codification",
"Paragraph": "1E",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(d)",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
},
"r187": {
"Name": "Accounting Standards Codification",
"Paragraph": "1F",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(a)",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
},
"r188": {
"Name": "Accounting Standards Codification",
"Paragraph": "1F",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(b)",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
},
"r189": {
"Name": "Accounting Standards Codification",
"Paragraph": "1F",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(b)(1)",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
},
"r19": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(30)(a)(3))",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r190": {
"Name": "Accounting Standards Codification",
"Paragraph": "1F",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(b)(2)",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
},
"r191": {
"Name": "Accounting Standards Codification",
"Paragraph": "1I",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(a)",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
},
"r192": {
"Name": "Accounting Standards Codification",
"Paragraph": "1I",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(b)",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
},
"r193": {
"Name": "Accounting Standards Codification",
"Paragraph": "1I",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(d)",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
},
"r194": {
"Name": "Accounting Standards Codification",
"Paragraph": "5",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(b)",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031898-161870"
},
"r195": {
"Name": "Accounting Standards Codification",
"Paragraph": "69B",
"Publisher": "FASB",
"Section": "55",
"SubTopic": "20",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612"
},
"r196": {
"Name": "Accounting Standards Codification",
"Paragraph": "69C",
"Publisher": "FASB",
"Section": "55",
"SubTopic": "20",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612"
},
"r197": {
"Name": "Accounting Standards Codification",
"Paragraph": "69E",
"Publisher": "FASB",
"Section": "55",
"SubTopic": "20",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612"
},
"r198": {
"Name": "Accounting Standards Codification",
"Paragraph": "69F",
"Publisher": "FASB",
"Section": "55",
"SubTopic": "20",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612"
},
"r199": {
"Name": "Accounting Standards Codification",
"Publisher": "FASB",
"Topic": "470",
"URI": "https://asc.fasb.org/topic&trid=2208564"
},
"r2": {
"Name": "Accounting Standards Codification",
"Publisher": "FASB",
"Topic": "205",
"URI": "https://asc.fasb.org/topic&trid=2122149"
},
"r20": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(30)(a)(4))",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r200": {
"Name": "Accounting Standards Codification",
"Paragraph": "13",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "505",
"URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
},
"r201": {
"Name": "Accounting Standards Codification",
"Paragraph": "13",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "505",
"URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
},
"r202": {
"Name": "Accounting Standards Codification",
"Paragraph": "13",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(d)",
"Topic": "505",
"URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
},
"r203": {
"Name": "Accounting Standards Codification",
"Paragraph": "13",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(e)",
"Topic": "505",
"URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
},
"r204": {
"Name": "Accounting Standards Codification",
"Paragraph": "13",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(g)",
"Topic": "505",
"URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
},
"r205": {
"Name": "Accounting Standards Codification",
"Paragraph": "13",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(h)",
"Topic": "505",
"URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
},
"r206": {
"Name": "Accounting Standards Codification",
"Paragraph": "13",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(i)",
"Topic": "505",
"URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
},
"r207": {
"Name": "Accounting Standards Codification",
"Paragraph": "13",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "505",
"URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
},
"r208": {
"Name": "Accounting Standards Codification",
"Paragraph": "14",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "505",
"URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644"
},
"r209": {
"Name": "Accounting Standards Codification",
"Paragraph": "14",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "505",
"URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644"
},
"r21": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(30))",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r210": {
"Name": "Accounting Standards Codification",
"Paragraph": "14",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)",
"Topic": "505",
"URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644"
},
"r211": {
"Name": "Accounting Standards Codification",
"Paragraph": "16",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "505",
"URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644"
},
"r212": {
"Name": "Accounting Standards Codification",
"Paragraph": "18",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "505",
"URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644"
},
"r213": {
"Name": "Accounting Standards Codification",
"Paragraph": "18",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "505",
"URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644"
},
"r214": {
"Name": "Accounting Standards Codification",
"Paragraph": "18",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(d)",
"Topic": "505",
"URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644"
},
"r215": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "505",
"URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644"
},
"r216": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "505",
"URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644"
},
"r217": {
"Name": "Accounting Standards Codification",
"Paragraph": "6",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "505",
"URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644"
},
"r218": {
"Name": "Accounting Standards Codification",
"Paragraph": "7",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "505",
"URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21521-112644"
},
"r219": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.3-04)",
"Topic": "505",
"URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
},
"r22": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(31))",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r220": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "50",
"Topic": "505",
"URI": "https://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775"
},
"r221": {
"Name": "Accounting Standards Codification",
"Publisher": "FASB",
"Topic": "505",
"URI": "https://asc.fasb.org/topic&trid=2208762"
},
"r222": {
"Name": "Accounting Standards Codification",
"Paragraph": "5",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "606",
"URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045"
},
"r223": {
"Name": "Accounting Standards Codification",
"Paragraph": "91",
"Publisher": "FASB",
"Section": "55",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "606",
"URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046"
},
"r224": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(d)(i)",
"Topic": "715",
"URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
},
"r225": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(d)(ii)",
"Topic": "715",
"URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
},
"r226": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(d)(iv)(01)",
"Topic": "715",
"URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
},
"r227": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(d)(iv)(02)",
"Topic": "715",
"URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
},
"r228": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(d)(iv)(02)(A)",
"Topic": "715",
"URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
},
"r229": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(d)(iv)(02)(B)",
"Topic": "715",
"URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
},
"r23": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(32))",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r230": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(d)(iv)(02)(C)",
"Topic": "715",
"URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
},
"r231": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(d)(iv)(03)",
"Topic": "715",
"URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
},
"r232": {
"Name": "Accounting Standards Codification",
"Paragraph": "17",
"Publisher": "FASB",
"Section": "55",
"SubTopic": "20",
"Topic": "715",
"URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921"
},
"r233": {
"Name": "Accounting Standards Codification",
"Paragraph": "5",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "80",
"Subparagraph": "(d)",
"Topic": "715",
"URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
},
"r234": {
"Name": "Accounting Standards Codification",
"Paragraph": "8",
"Publisher": "FASB",
"Section": "55",
"SubTopic": "80",
"Topic": "715",
"URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
},
"r235": {
"Name": "Accounting Standards Codification",
"Paragraph": "1D",
"Publisher": "FASB",
"Section": "35",
"SubTopic": "10",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899"
},
"r236": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "35",
"SubTopic": "10",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4534-113899"
},
"r237": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "35",
"SubTopic": "10",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899"
},
"r238": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5047-113901"
},
"r239": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)(1)",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
},
"r24": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(9))",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r240": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)(2)",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
},
"r241": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)(3)",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
},
"r242": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)(1)",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
},
"r243": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)(1)(i)",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
},
"r244": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)(1)(ii)",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
},
"r245": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)(1)(iii)",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
},
"r246": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)(1)(iv)",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
},
"r247": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)(1)(iv)(01)",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
},
"r248": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)(1)(iv)(02)",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
},
"r249": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)(1)(iv)(03)",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
},
"r25": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02.19(a))",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r250": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)(1)(iv)(04)",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
},
"r251": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)(2)(i)",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
},
"r252": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)(2)(ii)",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
},
"r253": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)(2)(iii)",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
},
"r254": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)(2)(iii)(01)",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
},
"r255": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)(2)(iii)(02)",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
},
"r256": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)(2)(iii)(03)",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
},
"r257": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(d)(1)",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
},
"r258": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(d)(2)",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
},
"r259": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(e)(1)",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
},
"r26": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02.19(b),22(b))",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r260": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(e)(2)",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
},
"r261": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(f)(2)",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
},
"r262": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(f)(2)(i)",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
},
"r263": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(f)(2)(ii)",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
},
"r264": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(f)(2)(iii)",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
},
"r265": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(f)(2)(iv)",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
},
"r266": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(f)(2)(v)",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
},
"r267": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(h)(1)",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
},
"r268": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(h)(1)(i)",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
},
"r269": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(i)",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
},
"r27": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02.19-26)",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r270": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(l)",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
},
"r271": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
},
"r272": {
"Name": "Accounting Standards Codification",
"Paragraph": "15",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "10",
"Subparagraph": "(e)",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
},
"r273": {
"Name": "Accounting Standards Codification",
"Paragraph": "15",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "10",
"Subparagraph": "(f)(1)",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
},
"r274": {
"Name": "Accounting Standards Codification",
"Paragraph": "15",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "10",
"Subparagraph": "(f)(2)",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
},
"r275": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SAB Topic 14.F)",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
},
"r276": {
"Name": "Accounting Standards Codification",
"Paragraph": "12",
"Publisher": "FASB",
"Section": "55",
"SubTopic": "20",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11149-113907"
},
"r277": {
"Name": "Accounting Standards Codification",
"Paragraph": "13",
"Publisher": "FASB",
"Section": "55",
"SubTopic": "20",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11178-113907"
},
"r278": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "730",
"URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
},
"r279": {
"Name": "Accounting Standards Codification",
"Paragraph": "8",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "10",
"Subparagraph": "(d)(2)",
"Topic": "740",
"URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277"
},
"r28": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02.20)",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r280": {
"Name": "Accounting Standards Codification",
"Paragraph": "8",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "10",
"Subparagraph": "(d)(3)",
"Topic": "740",
"URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277"
},
"r281": {
"Name": "Accounting Standards Codification",
"Paragraph": "31",
"Publisher": "FASB",
"Section": "55",
"SubTopic": "20",
"Subparagraph": "(a)",
"Topic": "805",
"URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5419-128473"
},
"r282": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "808",
"URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
},
"r283": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "808",
"URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
},
"r284": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "808",
"URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
},
"r285": {
"Name": "Accounting Standards Codification",
"Publisher": "FASB",
"Topic": "808",
"URI": "https://asc.fasb.org/topic&trid=5833765"
},
"r286": {
"Name": "Accounting Standards Codification",
"Paragraph": "19",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "810",
"URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683"
},
"r287": {
"Name": "Accounting Standards Codification",
"Paragraph": "25",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "810",
"URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
},
"r288": {
"Name": "Accounting Standards Codification",
"Paragraph": "25",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "810",
"URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
},
"r289": {
"Name": "Accounting Standards Codification",
"Paragraph": "1A",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)(1)",
"Topic": "810",
"URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
},
"r29": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02.21)",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r290": {
"Name": "Accounting Standards Codification",
"Paragraph": "1A",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)(1)",
"Topic": "810",
"URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
},
"r291": {
"Name": "Accounting Standards Codification",
"Paragraph": "1A",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c),(3)",
"Topic": "810",
"URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
},
"r292": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(bb)",
"Topic": "810",
"URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
},
"r293": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)",
"Topic": "810",
"URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
},
"r294": {
"Name": "Accounting Standards Codification",
"Paragraph": "4J",
"Publisher": "FASB",
"Section": "55",
"SubTopic": "10",
"Topic": "810",
"URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686"
},
"r295": {
"Name": "Accounting Standards Codification",
"Paragraph": "4K",
"Publisher": "FASB",
"Section": "55",
"SubTopic": "10",
"Topic": "810",
"URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686"
},
"r296": {
"Name": "Accounting Standards Codification",
"Paragraph": "6",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "40",
"Subparagraph": "(a)",
"Topic": "815",
"URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008"
},
"r297": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "40",
"Subparagraph": "(e)(3)",
"Topic": "815",
"URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
},
"r298": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "40",
"Subparagraph": "(e)(4)",
"Topic": "815",
"URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
},
"r299": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "40",
"Subparagraph": "(f)",
"Topic": "815",
"URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
},
"r3": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
},
"r30": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02.22(a)(1))",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r300": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "820",
"URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
},
"r301": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "820",
"URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
},
"r302": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(bbb)(1)",
"Topic": "820",
"URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
},
"r303": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(bbb)(2)",
"Topic": "820",
"URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
},
"r304": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)",
"Topic": "820",
"URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
},
"r305": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "820",
"URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
},
"r306": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "820",
"URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258"
},
"r307": {
"Name": "Accounting Standards Codification",
"Paragraph": "6A",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "820",
"URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL6742756-110258"
},
"r308": {
"Name": "Accounting Standards Codification",
"Paragraph": "11",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "825",
"URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13467-108611"
},
"r309": {
"Name": "Accounting Standards Codification",
"Paragraph": "12",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "825",
"URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13476-108611"
},
"r31": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02.22(a)(2))",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r310": {
"Name": "Accounting Standards Codification",
"Paragraph": "28",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(f)",
"Topic": "825",
"URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
},
"r311": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "230",
"Topic": "830",
"URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
},
"r312": {
"Name": "Accounting Standards Codification",
"Paragraph": "17",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "30",
"Topic": "830",
"URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
},
"r313": {
"Name": "Accounting Standards Codification",
"Paragraph": "20",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "30",
"Subparagraph": "(a)",
"Topic": "830",
"URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
},
"r314": {
"Name": "Accounting Standards Codification",
"Paragraph": "20",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "30",
"Subparagraph": "(b)",
"Topic": "830",
"URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
},
"r315": {
"Name": "Accounting Standards Codification",
"Paragraph": "20",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "30",
"Subparagraph": "(c)",
"Topic": "830",
"URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
},
"r316": {
"Name": "Accounting Standards Codification",
"Paragraph": "20",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "30",
"Subparagraph": "(d)",
"Topic": "830",
"URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
},
"r317": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "30",
"Topic": "830",
"URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
},
"r318": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(a)",
"Topic": "835",
"URI": "https://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
},
"r319": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "30",
"Topic": "835",
"URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399"
},
"r32": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02.22(a)(3))",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r320": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "30",
"Topic": "835",
"URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399"
},
"r321": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "30",
"Topic": "835",
"URI": "https://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629"
},
"r322": {
"Name": "Accounting Standards Codification",
"Paragraph": "8",
"Publisher": "FASB",
"Section": "55",
"SubTopic": "30",
"Topic": "835",
"URI": "https://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
},
"r323": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "20",
"Subparagraph": "(a)",
"Topic": "842",
"URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
},
"r324": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "20",
"Subparagraph": "(b)",
"Topic": "842",
"URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
},
"r325": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "20",
"Subparagraph": "(b)",
"Topic": "842",
"URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977"
},
"r326": {
"Name": "Accounting Standards Codification",
"Paragraph": "5",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "20",
"Subparagraph": "(c)",
"Topic": "842",
"URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977"
},
"r327": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(a)(1)",
"Topic": "842",
"URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980"
},
"r328": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(a)(3)",
"Topic": "842",
"URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980"
},
"r329": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(g)(1)",
"Topic": "842",
"URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980"
},
"r33": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02.22(a)(5))",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r330": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(g)(2)",
"Topic": "842",
"URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980"
},
"r331": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(g)(3)",
"Topic": "842",
"URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980"
},
"r332": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(g)(4)",
"Topic": "842",
"URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980"
},
"r333": {
"Name": "Accounting Standards Codification",
"Paragraph": "6",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Topic": "842",
"URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980"
},
"r334": {
"Name": "Accounting Standards Codification",
"Paragraph": "53",
"Publisher": "FASB",
"Section": "55",
"SubTopic": "20",
"Topic": "842",
"URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971"
},
"r335": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "10",
"Subparagraph": "(a)(3)(iii)(03)",
"Topic": "848",
"URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846"
},
"r336": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "850",
"URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864"
},
"r337": {
"Name": "Accounting Standards Codification",
"Paragraph": "7",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "852",
"URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
},
"r338": {
"Name": "Accounting Standards Codification",
"Paragraph": "7",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "852",
"URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
},
"r339": {
"Name": "Accounting Standards Codification",
"Paragraph": "10",
"Publisher": "FASB",
"Section": "55",
"SubTopic": "10",
"Topic": "852",
"URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
},
"r34": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02.22)",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r340": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(bb)(1)",
"Topic": "860",
"URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
},
"r341": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(bb)(2)",
"Topic": "860",
"URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
},
"r342": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(bb)(3)",
"Topic": "860",
"URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
},
"r343": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(c)(1)",
"Topic": "860",
"URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
},
"r344": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(c)(2)",
"Topic": "860",
"URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
},
"r345": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(c)(3)",
"Topic": "860",
"URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
},
"r346": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(b)(1)",
"Topic": "860",
"URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
},
"r347": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(b)(2)",
"Topic": "860",
"URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
},
"r348": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(b)(3)",
"Topic": "860",
"URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
},
"r349": {
"Name": "Accounting Standards Codification",
"Paragraph": "6",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "910",
"URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733"
},
"r35": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02.25)",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r350": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "25",
"SubTopic": "730",
"Topic": "912",
"URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433"
},
"r351": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SAB Topic 11.L)",
"Topic": "924",
"URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
},
"r352": {
"Name": "Accounting Standards Codification",
"Paragraph": "5",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Topic": "926",
"URI": "https://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959"
},
"r353": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "340",
"Topic": "928",
"URI": "https://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004"
},
"r354": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.9-03(1)(a))",
"Topic": "942",
"URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
},
"r355": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.9-03(10)(1))",
"Topic": "942",
"URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
},
"r356": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.9-03(11))",
"Topic": "942",
"URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
},
"r357": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.9-03(13))",
"Topic": "942",
"URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
},
"r358": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.9-03(16))",
"Topic": "942",
"URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
},
"r359": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.9-03(23))",
"Topic": "942",
"URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
},
"r36": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02.29-31)",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r360": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.9-03.15(5))",
"Topic": "942",
"URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
},
"r361": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.9-03.17)",
"Topic": "942",
"URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
},
"r362": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "220",
"Subparagraph": "(SX 210.9-04(22))",
"Topic": "942",
"URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
},
"r363": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "220",
"Subparagraph": "(SX 210.9-04(27))",
"Topic": "942",
"URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
},
"r364": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "220",
"Subparagraph": "(SX 210.9-04.9)",
"Topic": "942",
"URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
},
"r365": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "235",
"Subparagraph": "(SX 210.9-05(b)(2))",
"Topic": "942",
"URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
},
"r366": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "470",
"Subparagraph": "(c)",
"Topic": "942",
"URI": "https://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823"
},
"r367": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "470",
"Subparagraph": "e",
"Topic": "942",
"URI": "https://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823"
},
"r368": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.7-03(16))",
"Topic": "944",
"URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
},
"r369": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.7-03(a)(12))",
"Topic": "944",
"URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
},
"r37": {
"Name": "Accounting Standards Codification",
"Paragraph": "16",
"Publisher": "FASB",
"Section": "55",
"SubTopic": "20",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313"
},
"r370": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.7-03(a)(16))",
"Topic": "944",
"URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
},
"r371": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.7-03(a)(2))",
"Topic": "944",
"URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
},
"r372": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
"Topic": "944",
"URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
},
"r373": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
"Topic": "944",
"URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
},
"r374": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.7-03(a)(25))",
"Topic": "944",
"URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
},
"r375": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.7-03.(a),19)",
"Topic": "944",
"URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
},
"r376": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.7-03.15(a))",
"Topic": "944",
"URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
},
"r377": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "220",
"Subparagraph": "(SX 210.7-04(18))",
"Topic": "944",
"URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
},
"r378": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "220",
"Subparagraph": "(SX 210.7-04(23))",
"Topic": "944",
"URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
},
"r379": {
"Name": "Accounting Standards Codification",
"Paragraph": "7A",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "40",
"Subparagraph": "(d)",
"Topic": "944",
"URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439"
},
"r38": {
"Name": "Accounting Standards Codification",
"Paragraph": "21",
"Publisher": "FASB",
"Section": "55",
"SubTopic": "20",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313"
},
"r380": {
"Name": "Accounting Standards Codification",
"Paragraph": "13H",
"Publisher": "FASB",
"Section": "55",
"SubTopic": "40",
"Subparagraph": "(b)",
"Topic": "944",
"URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441"
},
"r381": {
"Name": "Accounting Standards Codification",
"Paragraph": "29F",
"Publisher": "FASB",
"Section": "55",
"SubTopic": "40",
"Topic": "944",
"URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441"
},
"r382": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "40",
"Subparagraph": "(e)",
"Topic": "944",
"URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
},
"r383": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "40",
"Subparagraph": "(f)(1)",
"Topic": "944",
"URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
},
"r384": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "40",
"Subparagraph": "(f)(2)",
"Topic": "944",
"URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
},
"r385": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "40",
"Subparagraph": "(g)(2)(i)",
"Topic": "944",
"URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
},
"r386": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "40",
"Subparagraph": "(g)(2)(ii)",
"Topic": "944",
"URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
},
"r387": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "40",
"Subparagraph": "(h)(2)",
"Topic": "944",
"URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
},
"r388": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "310",
"Subparagraph": "(SX 210.12-29(Footnote 4))",
"Topic": "948",
"URI": "https://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014"
},
"r389": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "440",
"Subparagraph": "(a)",
"Topic": "954",
"URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629"
},
"r39": {
"Name": "Accounting Standards Codification",
"Paragraph": "22",
"Publisher": "FASB",
"Section": "55",
"SubTopic": "20",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313"
},
"r390": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "360",
"Subparagraph": "(SX 210.12-28(Column B))",
"Topic": "970",
"URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
},
"r391": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "360",
"Subparagraph": "(SX 210.12-28(Column C))",
"Topic": "970",
"URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
},
"r392": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "360",
"Subparagraph": "(SX 210.12-28(Column D))",
"Topic": "970",
"URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
},
"r393": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "360",
"Subparagraph": "(SX 210.12-28(Column E))",
"Topic": "970",
"URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
},
"r394": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "360",
"Subparagraph": "(SX 210.12-28(Column F))",
"Topic": "970",
"URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
},
"r395": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "360",
"Subparagraph": "(SX 210.12-28(Column G))",
"Topic": "970",
"URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
},
"r396": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "360",
"Subparagraph": "(SX 210.12-28(Column H))",
"Topic": "970",
"URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
},
"r397": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "360",
"Subparagraph": "(SX 210.12-28(Column I))",
"Topic": "970",
"URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
},
"r398": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "360",
"Subparagraph": "(SX 210.12-28(Footnote 2))",
"Topic": "970",
"URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
},
"r399": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "310",
"Subparagraph": "(c)",
"Topic": "976",
"URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663"
},
"r4": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
},
"r40": {
"Name": "Accounting Standards Codification",
"Paragraph": "10A",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "220",
"URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580"
},
"r400": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "310",
"Subparagraph": "(b)",
"Topic": "978",
"URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691"
},
"r401": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Topic": "985",
"URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
},
"r402": {
"Name": "Exchange Act",
"Number": "240",
"Publisher": "SEC",
"Section": "12",
"Subsection": "b"
},
"r403": {
"Name": "Exchange Act",
"Number": "240",
"Publisher": "SEC",
"Section": "12",
"Subsection": "b-2"
},
"r404": {
"Name": "Exchange Act",
"Number": "240",
"Publisher": "SEC",
"Section": "12",
"Subsection": "d1-1"
},
"r405": {
"Name": "Form 10-Q",
"Number": "240",
"Publisher": "SEC",
"Section": "308",
"Subsection": "a"
},
"r406": {
"Name": "Forms 10-K, 10-Q, 20-F",
"Number": "240",
"Publisher": "SEC",
"Section": "13",
"Subsection": "a-1"
},
"r407": {
"Name": "Regulation S-K (SK)",
"Number": "229",
"Paragraph": "(a)",
"Publisher": "SEC",
"Section": "1402"
},
"r408": {
"Name": "Regulation S-K (SK)",
"Number": "229",
"Paragraph": "(a)",
"Publisher": "SEC",
"Section": "303",
"Subparagraph": "(5)"
},
"r409": {
"Name": "Regulation S-T",
"Number": "232",
"Publisher": "SEC",
"Section": "405"
},
"r41": {
"Name": "Accounting Standards Codification",
"Paragraph": "11",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "220",
"URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580"
},
"r410": {
"Footnote": "2",
"Name": "Regulation S-X (SX)",
"Number": "210",
"Publisher": "SEC",
"Section": "12",
"Subsection": "28"
},
"r411": {
"Footnote": "4",
"Name": "Regulation S-X (SX)",
"Number": "210",
"Publisher": "SEC",
"Section": "12",
"Subsection": "29"
},
"r412": {
"Name": "Regulation S-X (SX)",
"Number": "210",
"Paragraph": "Column B",
"Publisher": "SEC",
"Section": "12",
"Subsection": "28"
},
"r413": {
"Name": "Regulation S-X (SX)",
"Number": "210",
"Paragraph": "Column C",
"Publisher": "SEC",
"Section": "12",
"Subsection": "28"
},
"r414": {
"Name": "Regulation S-X (SX)",
"Number": "210",
"Paragraph": "Column D",
"Publisher": "SEC",
"Section": "12",
"Subsection": "28"
},
"r415": {
"Name": "Regulation S-X (SX)",
"Number": "210",
"Paragraph": "Column E",
"Publisher": "SEC",
"Section": "12",
"Subsection": "28"
},
"r416": {
"Name": "Regulation S-X (SX)",
"Number": "210",
"Paragraph": "Column F",
"Publisher": "SEC",
"Section": "12",
"Subsection": "28"
},
"r417": {
"Name": "Regulation S-X (SX)",
"Number": "210",
"Paragraph": "Column G",
"Publisher": "SEC",
"Section": "12",
"Subsection": "28"
},
"r418": {
"Name": "Regulation S-X (SX)",
"Number": "210",
"Paragraph": "Column H",
"Publisher": "SEC",
"Section": "12",
"Subsection": "28"
},
"r419": {
"Name": "Regulation S-X (SX)",
"Number": "210",
"Paragraph": "Column I",
"Publisher": "SEC",
"Section": "12",
"Subsection": "28"
},
"r42": {
"Name": "Accounting Standards Codification",
"Paragraph": "14",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "220",
"URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580"
},
"r420": {
"Name": "Regulation S-X (SX)",
"Number": "210",
"Paragraph": "(m)",
"Publisher": "SEC",
"Section": "4",
"Subparagraph": "(1)(iii)",
"Subsection": "08"
},
"r43": {
"Name": "Accounting Standards Codification",
"Paragraph": "14A",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "220",
"URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580"
},
"r44": {
"Name": "Accounting Standards Codification",
"Paragraph": "1A",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "220",
"URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580"
},
"r45": {
"Name": "Accounting Standards Codification",
"Paragraph": "1B",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "220",
"URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580"
},
"r46": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "220",
"URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
},
"r47": {
"Name": "Accounting Standards Codification",
"Paragraph": "5",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "220",
"URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
},
"r48": {
"Name": "Accounting Standards Codification",
"Paragraph": "6",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "220",
"URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
},
"r49": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(210.5-03(11))",
"Topic": "220",
"URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
},
"r5": {
"Name": "Accounting Standards Codification",
"Paragraph": "5",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765"
},
"r50": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-03(20))",
"Topic": "220",
"URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
},
"r51": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-03(25))",
"Topic": "220",
"URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
},
"r52": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-03(4))",
"Topic": "220",
"URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
},
"r53": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-03)",
"Topic": "220",
"URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
},
"r54": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-03.4)",
"Topic": "220",
"URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
},
"r55": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-03.7(b))",
"Topic": "220",
"URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
},
"r56": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-03.7)",
"Topic": "220",
"URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
},
"r57": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-03.9)",
"Topic": "220",
"URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
},
"r58": {
"Name": "Accounting Standards Codification",
"Paragraph": "14",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "230",
"URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585"
},
"r59": {
"Name": "Accounting Standards Codification",
"Paragraph": "15",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "230",
"URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585"
},
"r6": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(1))",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r60": {
"Name": "Accounting Standards Codification",
"Paragraph": "15",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "230",
"URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585"
},
"r61": {
"Name": "Accounting Standards Codification",
"Paragraph": "19",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "230",
"URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3444-108585"
},
"r62": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "230",
"URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3000-108585"
},
"r63": {
"Name": "Accounting Standards Codification",
"Paragraph": "24",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "230",
"URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585"
},
"r64": {
"Name": "Accounting Standards Codification",
"Paragraph": "25",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "230",
"URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585"
},
"r65": {
"Name": "Accounting Standards Codification",
"Paragraph": "28",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "230",
"URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
},
"r66": {
"Name": "Accounting Standards Codification",
"Paragraph": "28",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "230",
"URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
},
"r67": {
"Name": "Accounting Standards Codification",
"Paragraph": "28",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "230",
"URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
},
"r68": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "230",
"URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585"
},
"r69": {
"Name": "Accounting Standards Codification",
"Paragraph": "8",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "230",
"URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586"
},
"r7": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(15))",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r70": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "235",
"URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18726-107790"
},
"r71": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.4-08(c))",
"Topic": "235",
"URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
},
"r72": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.4-08(d))",
"Topic": "235",
"URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
},
"r73": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.4-08(e)(1))",
"Topic": "235",
"URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
},
"r74": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.4-08(f))",
"Topic": "235",
"URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
},
"r75": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.4-08(g)(1)(ii))",
"Topic": "235",
"URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
},
"r76": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.4-08(m)(1)(iii))",
"Topic": "235",
"URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
},
"r77": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.4-08(m)(2)(ii))",
"Topic": "235",
"URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
},
"r78": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.12-04(a))",
"Topic": "235",
"URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690"
},
"r79": {
"Name": "Accounting Standards Codification",
"Publisher": "FASB",
"Topic": "235",
"URI": "https://asc.fasb.org/topic&trid=2122369"
},
"r8": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(16))",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r80": {
"Name": "Accounting Standards Codification",
"Paragraph": "23",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "250",
"URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
},
"r81": {
"Name": "Accounting Standards Codification",
"Paragraph": "24",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "250",
"URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
},
"r82": {
"Name": "Accounting Standards Codification",
"Paragraph": "5",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "250",
"URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
},
"r83": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)(2)",
"Topic": "250",
"URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
},
"r84": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)(3)",
"Topic": "250",
"URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
},
"r85": {
"Name": "Accounting Standards Codification",
"Paragraph": "11",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "250",
"URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
},
"r86": {
"Name": "Accounting Standards Codification",
"Paragraph": "11",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "250",
"URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
},
"r87": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "250",
"URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
},
"r88": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "250",
"URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
},
"r89": {
"Name": "Accounting Standards Codification",
"Paragraph": "7",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "250",
"URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
},
"r9": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(17))",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r90": {
"Name": "Accounting Standards Codification",
"Paragraph": "7",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "250",
"URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
},
"r91": {
"Name": "Accounting Standards Codification",
"Paragraph": "8",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "250",
"URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
},
"r92": {
"Name": "Accounting Standards Codification",
"Paragraph": "9",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "250",
"URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
},
"r93": {
"Name": "Accounting Standards Codification",
"Paragraph": "10",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "260",
"URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256"
},
"r94": {
"Name": "Accounting Standards Codification",
"Paragraph": "16",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "260",
"URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256"
},
"r95": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "260",
"URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256"
},
"r96": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "260",
"URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1278-109256"
},
"r97": {
"Name": "Accounting Standards Codification",
"Paragraph": "55",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "260",
"URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e2626-109256"
},
"r98": {
"Name": "Accounting Standards Codification",
"Paragraph": "60B",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "260",
"URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256"
},
"r99": {
"Name": "Accounting Standards Codification",
"Paragraph": "60B",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(d)",
"Topic": "260",
"URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256"
}
},
"version": "2.1"
} |
